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Abstract 
 
Due to their great specificity and regulatory role in nearly all cellular processes, G 
protein-coupled receptors (GPCR) are a common therapeutic target. Investigating the molecular 
mechanisms that regulate receptor activity is essential for understanding how cells sense and 
adapt to their environment. The traditional model for GPCR activation occurs at the plasma 
membrane. Upon agonist binding, receptors are quickly post-translationally modified and 
activate signal transduction cascades. Receptor post-translational modifications are believed to 
regulate signaling outcomes, and initiate receptor endocytosis and down regulation. Over the past 
decade, it has become increasingly apparent that GPCR localization is a master regulator of cell 
signaling. However, the molecular mechanisms involved in this process are poorly understood. 
Using CXC chemokine receptor 4 (CXCR4) as a model GPCR, my thesis work investigates how 
clathrin and clathrin-independent endocytic pathways and intracellular localization regulate 
CXCR4 signaling and post-translational modification.  
In Chapter 2, I present data that supports an expanded role for endocytosis in regulating 
CXCR4 signaling and post-translational modification. Clathrin heavy chain knockdown resulted 
in increased steady state and agonist-induced ERK1/2 phosphorylation. Interestingly, CXCR4 
lipid raft localization has been implicated as a positive regulator of ERK1/2 signaling. In support 
of this hypothesis, we found that lipid rafts were necessary for CXCR4-dependent ERK1/2 
phosphorylation and clathrin knockdown increased CXCR4 colocalization with caveolin-1. 
During this work, we also identified a new antibody to study CXCR4 post-translational 
 xii 
modification and discovered that clathrin knockdown increases steady-state CXCR4 post-
translational modification. Together, these results suggest that endocytic pathways compensate 
for one another and differentially modulate receptor signaling and post-translational 
modification.  
 In Chapter 3, we shifted our attention from understanding how plasma membrane 
microdomains differentially regulate CXCR4 biology to investigate how intracellular GPCRs 
contribute to signaling. While receptor activation is traditionally thought to occur at the plasma 
membrane, there is growing evidence that intracellular GPCR activation also contributes to cell 
signaling. Through this work we discovered a new mechanism of intracellular GPCR activation. 
We found that upon agonist stimulation, both plasma membrane and intracellular pools of 
CXCR4 are post-translationally modified in a β-arrestin-1-dependent mechanism. Interestingly, 
intracellular CXCR4 activation increased CXCL12-dependent Egr1 transcription. Notably, these 
observations may explain that while CXCR4 overexpression is highly correlated with cancer 
metastasis and mortality, plasma membrane localization is not. Together these data support a 
model were a small initial pool of plasma membrane-localized GPCRs are capable of activating 
internal receptor-dependent signaling events.  
 Identification of protein-protein interactions is one of the first steps in identifying a 
molecular mechanism. However, due to difficulty isolating GPCR signaling complexes, many of 
the molecular players involved in these processes remain unknown. In Chapter 4, I share our 
progress using spatially resolved proteomics to identify new CXCR4 interacting partners and 
investigate how the CXCR4 interactome changes during endocytic trafficking. Finally in Chapter 
5, I use my work as an example to illustrate the importance of understanding the assumptions of 
 xiii 
biological measurements and highlight several cases where measurement assumptions influence 
result interpretation.   
  In summary, the presented data support an increased role for receptor localization as a 
master regulator of cell signaling. By improving our understanding of receptor regulation, I hope 
that this research can lead to the identification of new molecular mechanisms that regulate cell 
signaling and potentially therapeutic strategies that target aberrant GPCR function.  
 1 
Chapter 1 Introduction 
 
1.1 How do cells sense their environment?  
The ability for a cell to sense the environment and appropriately respond is essential to 
life. Cell membrane receptors are one class of proteins used by cells to do so. Receptors are well 
suited for this task because of their structure. They have three major domains: an ectodomain that 
is extracellular and allows a receptor to bind molecules from the environment, a transmembrane 
domain that helps receptors to stably reside in the cell membrane barrier and serves as a signal 
transducer, and an intracellular domain that translates ligand binding into an actionable 
intracellular signal by changing receptor-protein interactions. Ligand-dependent receptor-protein 
interactions activate intracellular programs that allow cells to accurately respond to the 
extracellular stimuli. From receptors that respond to mechanical and electrical inputs to those 
sensitive to light or extracellular molecules and proteins, cells employ a diverse array of cell 
membrane receptors to sense and respond to their environment.  
1.2 A brief history on cell membrane receptors 
The idea that cells had cell surface (plasma membrane) molecules originated in the late 
19th century from Paul Ehrlich1. Ehrlich hypothesized that mammalian cells had side chains on 
their surface that were responsible for sensing the extracellular environment. The “side chain 
theory” postulated the existence of receptors that bind antigens and identified these molecules as 
antibodies – which are analogous to what we know as B cell receptors today1. This idea was not 
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widely accepted. However, ideas from J.N. Langley at the turn of the 20th century built upon 
Ehrlich’s hypothesis and postulated that receptors had two connected functions. Langley 
believed that receptors interacted with environmental signals and that upon binding, were able to 
activate intracellular effector molecules to alter cell function2,3. This idea was further developed 
by Henry Dale and Raymond Ahlquist who hypothesized the existence of different classes of 
receptors defined by their ability to differentially bind molecules3–5. Clark, Ariens, Stephenson, 
Black, and Furchgott later applied the law of mass action to describe receptor agonist binding as 
well as developed initial antagonists (β-blockers) to inhibit or modulate receptor function6–8. 
Since then, experimental advances using radiolabeled ligands as well as the purification and 
cloning of cell membrane receptors led to the universal consensus of the importance of this 
specialized class of proteins for cell physiology. By the early 21st century, through advancements 
in genetic editing, fluorescence microscopy, and modern cell and molecular biology techniques 
we had developed a foundational model for how cells use membrane receptors to sense the 
environment as well as an understanding that these activities are linked to cell function. 
However, how membrane receptor activation regulates diverse cellular function remains an 
active area of research. Today, cell membrane receptors represent approximately 4% of all 
translated proteins. The two major classes of ligand-dependent membrane receptors are receptor 
tyrosine kinases (RTK) and G protein-coupled receptors (GPCRs).  
1.2.1 Receptor tyrosine kinases (RTKs)  
RTKs were initially discovered by Levi-Montalini and Cohen when they were studying 
the effects of nerve growth factor (NGF) and epidermal growth factor (EGF) stimulation on cell 
growth9–11. These initial studies also identified receptor signaling as a potent cellular regulator as 
they found that compared to normal cells, cancer cells required less serum growth factors for cell 
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proliferation12–14. By this time, insulin was a proposed treatment for diabetes and radiolabeled 
ligand experiments quickly led to the identification of the insulin receptor15. Soon after, 
additional research identified that these receptors contained tyrosine kinase motifs and that 
receptor dimerization and clustering was important for function16–19.  
RTKs are single-pass membrane proteins that have an intracellular tyrosine kinase 
domain. Ligand binding activates intrinsic catalytic tyrosine kinase activity which leads to 
receptor phosphorylation20. While receptor dimerization is often driven by ligand binding, in 
some circumstances, RTKs oligomerization can occur independent of ligand and is necessary for 
ligand binding and kinase activity21. Phosphorylation of the C-terminal regulatory domain 
promotes recruitment of signaling proteins and endocytic adapters that facilitated downstream 
receptor signaling events and receptor internalization to intracellular vesicles. 
Today, 58 human RTKs have been identified and shown to regulate a variety of cellular 
processes including cell proliferation, differentiation, and metabolism20. As a result, aberrant 
function is a hallmark of diseases such as cancer and diabetes. Epidermal growth factor receptor 
(EGFR) family members exemplify how both receptor overexpression and mutation lead to 
disease. EGFR family member, HER2, overexpression is found in approximately 30% of all 
breast cancers22 and an activating EGFR mutation is associated with non-small cell lung 
cancer23.   
1.2.2 G protein-coupled receptors (GPCRs)  
Defined by their seven transmembrane domain architecture6, GPCRs are the most 
numerous and diverse class of cell membrane receptor24. Earliest evidence for the existence of 
GPCRs dates back approximately 1.2 billion years prior to the evolution of plants, fungi, and 
animals from a common ancestor25. Over time GPCR diversity has drastically expanded due to 
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gene, chromosome, and whole genome duplication events and led to their role in regulating 
nearly all cellular processes25,26. Over 800 GPCRs have been identified and are classified by 
sequence and structural similarity into 5 families: rhodopsin (family A), secretin (family B), 
glutamate (family C), frizzled/Taste2, and adhesion27.  From regulation of immune response and 
neurotransmission, to cancer metastasis and pathogen invasion, GPCRs contribute to both 
normal and aberrant cellular functions24,28. GPCRs are known for tightly controlled and 
oftentimes tissue-specific expression profiles and ligand specificity. Consequently, these 
receptors have been targeted for a wide array of therapeutic applications from pain management 
(opioid receptors), cancer (chemokine receptors), viral infection (chemokine receptors), and 
cardiovascular disease (β-adrenergic receptors). A distinguishing feature from RTKs is that 
GPCRs themselves are not catalytically active and this property played an important role in their 
discovery.  
While the discovery of cyclic AMP (cAMP) was an important initial step in identifying 
the mechanism of GPCR signaling29, it wasn’t until Rodbell and Gilman discovered that guanine 
nucleotide regulatory proteins were the intermediary effector molecules between activated 
receptors and adenylyl cyclase activity that the traditional mechanism of GPCR signaling was 
revealed30,31. Similarly to RTKs, radioligand binding assays were vital for early GPCR research 
and led to the proposition of the ternary complex model to explain β2-adrenergic receptor 
signaling32. This model postulated that the minimal system for receptor signaling consisted of a 
receptor, an agonist, and a G protein32. Purification and reconstitution of β2-adrenergic receptor 
on phospholipid vesicles confirmed this model and for the first time established that ligand-
induced cAMP production was dependent on GPCR and G protein (Gαs) activation33–36. While 
receptor purification was a major advancement, cloning of the first GPCRs in the 1980s led to 
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the discovery of their conserved seven transmembrane structure and resemblance to rhodopsin37. 
Mutagenesis studies and generation of chimeric receptors by swapping receptor extracellular and 
C-terminal motifs contributed to our early understanding of how GPCRs coupled to G proteins as 
well as provided a connection between receptor sequence/structure and signaling activity – i.e. 
ligand binding and cAMP activity38,39.  At this point, researchers began to investigate how GPCR 
signaling activities were regulated.  
 Tight regulation of receptor signaling is essential as cellular resources are limiting and 
hyperactivation can lead to a costly disproportionate response. Protein post-translational 
modification (PTM) is one way that cells regulate activity at the protein level. PTMs are small 
molecules (phosphate, methyl groups etc.) or small proteins (ubiquitin) that are enzymatically 
added to proteins to modulate protein structure, disrupt or facilitate protein-protein interactions, 
and/or function as a tag for protein degradation or localization. This mechanism is fast, 
reversible, occurs with great precision, and is used ubiquitously to regulate protein function.  
Receptor phosphorylation was initially identified from an observation that β2-adrenergic 
receptor SDS-PAGE migration was altered post receptor stimulus and was subsequently found to 
regulate receptor signaling40. This led to the discovery of G protein coupled receptor kinases 
(GRKs) and characterization of their role in agonist-dependent GPCR phosphorylation41–43. At 
the time, it was known that rhodopsin was also phosphorylated and that a 48 kDa protein 
associated with phosphorylated receptors and regulated rhodopsin-transducin (transducin is a 
photoreceptor G protein) interactions44. This protein became known as arrestin and soon after 
related proteins, β-arrestins, were discovered to bind to phosphorylated GPCRs and regulate 
activity45,46. In the decades of research that followed, β-arrestins and GRKs have been shown to 
be master regulators for GPCR desensitization and signaling6.   
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Unlike RTKs, GPCR function is not tied to intrinsic enzymatic activity but through 
coupling to small heterotrimeric GTPases, known as G proteins. Ligand binding stabilizes GPCR 
confirmations that promote G protein guanidine nucleotide exchange activity, which results in 
the exchange of GDP for GTP. This exchange results in the disassociation/activation of the G 
protein subunits from the activated GPCR. The heterotrimeric G protein subunits are α, β, and γ. 
The Gβ and Gγ subunits form a stable dimeric complex referred to as Gβγ. There are 16 Gα, 5 
Gβ, and 12 Gγ G protein subunits that differentially interact with each other and each class of 
GPCRs47. This accounts for a massive number of potential combinations and consequently 
signaling diversity. The Gα subunit is the GTPase and is activated by receptor stimulus48. There 
are 4 Gα subfamilies that have different signaling implications. Gαs subunits activate adenylate 
cyclase while Gαi are inhibitory48. Gαq activates phospholipase C and Gα12/13 regulates the actin 
cytoskeleton by directly activating RhoGEFs48,49. Upon Gα GTP exchange, the Gβγ dimer is 
released from the trimeric complex and interacts with a variety of downstream signaling 
molecules – Gβγ itself is not catalytic 50. Early work illustrated that the Gβγ subunits are 
necessary for GPCR signaling as Gβγ prenylation helps membrane trafficking for Gα subunits50. 
Interestingly, structural studies using GPCR peptide mimics have also shown that Gβγ directly 
interacts with GPCRs50. In addition to mediating GPCR-dependent Gα interactions, Gβγ 
regulates a myriad of downstream signaling events itself. While initially shown to be important 
for regulating ion channel activation51, Gβγ activation has also been linked to ERK1/2 
activation50. Interestingly, most Gβγ-dependent signaling appears to arise from Gαi-associated 
GPCRs as Gβγ signaling processes are not universally activated by all GPCRs50. One of the 
major downstream implications of Gβγ activation is the recruitment and activation of GRKs to 
the plasma membrane to phosphorylate activated GPCRs52,53. GRK-mediated GPCR 
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phosphorylation serves 2 purposes: to facilitate the binding of adaptor proteins such as β-
arrestins and to initiate receptor internalization by endocytosis. While β-arrestin binding was 
originally thought to arrest G protein signaling and prevent activated receptors from interacting 
with additional G proteins, recently G protein-independent β-arrestin signaling events have been 
reported suggesting a larger role for β-arrestins in regulating GPCR signaling54.  
1.2.3 Chemokine Receptors and CXCR4  
Chemokine receptors are 50 rhodopsin-like family GPCRs that bind small, secreted 
proteins known as chemokines55,56. There are two groups of chemokine receptors –atypical and 
typical. Atypical chemokine receptors are believed to be involved in G protein-independent 
chemokine scavenging and not contribute to canonical G protein-dependent signaling57. There 
are four types of typical chemokine receptors and are defined by the localization of their N-
terminal cysteine residues: CXC, CC, C, and CX3C55,56. These receptors primarily couple to Gαi, 
pertussis sensitive Gα subunits, which inhibit adenylate cyclase activity. However they have 
been shown to bind to the other Gα subunits as well including Gαq and Gα12/1358. Chemokine 
receptors are primarily expressed in immune cells such as leukocytes and are known for their 
important role in regulating immune cell migration57. 
CXC chemokine receptor 4 (CXCR4) was initially discovered in leukocytes59 and 
signaling activity is important for a variety of biological processes including immune cell 
homeostasis, embryonic development, and cell migration60–65. It is expressed in multiple 
different cell types including, leukocytes, hematopoietic progenitor and stem cells, lymphoid 
tissues such as bone marrow and lymph nodes as well as endothelial and epithelial cells66. 
CXCR4 signaling is activated by agonist (CXCL12 also known as SDF-1) binding and 
depending on CXCL12 isoform and/or CXCR4 C-terminal tail PTM, regulates cell proliferation 
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and growth, chromatin remodeling, or cell migration and chemotaxis60,61. Additionally, while 
CXCR4 can bind extracellular ubiquitin67, macrophage migration inhibitory factor (MIF)68 and 
HIV envelope protein gp120, CXCL12 is its only known chemokine ligand58. Conversely, 
CXCL12 also binds to CXCR7 – also known as atypical chemokine receptor 3 (ACKR3) – 
which has been shown to scavenge CXCL12 but not activate G protein signaling58,69. In contrast 
to other chemokine receptors, knockout of CXCR4 or CXCL12 leads to perinatal death in 
mice58,62. Interestingly CXCR7 knockout is also lethal and leads to aberrant cardiac development 
in rodents58. CXCL12 has greater that 90% nucleotide and protein sequence identity in humans 
and mice70 and similar protein orthologs in other vertebrates such as Xenopus and zebrafish71,72. 
Together these observations suggest that there is significant pressure to retain the 
CXCR4/CXCL12 receptor pair during evolution and highlights the importance of the 
CXCR4/CXCL12/CXCR7 signaling axis. 
Additionally, aberrant CXCR4 expression can lead to multiple pathologies including 
cancer and rheumatoid arthritis58. CXCR4 expression is dysregulated in 23 cancers and has been 
shown to increase cancer cell metastasis towards CXCL12 expressing cells73–76. Additionally, 
meta-analysis studies of breast and lung cancer patients have shown that CXCR4 overexpression 
is highly correlated with poor survival outcomes77,78. To date, efforts to pharmacologically target 
CXCR4 have been largely unsuccessful79. Plerixafor (AMD3100) is the only FDA-approved 
CXCR4 antagonist 80. Plerixafor blocks CXCL12-mediated retention of hematopoietic stem cells 
in bone marrow, mobilizing them into the bloodstream for collection and autologous 
transplantation in non-Hodgkin’s lymphoma and multiple myeloma patients80. Unfortunately, 
tumor cell mobilization is a potential side effect of this treatment and thus application of this 
drug is limited. Consequentially, CXCR4 drug development research has recently shifted away 
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from receptor antagonism to the development of bias-agonists and/or inhibiting downstream 
“pro-metastasis” pathways. CXCR4 is also well known for its role as a co-receptor for HIV and 
inhibition of CXCR4 has been investigated as treatment strategy to limit HIV infection81. 
Interestingly, WHIM syndrome (Warts, Hypogammaglobulinemia, Infection, and 
Myelokathexis) is the only known immunological disease directly resulting from CXCR4 
mutagenesis82,83. WHIM syndrome arises from a deletion of the final 19 C-terminal residues of 
CXCR4 and leads to aberrant receptor activation and attenuated internalization82,83.  
CXCR4 signaling is largely thought to be G protein-dependent and the receptor has been 
shown to couple to multiple different Gα subunits – Gαi, Gαq, and Gα12/1358 – to activate the 
phosphatidylinositol-3 kinase pathway (PI3K/AKT) and the mitogen-activated protein kinase 
(MAPK/ERK1/2) signaling pathways as well as induce intracellular calcium mobilization84. It 
has also been associated with G protein-independent JAK-STAT signaling 58. Similarly to other 
GPCRs, CXCR4 forms both homo- and heterodimers with other receptors 66,85,86. This can occur 
either pre- or post-CXCL12 binding85,86. Interestingly, CXCL12 has also been shown to 
oligomerize at high concentrations which may contribute to agonist-dependent CXCR4 
oligomerization84. It is thought that CXCR4 and/or CXCL12 oligomerization leads to distinct 
signaling outcomes84,87 including potentially G protein-independent pathways; however this 
remains poorly understood 84.  
1.4 The cell signaling bottleneck  
While extracellular signals, receptors that detect them, and cellular responses are diverse, 
intermediary signaling hubs are often limited and conserved. This effectively creates a bottleneck 
effect during the signal transduction step. Consider the following example with Protein Kinase B 
(also known as AKT) signaling. AKT is a serine/threonine kinase and a centralized signaling hub 
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downstream of an array of signaling pathways that plays an important role in regulating cellular 
decision-making88. While mechanosensitve proteins such as integrins activate AKT, it is also 
activated by a multitude of ligand-activated receptors – such as GPCRs, RTKs and B cell 
receptor (BCR) – that bind fundamentally distinct ligands. Interestingly, while all of these 
receptor-signaling pathways converge on a signaling hub, the transcriptional outcomes are at 
least equally diverse as the extracellular inputs (Figure 1-1). From an evolutionary perspective, 
this is advantageous as reusing signaling machinery for multiple purposes preserves cellular 
resources. However, how cells are able to maintain input information diversity during this 
process remains poorly understood. There are several potential hypotheses to explain how 
multicellular organisms overcome this bottleneck effect: cell type specificity, ligand 
accessibility, and spatiotemporal signaling.  
 
 
Figure 1-1 The signaling bottleneck dilemma 
AKT is activated by a variety of different receptors to elicit distinct cellular responses. 
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1.4.1 Cell type specificity hypothesis 
One mechanism that could resolve the cell signaling bottleneck is that receptor 
expression, intermediary signaling proteins, and/or transcriptional programs are cell type 
specific. The logic for this is that depending on cell type, cells only express a subset of all 
receptors and therefore relieve potential mixed signaling effects via a single centralized signaling 
hub. One of the reasons why cell membrane receptors are great drug targets is that their 
expression is oftentimes cell type specific. This is advantageous from a disease treatment 
standpoint as it limits unintended negative drug effects on non-target cells. Therefore, it is 
possible that by restricting expression of receptors that signal via the same signaling hub 
proteins, cells do not have to worry about deciphering different signals.  
Cell type specific responses can also occur at the level of transcription. In this scenario, a 
single cell membrane receptor may activate different transcriptional programs depending on the 
cell type. This has been observed with CXCL12 stimulation. Researchers found that CXCL12 
stimulation had profoundly different transcriptional responses in N15C6 (non-transformed 
prostate epithelial cells) and LNCaP (transformed prostate epithelial cells) cell lines 89. This 
could be possible due to the differential expression of signaling co-factors such as transcription 
factors in different tissues as well as differential chromatin architecture that permit tissue-type 
specific transcriptional programming. Development is a common example of this as receptor 
expression or functional downstream signaling implications often evolve during differentiation.  
1.4.2 Ligand accessibility hypothesis 
A second mechanism that multicellular organism could use to overcome the cell signaling 
bottleneck is ligand accessibility. In a multicellular organism, extracellular signaling molecules 
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often originate at different parts of the organism.  Therefore, if cells located in a different area 
rarely receive a signal then expressing multiple receptors that activate different transcriptional 
programs via a conserved signaling hub likely will not be an issue. This is apparent during 
development. A fundamental idea in embryogenesis is the ability for cells to differentially 
differentiate in space and time. Morphogen (ligand) gradients play an essential role in regulating 
this process as they provide cells with instructions of how and when to induce a specific and 
often dose-dependent transcriptional response to drive differentiation. Well-studied extracellular 
gradients include WNT, hedgehog, FGF and TGF-β ligands. While in some cases morphogen 
gradients have been shown to freely diffuse, oftentimes cells actively regulate this process either 
by endocytic uptake of morphogens90 or the use of extracellular proteins such as heparin sulfate 
proteoglycans (HSPGs) to antagonize morphogen diffusion91.  Interestingly, chemokines such as 
CXCL12 have been shown to interact with HSPGs to define ligand gradients92,93.  Morphogen 
gradients have also been implicated in cell polarity in both embryogenesis94,95 and chemotaxis 
which impacts cancer metastasis and other diseases96. 
1.4.3 Spatiotemporal hypothesis 
Given that individual cells often express upwards of 100 different GPCRs97, a third 
mechanism that cells use to overcome the cell signaling bottleneck is spatiotemporal signaling. 
This idea has rapidly gained acceptance in the field over the last decade as an increasing number 
of examples of spatiotemporal signaling have been described. In this mechanism, the result of the 
signaling event is dependent on the timing and location of the signal. For example, a receptor 
signaling at the plasma membrane may lead to a different signaling outcome than the same 
receptor when it signals from an intracellular compartment. Spatiotemporal GPCR signaling can 
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be divided into 3 major categories: plasma membrane microdomain specific, endocytic 
trafficking dependent, and independent GPCR signaling.  
1.5 Plasma membrane microdomain dependent GPCR signaling 
The plasma membrane is a highly heterogeneous environment composed of complex 
arrangements of lipids and proteins and over the past two decades the importance of different 
microdomains in regulating receptor signaling has become increasingly apparent98,99. To explore 
plasma membrane heterogeneity and its contribution is signaling regulation, researcher have 
developed a variety of tools and techniques to study membrane organization using fluorescent 
molecular probes that partition to areas of ordered or disordered membrane100 and 
pharmacological sequestering agents of plasma membrane cholesterol to modulate plasma 
membrane microdomain composition.  
Ordered membrane domains are often referred to as lipid rafts and have been implicated 
as an essential regulator of CXCR4 signaling. Early work showed that CXCR4 localizes to 
cholesterol-rich regions of the cell membrane and that this localization is important for HIV 
endocytosis into cells101. Localization in lipid rafts also impacts CXCR4 signaling. Malik et al. 
reported that CXCR4 localization in cholesterol-rich microdomains is required for ERK1/2 
signaling102 and lipid composition has also been implicated as a key regulator for CXCL12-
dependent cell migration102–104. The importance of ordered microdomains has been also observed 
with other GPCRs as abolishment of lipid rafts using cholesterol-sequestering agents also 
reduces NH1 and Serotonin 1A receptor signaling102,105,106. 
Lipid rafts have also been shown to organize receptor signaling effector molecules such 
as G proteins and endocytic proteins98. Interestingly, β2 adrenergic receptor has been shown to 
differentially traffic to plasma membrane microdomains depending on whether the receptor was 
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recycled or newly synthesized via the biosynthetic pathway107,108. Researchers found that while 
β2 adrenergic receptors initially coupled to Gαs, after receptor recycling these receptors 
associated with Gαi in cardiomyocytes and speculated that this was due to enrichment of specific 
G protein subunits in different plasma membrane microdomains108. GPCRs can either traffic 
directly to lipid rafts or diffuse to lipid rafts upon ligand stimulus. GnRH receptor has been 
shown to almost exclusively reside in ordered membrane microdomains irrespective of ligand 
stimulus in specific cell lines109. On the other hand, the Veatch lab discovered that upon receptor 
stimulus, B cell receptors (BCR) cluster in ordered lipid microdomains and propose a model 
where these higher ordered structures are capable of sorting important regulatory effectors for 
BCR signaling100,110. Lipid rafts have also been shown to regulate receptor endocytic trafficking 
and consequently signaling111. Kinin B1 receptor translocation between ordered and disordered 
membrane domains has been shown to modulate its accessibility to different endocytic 
pathways111. Interestingly, aging disorders have also been linked to changes in membrane 
composition (specifically sphingosine kinase function) and GPCR signaling111. Together these 
data support a model were partitioning of receptors and downstream effector molecules in 
ordered vs. disordered plasma membrane microdomains allow cells to differentiate signaling 
response based on receptor localization.  
1.6 Endocytic trafficking dependent GPCR signaling 
While receptor endocytosis was initially thought to be solely involved with 
desensitization, over the last decade, it has become increasingly clear that endocytosis has a 
larger role in not only quenching, but also potentiating receptor signaling. Endocytic pathways 
are commonly divided into two major categories based on their dependency on clathrin: clathrin-
mediated endocytosis (CME) and clathrin-independent endocytosis (CIE). CME is the best-
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characterized pathway and is well documented to play a major role in regulating GPCR signaling 
and internalization including CXCR461,102,112–114. Comparatively, little is known about CIE, but it 
is becoming increasingly evident that these pathways also play a critical role in receptor 
regulation115,116. There are many types of CIE including caveolin-, flotillin-, and RhoA- 
dependent endocytosis117. Interestingly, significantly less is known about how the dynamic 
interplay between different endocytic pathways as well as how cell membrane heterogeneity 
regulates receptor biology. 
Several groups have illustrated that transforming growth factor β (TGFβ) receptor and 
EGFR are internalized by both CME and CIE pathways and that the balance between these 
endocytic pathways is dependent on ligand concentration115,116,118,119. Initial evidence for this was 
the presence of internalized TGFβ receptors in both caveolin- (CIE) and EEA1 (early endosome 
antigen 1)- (CME) positive vesicles118. Interestingly, researchers found that CME internalization 
led to sustained TGFβ signaling. In contrast, CIE internalization increased Smad7-Smurf2 bound 
TGFβ receptor complexes and was associated with receptor turnover118. Others have investigated 
ligand-free internalization and have similarly shown that EGFR internalizes through clathrin-
independent mechanisms upon UV radiation and oxidative stress 120,121. In both cases (EGF and 
TGFβ receptors), differential receptor PTM was responsible for modulating the balance of CME- 
and CIE-dependent internalization116,120,121. Interestingly, CME and CIE internalization has also 
been observed with GPCRs122–124. While it is known that CME plays an important role in 
CXCR4 internalization and signaling61,114,125, there is evidence to suggest CIE-dependent 
CXCR4 regulation. In contrast to an early report that did not find CXCR4 colocalization with 
caveolar (type of CIE) protein, cavin-1, positive vesicles125, recent research has shown that 
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CXCR4 caveolar localization (membrane) is critical for CXCL12-induced phospho-ERK1/2 
activation102. G proteins have also been shown to localize to CIE pits, including caveolae 126.   
Endocytic machinery proteins themselves have also been implicated as important 
regulators of receptor signaling. Garay et al. found that knockdown of clathrin significantly 
reduced EGF-induced AKT phosphorylation and that this was independent of receptor 
internalization as perturbation of dynamin 2 did not affect EGF-induced AKT 
phosphorylation127. Others have postulated that specialized signaling endocytic pits exist. 
Rosselli-Murai et al. discovered that EGFR signaling was primarily initiated in short-lived 
clathrin-coated pits (CCPs) and that shifting the relative abundance of these pits by depleting 
tumor suppressor PTEN influenced EGFR signaling128. Together these data support an expanded 
role for endocytosis and endocytic proteins themselves as important regulators of signaling and 
not only as a mechanism to reduce plasma membrane localization and receptor desensitization.  
 In addition to regulating receptor signaling at the plasma membrane, receptor 
internalization has also been shown to be essential for complete signaling for some GPCRs. 
Initial evidence that endocytosis was required for complete GPCR signaling was facilitated by 
the use of cAMP biosensors that revealed sustained cAMP signaling post-receptor 
internalization129,130. This led to a new model for GPCR signaling and hypothesis that receptor 
signaling occurrs in two steps: first at the plasma membrane and secondly post-internalization at 
intracellular compartments such as endosomes. The development of receptor nanobodies – 
genetically encoded, fluorescently tagged small antibody fragments that recognize activated 
receptor conformations – confirmed this hypothesis and showed that β2 adrenergic receptors 
were indeed activated at endosomes to elicit a second wave of signaling131. Researchers 
discovered that endosomal GPCR activation was distinct from plasma membrane pools and 
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resulted in distinct downstream signaling consequences132. For β2 adrenergic receptor endosomal 
signaling was necessary for PCK1 transcription133 and alpha arrestin ARRDC3 was shown to 
regulate endosomal residence time for β2 adrenergic receptors to regulate this signaling 
response134. Since then endosomal signaling has also been reported for other GPCRs including 
CXCR4135–138. English et al. reported that blocking CXCR4 internalization significantly 
decreased CXCL12-dependent AKT signaling and concluded that this was due to the fact that 
endosomal signaling was necessary for complete AKT phosphorylation135. Endocytosis and 
endosomal signaling has also been linked to action potential firing. Researchers found that 
dopamine receptors (D1R) internalized much quicker than previously anticipated and that 
inhibition of endocytosis ablated agonist-dependent action potential firing in neurons139. 
Sustained agonist-induced luteinizing hormone receptor (LHR) and β1 adrenergic receptor 
ERK1/2 signaling was found to require both receptor internalization and correct targeting to 
endosomal compartments in a GIPC (Gai-interacting protein C-terminus)-dependent 
mechanism97,140. This finding highlights that, similarly to plasma membrane microdomains, there 
is compartmental bias at intracellular endosomes97. In addition to endosomes, GPCR signaling 
has also been shown at other intracellular endocytic compartments including late endosomes and 
has been shown to impact WNT signaling141,142.  
 The role of β-arrestins in regulating localized GPCR signaling events remains unclear. 
While it was initially thought that G protein and β-arrestin-GPCR binding were mutually 
exclusive, recent biochemical and structural evidence suggest that β-arrestins, activated GPCRs, 
and G proteins can form stable mega-signaling complexes at intracellular compartments143–146. 
Using single particle electron microscopy, researchers were recently able to visualize a single 
GPCR in complex with β-arrestins and Gβγ. Furthermore, the researchers found that GPCR-β-
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arrestin coupling conformation dictated downstream functions147. In cells, using parathyroid 
hormone receptor (PTHR) as a model, the Vilardaga group discovered that Gβγ and β-arrestins 
form functional intracellular/endosomal-signaling complexes143,144. Additionally, they recently 
revealed that Gβγ exchange between activated β2 adrenergic receptors and PTHR promoted 
sustained endosomal PTHR cAMP signaling143. 
1.7: Endocytic trafficking-independent GPCR signaling 
 GPCRs have also been shown to signal from intracellular compartments such as the 
nuclear membrane, endoplasmic reticulum (ER) and Golgi independent of endocytosis. While 
nuclear GPCR localization is well established, its role in receptor signaling remains poorly 
understood148. Multiple GPCRs have been shown to localize to the nuclear membrane including 
CXCR4148, metabotropic glutamate receptors149, and β-adrenergic receptors150. In fact, some 
GPCRs even contain nuclear localization sequences148. Researchers have postulated that nuclear 
GPCR localization are physiologically relevant as nuclear localization is conserved in both C. 
elegans and mammals151 CXCR4 nuclear localization is correlated with metastatic potential in 
renal cell carcinoma (RCC) where increased CXCR4 association with HIF-1a has been shown to 
promote HIF-1a target gene transcription148. Interestingly, others have shown that many of the 
canonical GPCR signaling proteins also reside at nuclear membranes including G proteins, 
GRKs, adenylate cyclase, and β-arrestin-1151 suggesting that nuclear GPCRs may be signaling-
competent. In fact, researchers were able to activate β-adrenergic receptor agonist-dependent 
adenylate cyclase signaling using isolated nuclei from rat and mouse cardiomyocytes150.  
However, one outstanding question in this field is how nuclear GPCRs are activated in cells and 
whether this is ligand-dependent.  
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 GPCRs have also been shown to localize at the endoplasmic reticulum (ER). GPR30, an 
estrogen receptor, is an example of ER-localized GPCR signaling. Upon estrogen stimulus, 
GPR30 has been shown to functionally regulate intracellular calcium mobilization and nuclear 
phosphatidylinositol 3,4,5-triphosphate synthesis152. Research investigating GABA B receptor 
subunits provides further evidence of ER-localized GPCR signaling. Without GABA B2, GABA 
B1 receptor subunits are often retained in the ER. While in some cell types GABA B2 is 
necessary for GABA B1 function, GABAB1 has much broader expression profile in the central 
nervous system compared to GABA B2 suggesting that intracellular GABA B1 are functional 
and physiologically relevant151.  
 Many GPCRs have also been shown to localize to the Golgi and have functional 
implications153–156. δ opioid receptor Golgi localization in neurons has been reported for 
decades155,157–159 and provided initial evidence for the importance of intracellular GPCR 
localization.  There are two hypotheses for how Golgi localized receptors exist: endocytic 
trafficking of receptors to the Golgi post receptor internalization or active retention of newly 
synthesized receptors. Endocytic trafficking-dependent Golgi localization was recently reported 
for TSH receptors where trafficking to the Golgi post-receptor internalization was shown to 
induce specific Gogli-localized Gαs signaling160. Work from the Puthenveedu group recently 
illustrated that newly synthesized δ opioid receptors are localized at the Golgi and that their 
plasma membrane trafficking was regulated by kinase-phosphatase pair PI3K and PTEN 
competition155,161. COPII vesicles appear to be involved in receptor retrograde transport and 
Golgi retention155,161. Interestingly, increasing δ opioid plasma membrane localization sensitized 
mice to previously ineffective opioid agonist (SCN80) for pain management155,161. The 
physiological role of Golgi-localized δ opioid receptor in neurons remains elusive; however, 
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membrane permeable small molecule ligands have been shown to activate Golgi-localized δ 
opioid receptors162 and others have postulated that this intracellular pool might be important for 
quick replenishment of plasma membrane receptors post-stimulus156. Additional work has 
revealed that specific C-terminal motifs R-X-R and K-X-K present on multiple GPCR C-
terminal tails are involved in regulating GPCR-Golgi retention. Interestingly, CXCR4 also has a 
C-terminal K-X-K and may play a role in poor CXCR4 membrane localization in some cell types 
and tumor models 148,163 . 
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Figure 1-2 Overview of localized GPCR signaling within cells 
(A) Schematic of GPCR activation at different plasma membrane and/or endocytic 
microdomains and intracellular compartments. Activation of Golgi-localized GPCRs has been 
shown to occur either by direct activation by membrane permeable ligands (OCT3 cation 
channel) or during endocytic trafficking from endosomes (TSH receptor trafficking). G proteins 
and β-arrestins are involved in propagating signaling at different locations. (B) There are 
multiple waves of receptor signaling events based on the location of the receptor. Plasma 
membrane-restricted events are thought to induce an initial fast signaling response (red lines) 
whereas intracellular signaling is believed to represent a second more attenuated wave (blue 
line). Interestingly, signaling from the Golgi can in theory occur at either time as it can occur 
either by direct ligand binding or during endocytic trafficking. Regardless, recent research 
supports that distinct downstream transcriptional programs are activated depending on where 
receptors are activated.  
 
Golgi-localized GPCR signaling has also been suggested to play a role in cardiovascular 
function. β1 adrenergic receptor was recently shown to be present at the Golgi and be activated 
by dobutamine153. Researchers found that β1 adrenergic receptor signaling activity was 
dependent on a cation transporter OCT3 which actively pumps extracellular small molecule 
ligands into the cell where they are able to activate the Golgi-localized receptors153. G proteins 
have also been shown to localize to the Golgi to induce PI4P hydrolysis by PLCε154. Researchers 
found that selective inhibition of G protein signaling at the Golgi or prevention of norepinephrine 
transport via OCT3 blocked norepinephrine-dependent cardiac myocyte hypertrophy154,164.  
Together these data are summarized in Figure 1-2 and illustrate the importance and complexity 
of GPCR localization in regulating cell decision-making.  
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1.8 Dissertation outline 
 Using CXCR4 as a model GPCR, in the following chapters I will investigate how 
endocytosis and receptor localization regulate CXCR4 signaling and post-translational 
modification.  In Chapter 2, I will present data that supports an expanded role for clathrin and 
clathrin-independent endocytosis in regulating CXCR4 signaling as well as identify a new 
antibody to study CXCR4. Next in Chapter 3, I will present work that supports a new mechanism 
for intracellular GPCR activation that is independent of receptor endocytosis and membrane 
permeable ligands. Afterwards, I will describe our progress using spatially resolved APEX2 
proteomics to study how the CXCR4 protein interactome changes during endocytic trafficking in 
Chapter 4. In Chapter 5, I will deliberate several biometrology insights that I have learned while 
carrying out my cell biology research that raises questions regarding how we evaluate and 
interpret receptor-signaling data. Finally, Chapter 6 summarizes important findings from the 
work and explores future directions for localized GPCR signaling.  
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Chapter 2 Endocytosis Regulates CXCR4 Signaling and Post-
Translational Modification 
 
This chapter was published in the Frontiers in Cell and Developmental Biology special 
edition on membrane trafficking (2019). Author Contributions: M.S.D. designed research, 
analyzed data, and wrote the manuscript. L.K.R contributed some reagents. A.P.L. and S.S. 
provided experimental advice, edited the manuscript, and provided funding.  
2.1 Abstract 
Recent research has implicated endocytic pathways as important regulators of receptor 
signaling. However, the role of endocytosis in regulating chemokine CXC receptor 4 (CXCR4) 
signaling remains largely unknown. In the present work we systematically investigate the impact 
of clathrin knockdown on CXCR4 internalization, signaling, and receptor post-translational 
modification. Inhibition of clathrin-mediated endocytosis (CME) significantly reduced CXCR4 
internalization. In contrast to other receptors, clathrin knockdown increased CXCL12-dependent 
ERK1/2 signaling. Simultaneous inhibition of CME and lipid raft disruption abrogated this 
increase in ERK1/2 phosphorylation suggesting that endocytic pathway compensation can 
influence signaling outcomes. Interestingly, using an antibody sensitive to CXCR4 post-
translational modification, we also found that our ability to detect CXCR4 was drastically 
reduced upon clathrin knockdown. We hypothesize that this effect was due to differences in 
receptor post-translational modification as total CXCR4 protein and mRNA levels were 
unchanged. Lastly, we show that clathrin knockdown reduced CXCL12-dependent cell migration 
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irrespective of an observed increase in ERK1/2 phosphorylation. Altogether, this work supports a 
complex model by which modulation of endocytosis affects not only receptor signaling and 
internalization but also receptor post-translational modification. 
2.2 Introduction 
Tight regulation of how cells interact with their environment and process extracellular 
information is essential for survival. Consequentially, mammalian cells have evolved several 
tightly regulated yet partially redundant pathways to control cell communication165–167. While 
endocytic pathways are predominantly known for their role in receptor internalization and 
desensitization, recent technological advancements have allowed researchers to interrogate 
endocytic dynamics in the context of cognate receptor-cargo pairs and systems-level studies have 
increased our understanding of endocytic pathways functioning a master regulators of receptor 
signaling, recycling and degradation168–173.  
G protein-coupled receptors (GPCRs) play an important role for both essential and 
pathogenic biological processes and are a common cargo of endocytic pits. CXC chemokine 
receptor 4 (CXCR4) is a type 1 GPCR important for a variety of biological processes including 
immune cell homeostasis, embryonic development, and cell migration174–178. CXCR4 signaling is 
activated by agonist C-X-C ligand 12 (CXCL12) binding179. Depending on CXCL12 isoform 
and/or CXCR4 C-terminal tail post-translational modifications (PTM), CXCR4-CXCL12 
signaling regulates cell proliferation and growth, chromatin remodeling, or cell migration and 
chemotaxis174,179–181. CXCR4 expression is deregulated in 23 cancers and has been shown to 
increase cancer cell metastasis towards CXCL12 expressing cells182,183. Aside from being the 
most commonly deregulated GPCR found in cancer, CXCR4 was also identified as an HIV co-
receptor184. Additionally, WHIM syndrome (Warts, Hypogammaglobulinemia, Infection, and 
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Myelokathexis) is the only known immunological disease directly results from aberrant CXCR4 
function, and it has been attributed to a deletion of C-terminal residues of CXCR4 that prevents 
proper receptor internalization185.  
Receptor tyrosine kinases and GPCRs such as CXCR4 commonly activate the ERK1/2 
signaling pathway in an agonist-dependent manner180,186,187. ERK1/2 are serine/threonine protein 
kinase members in the MAPK signaling cascade and are involved in regulating numerous 
biological processes including cell migration and chemotaxis188–190. While the precise 
mechanism by which CXCL12 activates the MAPK cascade is unclear, the non-visual arrestins 
(beta 1 and 2) and CXCR4 PTMs have been implicated as key regulators of this process180,191,192. 
Furthermore, multiple lines of evidence suggest tight spatial and temporal control is necessary 
for proper ERK1/2 activation193. While the importance of spatiotemporal control and 
compartmentalization of receptor signaling have recently been shown to play a significant role in 
regulating receptor signaling, the molecular mechanisms that regulate this process remain largely 
unknown.  
Recently, endocytosis and receptor localization in membrane microdomains have been 
implicated as key regulators of agonist-induced receptor signaling172,193–195. It was shown that 
drug perturbation as well as genetic silencing of clathrin heavy chain (CHC) significantly 
decreased EGF-induced EGFR internalization and AKT signaling and that these effects are 
rescued by ERBB2 expression in HeLa cells172. Interestingly, EGFR surface expression 
and phosphorylation state was unaffected by clathrin inhibition172. Additionally, recent work 
from our group suggested that a specific subset of clathrin-coated pits (CCPs) are specialized for 
signaling and concluded that clathrin acts as a scaffold for EGF-induced AKT phosphorylation at 
the cell membrane173. Clathrin-independent endocytosis and lipid rafts have also been implicated 
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as essential regulators of receptor signaling193,195,196. In particular, disruption of caveolae by 
depleting cholesterol or caveolin-1 genetic silencing significantly reduced CXCL12-induced 
ERK1/2 signaling193. Interestingly, this effect appeared to be CXCR4-specific as EGFR 
activation was unaffected by cholesterol depletion193. Altogether, a model emerges in which 
endocytosis plays an essential role in ensuring complete receptor signaling pathway activation. 
While it is known that caveolin-1 plays an important role in CXCR4 signaling and CXCR4 is 
believed to primarily internalize via CME, it remains unclear how CME regulates CXCR4 
signaling, PTMs, and protein levels.  
In this study, we investigated the effects of clathrin genetic silencing on CXCR4 
internalization, signaling, receptor protein levels, and PTM. We found that CHC knockdown 
significantly decreased CXCL12-induced CXCR4 internalization. In contrast to decreased 
ERK1/2 activation upon caveolin-1 knockdown, we observed an increased in ERK1/2 activation 
upon CHC knockdown. Using an antibody sensitive to CXCR4 PTM, we observed that increased 
signaling potential coincided with an increase in CXCR4 PTM, while total CXCR4 protein and 
mRNA levels were unaffected by clathrin knockdown. Interestingly, we also discovered that 
clathrin knockdown significantly impaired CXCL12-dependent cell migration irrespective of the 
observed increase in ERK1/2 phosphorylation. Altogether, our data support a more complex 
model in which clathrin is an important regulator of receptor signaling, internalization, and PTM. 
2.3 Materials and Methods 
Cell Culture 
HeLa Cells were originally obtained from ATCC. Retinal pigment epithelial (RPE) cells 
were obtained from Dr. Sandra Schmid at UT Southwestern and all stable cell lines were derived 
directly from this line. HeLa cells were cultured in DMEM media (Corning) supplemented with 
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10% FBS while RPE cell lines were cultured in DMEM/F12 media (Corning) supplemented with 
10% FBS.  
 
Stable Cell Lines 
Stable RPE cell lines expressing FLAG-CXCR4 WT (+/- c-terminal myc tag) receptors 
were generated using lentiviral transduction produced from the pLVX vector. Lentiviruses were 
generated in our lab by co-transfecting HEK293T cells (ATCC) with the transfer plasmid, 
psPAX2, and pMD2.G lentiviral envelope and packaging plasmids. Cell supernatant containing 
mature lentiviral particles was collected 4 days after transfection. RPE cells were transduced in 
DMEM/F12 media supplemented with FBS and 10 µg/mL polybrene and stable cell lines were 
generated through puromycin selection (3 µg/mL).  
 
Cell Signaling, Cycloheximide Experiments, and Western Blotting 
Cells were plated onto 12 well plates (Cell Treat) 24 hrs before each signaling 
experiment. Prior to each experiment cells were wash 1x with PBS and serum-starved for 4 hrs. 
Cells were stimulated with ligand (specified in figure legends) (R&D Systems) diluted in serum-
free media for 0, 5, or 20 min as indicated in each figure legend. For clathrin knockdown 
experiments, cells were transduced with pKLO.1 clathrin heavy chain (CHC 17) (sequence 1: 
Sigma TRCN0000342755, 
CCGGCGGTTGCTCTTGTTACGGATACTCGAGTATCCGTAACAAGAGCAACCGTTTTT
G (2755), sequence 2: Sigma TRCN0000007981, 
CCGGCGTGTTCTTGTAACCTTTATTCTCGAGAATAAAGGTTACAAGAACACGTTTTT 
(7981) or scramble non-targeting control Sigma-SCH002) shRNA containing lentiviral particles 
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5 days prior to the signaling experiment. 72 hrs post transduction, cells were selected using 2 
µg/mL (HeLa) or 3 µg/mL puromycin (RPE).  
 
 
 
 
Figure 2-1 Clathrin heavy chain knockdown efficiency 
Representative western blot of clathrin heavy chain shRNA knockdown efficiency.  
 
Knockdown efficiencies ranged from 55-85% for all experiments (Figure 2-1). Cells were 
plated 24 hrs prior to each signaling experiment as described above. After each signaling 
experiment, cells were washed with PBS 1x and lysed using RIPA buffer (Pierce) supplemented 
with protease (EDTA Peirce Cocktail and phosphatase inhibitor cocktails (HALT Phosphatase 
Inhibitor) for 10 min on ice. Afterwards, cells were scraped, lysate added to 1.5 mL tubes, and 
centrifuged at 4 oC for 45 min at 16,100 g. Approximately 10-50 µg of protein were loaded for 
SDS-PAGE gels (BioRad) analysis depending on the abundance of the target protein. PDVF 0.2 
µm membranes (Thermo Fisher Scientific) were used for all western blotting experiments and 
transferred using the iBlot transfer system suitable for mixed range proteins. Blots were blocked 
using 5% BSA in TBS not supplemented with Tween for 1 hr rocking at room temperature. Blots 
were then incubated overnight with primary antibodies diluted in 5% BSA supplemented with 
1% Tween 20 in TBS (TBST). Blots were washed 3x for 5 minutes with TBST after which they 
were incubated with secondary antibodies (Table 2-1). All blots were imaged using the LiCor 
Odyssey Imaging System. Bands were quantified using the LiCor Image Analysis Software in 
accordance with manufacturer guidelines. We established that our knockdowns did not 
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significantly alter GAPDH expression using the REVERT total Protein Stain and therefore used 
GAPDH as a loading control and for normalization of all experiments. As previously described, 
all signaling experiments were additionally normalized to the scramble control at the 5-min 
stimulus time point172. For the cycloheximide (CHX) experiments, RPE cells overexpressing 
CXCR4 were grown as described above and treated with cycloheximide (50 µM) described in 
the figure legend. The exact western blot protocol used for signaling assays was used for CHX 
experiments as well.  All statistics were conducted using paired 2 tailed t-test (* represents p < 
0.05).  
 
Immunofluorescence Assays 
Cells were plated onto 6-well plates on glass coverslips 24 hrs prior to each experiment. 
Cells were washed 1x with PBS and serum-starved for 4 hrs as described above. Cells were 
stimulated as specified in each figure legend and immediately washed with cold PBS 2x and 
fixed in 4% paraformaldehyde for 15 min on ice. Cells were permeabilized for 5 min at room 
temperature with 0.2% Triton-X100 diluted in PBS and then blocked with 2.5% BSA in PBS for 
1 hr. Cells were incubated with primary antibody diluted in 2.5% BSA and incubated overnight 
at 4 oC (Table 2-1). Slides were wash 3x for 5 min each with PBS and incubated with secondary 
antibodies diluted in 2.5% BSA for 1 hr at room temperature (Table 1). Cells were washed with 
PBS 3x, 5 min per wash and incubated with DAPI (Table 1) diluted in PBS for 5 min at room 
temperature. Afterwards, cells were washed with PBS and mounted onto glass slides with 
Fluoromount-G (Invitrogen). Slides were imaged by spinning disk confocal microscopy, TIRF 
microscopy, or epifluorescence (using a laser-based system). Different experimental samples 
were imaged using the same imaging settings each day and antibody controls (secondary and 
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non-permeabilized samples) were included in each experiment to account for background 
staining. 
 
Internalization Assays 
Cells were plated onto 10 cm dishes 24 hrs prior to each experiment, washed and serum-
starved as described above. Afterwards, cells were non-enzymatically disassociated from each 
plate using 50 µM EDTA in Ca2+-free PBS. Cells were pelleted by centrifugation (500 g for 10 
min) and resuspended in serum-free media on ice. Cells were transferred into 1.5 ml eppendorf 
tube and treated with either a vehicle or ligand and transferred to a hot plate at 37 oC for a time 
course (described in figure legends). Immediately afterwards, cells were transferred back on ice, 
pelleted (centrifuged 3,000g for 3 min), and resuspended in 4% paraformaldehyde for 10 min on 
ice. Cells were pelleted and incubated with conjugated antibody (Table 2-1) diluted in 2.5% BSA 
for 1.5 hrs on ice. Afterwards, cells were washed 1x with PBS and 10,000 cells were analyzed by 
the Guava EasyCyte Flow Cytometer and its accompanied software. Internalization was 
quantified as previously described197. All statistics were conducted using paired 2 tailed t-test (* 
represents p < 0.05). 
 
RT-qPCR Assays  
Scramble- or clathrin-silenced HeLa cells were plated onto 12 well dishes at similar confluency 
24 hr prior to each experiment and subsequently serum-starved or treated with fresh 10% FBS 
containing medium for 4 hr. RNA was extracted using the RNAeasy kit (BioRad) and 1 µg of 
cDNA prepared in accordance with the iScripts cDNA synthesis protocol (BioRad). qPCR assays 
 31 
quantify gapdh (Fw-GAGTCAACGGATTTGGTCGT, Rev-
CTTGATTTTGGAGGGATCTCGC), actin (Fw-CATGTACGTTGCTATCCAGGC, Rev-
CTCCTTAATGTCACGCACGAT), chc (Fw-ACAGAGACACAACCCATTGTTT, Rev-
CGGTGGTGCGGTATAACCAT), cxcr4 (Fw-CCTATGCAAGGCAGTCCATGT, Rev-
GGTAGCGGTCCAGACTGATGA), and egfr (Fw-AGGCACGAGTAACAAGCTCAC, Rev-
ATGAGGACATAACCAGCCACC). Relative transcript levels were quantified using the ΔΔCt 
method as previously described. Briefly, the change in C(t) values between scramble and clathrin 
knockdown samples were determined. Afterwards the change between the deltas of paired 
scramble and clathrin knockdowns was calculated (i.e. ΔΔCt) and relative transcript levels was 
determined by calculating 2-ΔΔCt. Results were collected in duplicate from 4 independent 
experiments; log2 transformed, and plotted mean +/- standard deviation.  
 
Migration Assays 
HeLa cells expressing either scramble or CHC shRNA were plated onto 24 well plates at 100% 
confluence. After 24 hr, cells were serum-starved (DMEM (-) FBS) for 4 hr and a vertical 
scratch was created using a 200 µl pipet tip. Afterwards, cells were treated with either complete 
media (10% FBS + DMEM) or CXCL12 media (25 nM CXCL12 + DMEM). Cell migration was 
monitored, imaged and quantified after 20 hr using phase contrast microscopy on a Cytation 5 
automated plate reader at 4x magnification. Migration was quantified by measuring the area 
remaining between the cell borders by using ImageJ as previously described173. Results were 
collected from 3 independent experiments and are plotted mean +/- standard deviation.  All 
statistics were conducted using paired 2 tailed t-test (* represents p < 0.05). 
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Table 2-1 Reagents 
Reagent Supplier Dilution Assay 
ms-FLAG-647 Genscript 1:1000 FC, IF 
Gt-anti-rb Dylight 800 Invitrogen 1:10000 WB 
Gt-anti-ms Dylight 680 Invitrogen 1:10000 WB 
Human CXCR4 R-PE Invitrogen 1:500 FC 
ms-GAPDH Santa Cruz 1:1000 WB 
rb-Phospho-pERK1/2 CST 1:2000 WB 
ms-Total ERK1/2 CST 1:1000 WB 
rb-CXCR4 UMB2 Abcam 1:1000 WB, IF 
Rb-EEA1 CST 1:500 IF 
Gt-anti-rb-AF488 Invitrogen 1:1000 IF 
Rb-Caveolin-1 CST 1:500 IF 
Ms-EGFR (A-10) Santa Cruz 1:1000 WB 
 
2.4 Results 
CXCR4 overexpression in retinal pigment epithelial (RPE) cells recapitulates endogenous 
CXCR4 internalization and signaling in HeLa cells.  
To study the effects of CXCR4 overexpression without background from endogenous 
receptors and other chemokine receptors responsive to CXCL12 (e.g., CXCR7), we used both 
HeLa and an exogenous CXCR4 overexpression cell line model. To limit background from 
endogenous CXCR4 and CXCR7, we overexpressed CXCR4 in retinal pigment epithelial cells 
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(RPE) because this cell line has very low CXCR4 expression 198. As expected, CXCL12 stimulus 
rapidly induced both ERK1/2 phosphorylation in both HeLa and RPE cells stably overexpressing 
CXCR4 as early as the 5 minutes time point (Figure 2-2A). Likewise, agonist-induced receptor 
internalization was not significantly different between HeLa and RPE CXCR4 (Figure 2-2B). 
Lastly, to ensure that the overexpressed CXCR4 construct localized and trafficked properly in 
RPE cells, we found that CXCR4 colocalized with known early endosome marker EEA1 20 min-
post CXCL12 addition, as expected (Figure 2-2C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2 Overexpressed CXCR4 in RPE cells recapitulate endogenous CXCR4 signaling 
and internalization dynamics.  
(A) Representative western blot of CXCL12-induced ERK1/2 phosphorylation in HeLa and RPE 
cells overexpressing CXCR4. (B) Flow cytometry analysis of CXCR4 internalization in HeLa 
(endogenous) and RPE CXCR4 (overexpressed receptor). Relative surface expression was 
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calculated by taking the mean fluorescence between a paired stimulus and vehicle control at each 
timepoint. The mean of 4 independent experiments is plotted +/- SEM. (C) Confocal microscopy 
images of CXCR4 internalization labeled by FLAG antibody in RPE cells and an endosomal 
marker EEA1 antibody before and after 25 nM of CXCL12 treatment. Scale bars are 10 µm. 
 
 
Clathrin silencing decreases CXCR4 internalization and increases CXCL12-induced 
ERK1/2 phosphorylation.   
Having established an experimental model to study CXCR4 in RPE cells, we next 
examined the effect of CHC knockdown on CXCR4 internalization and signaling. It has 
previously been hypothesized that CXCR4 is primarily internalized by CME199. To test this 
hypothesis, we used shRNA to reduce functional clathrin triskelia and measured CXCL12-
induced receptor internalization by flow cytometry. Consistent with this hypothesis, CXCR4 
internalization was significantly attenuated, both in rate and in final level (Figure 2-3A). 
However, CXCR4 surface expression was unchanged by clathrin knockdown (Figure 2-3B). 
Next we investigated the effect of clathrin knockdown on CXCL12-CXCR4-mediated ERK1/2 
signaling. In accordance with previous literature, we hypothesized that clathrin knockdown 
would reduce CXCL12-induced signaling. Surprisingly, clathrin knockdown significantly 
increased CXCL12-induced ERK1/2 phosphorylation both pre- and post-agonist addition (Figure 
2-3C-D). To establish that these effects were not artifacts of receptor overexpression, we 
confirmed these observations in HeLa cells (Figure 2-4). Previous reports have indicated that 
caveolae/lipid rafts are essential for complete CXCL12-mediated ERK1/2 phosphorylation193. 
Consistent with this result, we found that inhibition of caveolae/lipid raft (using cholesterol 
depleting agent and caveolae inhibitor nystatin) reduced CXCL12-mediated ERK1/2 
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phosphorylation irrespective of clathrin knockdown (Figure 2-3C-D). As expected, total ERK1/2 
levels were unchanged upon clathrin knockdown (Figure 2-3E-F). It has previously been 
reported that upon receptor stimulus, CXCR4 colocalizes with both adapter protein 2 (AP2) and 
caveolin-1193. Therefore, we hypothesized that clathrin knockdown may increase agonist-induced 
CXCR4 colocalization with caveolin-1. While not statistically significant, a slight increase in 
CXCR4 colocalization with caveolin-1 was observed upon clathrin knockdown after 5-minute 
agonist addition (Figure 2-5A-B). In contrast to previous work, CXCR4 colocalization with 
caveolin-1 was limited irrespective of clathrin knockdown. However, others have shown that 
CXCR4 localizatizes to lipid rafts more generally200,201. Thus, it is plausible that clathrin 
knockdown may shift CXCR4 localization to both caveolin-1 positive and negative lipid rafts. 
Together, these observations support a model where endocytic pathway redundancy may play a 
role in modulating receptor internalization and signaling. Interestingly, a statistically significant 
increase in ERK1/2 phosphorylation was also observed at the 0-min time point (Figure 2-3D) in 
RPE cells overexpressing CXCR4. We believe that this might be due to ineffective clearance of 
activated CXCR4 during serum starvation as receptor internalization is significantly reduced 
upon clathrin knockdown (Figure 2-3A). An increase in ERK1/2 phosphorylation at the 0-min 
time point was not observed with HeLa cells with clathrin knockdown. We believe that this 
discrepancy is likely due to cell type specificity or difference in signal intensity and consequently 
detection sensitivity. 
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Figure 2-3 Clathrin inhibition reduces agonist-induced CXCR4 internalization and 
increases ERK1/2 phosphorylation.  
(A) Flow cytometry analysis of CXCL12-induced CXCR4 internalization upon scramble or 
clathrin knockdown (shRNA 2755 or 7981). Relative surface expression was calculated by 
taking the mean fluorescence between a paired stimulus and vehicle control at each time. The 
mean of 4 independent experiments is plotted +/- SEM. (B) Quantification of relative CXCR4 
surface expression upon clathrin knockdown (shRNA 2755 or 7981). CXCR4 surface expression 
was detected using the FLAG antibody in RPE cells overexpressing CXCR4 and measured by 
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flow cytometry (n = 4, normalized mean +/- SEM). (C-D) Representative western blots and 
quantification of CXCL12-induced ERK1/2 phosphorylation upon scramble or clathrin 
knockdown +/- nystatin (NYS) treatment (50 µM, 30 min pretreatment). For all experiments, 
RPE cells overexpressing CXCR4 were transduced with either scramble or clathrin heavy chain 
shRNA (shRNA 2755) and stimulated with 25 nM CXCL12 for the labeled time course. 
Signaling experiments were conducted in pairs. Western blot bands were normalized to GAPDH 
as well as to 5-min stimulus in the scramble condition. The mean of 4 independent experiments 
is plotted +/- SEM. (E-F) Representative western blot and quantification showing that relative 
ERK1/2 levels are unchanged upon clathrin (shRNA 2755) knockdown. Total ERK1/2 
expression was normalized to GAPDH. The mean of 4 independent experiments is plotted +/- 
SEM. (* denotes statistical significance p < 0.05). 
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Figure 2-4 Clathrin knockdown reduces CXCR4 internalization and increases ERK1/2 
phosphorylation in HeLa Cells.  
(A) Representative western blot showing the effects of clathrin knockdown (shRNA 2755) in 
ERK1/2 phosphorylation in HeLa cells. (B) Quantification of relative CXCL12-induced ERK1/2 
phosphorylation in HeLa cells. Relative ERK1/2 phosphorylation was normalized to ERK1/2 
phosphorylated at 5 min post-CXCL12 stimulus of the scramble knockdown condition. (C) 
Relative reduction of CXCR4 internalization upon clathrin knockdown (shRNA 2755 or 7981) 
by flow cytometry analysis (n = 3, mean +/- SEM, * denotes statistical significance p < 0.05).  
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Figure 2-5 CXCR4 and caveolin-1 colocalization upon clathrin knockdown.  
(A) Representative images of CXCR4 caveolin-1 colocalization in RPE cells stably 
overexpressing CXCR4 (scale bar 10 µm) +/- scramble or clathrin knockdown (shRNA 7981).  
Cells were serum-starved for 4 hrs and stimulated with 25 nM CXCL12 for 5 min. After 
immunofluorescence labeling (FLAG and caveolin-1 antibodies), cells were imaged by TIRF 
microscopy. (B) Quantification of CXCR4-caveolin-1 colocalization in cropped images (Pearson 
correlation coefficient, n = 6, mean +/- SEM) is plotted. While an increase in colocalization is 
observed with clathrin knockdown, it is not statistically significant.   
 
 
The CXCR4 UMB2 antibody immunoblotting is a robust method to detect changes in 
CXCR4 PTM.  
To further investigate the mechanism by which clathrin knockdown increased CXCR4 
signaling, we tested whether clathrin knockdown influenced CXCR4 protein expression. Upon 
conducting these experiments, we noticed that the CXCR4 UMB2 antibody differentially 
detected CXCR4 post receptor stimulus (Figure 2-6A). To validate that the decrease in receptor 
western blot intensity was not due to rapid receptor degradation, we co-labeled overexpressed 
FLAG-CXCR4 with FLAG and UMB2 antibodies pre- and post-CXCL12 stimulus. Consistent 
with our hypothesis, the FLAG antibody robustly detected CXCR4 pre- and post-CXCL12 
stimulus while the UMB2 antibody signal was significantly reduced post-stimulus (Figure 2-6B). 
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To confirm that the UMB2 disappearance was dependent on CXCL12, we stimulated cells with 
EGF and monitored relative CXCR4 levels. As expected, while CXCL12 addition quickly led to 
the disappearance of the UMB2 CXCR4 band, EGF stimulus did not affect CXCR4 detection 
(Figure 2-6C). To exclude that CXCR4 was moving to an insoluble compartment post-stimulus, 
we generated a stable cell line expressing a c-terminally tagged myc CXCR4 construct (CXCR4-
myc) (Figure 2-6D). As expected, while the CXCR4 UMB2 antibody’s ability to detect CXCR4 
post-stimulus was diminished, the myc antibody staining remained constant (Figure 2-6E), and 
hence we do not believe the receptors were degraded. Since the cytosolic c-terminal tail of 
CXCR4 is rapidly post-translationally modified by phosphorylation and ubiquitination upon 
CXCL12 addition, our results suggest that the UMB2 antibody is sensitive to changes in CXCR4 
PTM. Equipped with this new tool, we asked whether overexpressed CXCR4 had different PTM 
kinetics than endogenous CXCR4, and observed no significant changes in CXCR4 PTM kinetics 
between HeLa and RPE CXCR4 cells (Figure 2-6F).  
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Figure 2-6 The UMB2 monoclonal CXCR4 antibody detects changes in agonist-induced 
CXCR4 PTMs.  
(A) Representative western blot of CXCR4 detection upon CXCL12 addition in HeLa cells. 
Cells were stimulated with 25 nM for the described time course and CXCR4 protein levels were 
quantified using the UMB2 monoclonal antibody and normalized to GAPDH. (B) Confocal 
microscopy images of overexpressed FLAG-tagged CXCR4 in RPE cells. CXCR4 was labeled 
using both FLAG and UMB2 antibodies pre- and post-CXCL12 addition (25 nM). Scale bars are 
10 µm). (C) Reduced detection of CXCR4 using the UMB2 antibody is ligand-specific. RPE 
cells overexpressing CXCR4 were treated with either 25 nM CXCL12 or 20 nM EGF for the 
described time course. (D) Schematic of CXCR4 and CXCR4-myc overexpression constructs 
illustrating where the different antibodies used bind to CXCR4. (E) RPE cells overexpressing 
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CXCR4-myc were treated with 25 nM CXCL12 or 20 nM EGF for the described time course and 
CXCR4 was detected by western blotting using the myc or UMB2 antibody. (F) Western blot 
quantification of CXCR4 detection by UMB2 antibody in HeLa and RPE CXCR4 cells. CXCR4 
intensity was normalized to GAPDH and plotted mean +/- SEM from 4 independent 
experiments. 
 
Clathrin inhibition increases CXCR4 PTMs.  
Using the UMB2 antibody, we observed that clathrin knockdown significantly reduced 
CXCR4 detection in both HeLa and RPE cells overexpressing CXCR4 (Figure 2-7A-C). To 
determine whether this was due to a change in receptor expression or PTM state, we used flow 
cytometry and qPCR to assess total endogenous CXCR4 protein and mRNA levels upon clathrin 
knockdown. Interestingly, clathrin inhibition did not affect total endogenous CXCR4 protein 
(Figure 2-7D) or mRNA levels in HeLa cells (Figure 2-8A-B). Cycloheximide chase 
experiments in RPE cells overexpressing c-terminal myc tagged CXCR4 further confirmed that 
clathrin knockdown did not lead to a change in CXCR4 degradation kinetics (Figure 2-8C-D) 
and additionally total CXCR4 labeling using the myc antibody confirmed that CXCR4 total 
protein levels were unchanged in the overexpression CXCR4 model as well (Figure 2-8E). To 
test whether this phenomenon was specific to CXCR4 or more broadly applicable to other 
receptors, we measured EGFR protein levels using an antibody (A-10 clone) not expected to be 
sensitive to receptor PTM202. Interestingly, clathrin knockdown significantly reduced EGFR 
detection in both HeLa and RPE cells as well. EGFR mRNA levels were also unchanged (Figure 
2-8C-D). Since EGFR is internalized by both CME and clathrin-independent 
internalization196,203,204, it is possible that upon clathrin knockdown EGFR internalization is 
compensated by clathrin-independent internalization and consequentially leads to increased 
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receptor degradation as previously reported. Reliable quantification of changes of CXCR4 PTM 
kinetics was not possible for the clathrin knockdown condition in HeLa cells due to the limited 
linear detection range of fluorescent imagers since these cells had a drastically lower initial 
CXCR4 detection intensity. Consequentially, we explored whether clathrin knockdown had any 
effect on CXCR4 PTM kinetics in the overexpression context. As previously reported with 
EGFR172, we did not see a significant change in agonist-induced CXCR4 PTM kinetics upon 
clathrin knockdown in RPE cells overexpressing CXCR4 (Figure 2-7E).   
 
 
Figure 2-7 Clathrin knockdown increases CXCR4 PTM.  
(A-B) Representative western blots showing the effect of clathrin knockdown on CXCR4 and 
EGFR protein levels in (A) HeLa or (B) RPE CXCR4 cells. (C) Quantification of western blot 
analysis of CXCR4 and EGFR protein levels upon clathrin knockdown. Relative receptor 
detection was calculated by taking the ratio of normalized receptor intensity (receptor:GAPDH) 
between scramble and clathrin shRNA transduced cells (0 min time point). Cells were transduced 
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with scramble or clathrin shRNA (2755) for 5 days and serum-starved for 4 hrs prior to each 
signaling/receptor detection experiment. Quantification is mean +/- SEM from 4 independent 
experiments (D) Relative detection of CXCR4 by UMB2 with and without clathrin knockdown 
in RPE cells overexpressing CXCR4. Relative CXCR4 detection was calculated upon receptor 
stimulus (25 nM CXCL12) for scramble and clathrin knockdown cells. CXCR4 detection was 
normalized to the 0 min time point and plotted as mean +/- SEM (n = 4). Similar analysis was 
not carried out for HeLa cells as the signal was outside of the linear range of detection (see (A)). 
(E) Total endogenous CXCR4 detection in HeLa cells. Cells were infected with either clathrin or 
scramble shRNA and serum-starved for 4 hr.  After permeabilization and immunofluorescence 
labeling of endogenous CXCR4, total CXCR4 protein level was measured by flow cytometry. 
Mean +/- SEM is plotted from 3 independent experiments.  
 
 
 45 
 
Figure 2-8 Clathrin knockdown does not change overexpressed CXCR4 degradation 
kinetics in RPE cells or mRNA levels in HeLa cells.  
(A-B) RT-qPCR quantification of clathrin heavy chain (chc), actin, cxcr4, and egfr transcript 
levels upon clathrin knockdown (shRNA 2755) in (A) serum-free or (B) serum conditions. 
Relative transcript levels were calculated using the ΔΔCt method and normalized to gapdh. The 
mean relative gene expression (log2 transformed) +/- SD is plotted. Data was collected with 
duplicate technical replicates from 4 biologically independent experiments. (C) A representative 
western blot showing the effects of clathrin knockdown (shRNA 2755) on overexpressed 
CXCR4-myc protein degradation kinetics. In serum-supplemented media, cells were treated with 
50 µM cycloheximide for the described time course and CXCR4 was detected using UMB2 and 
myc antibodies. (D) Relative UMB2 detection is plotted with mean +/- SEM from 3 independent 
experiments upon scramble or clathrin knockdown. Relative normalized CXCR4 detection was 
calculated by taking the ratio of GAPDH normalized UMB2 detection to the initial time point. 
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No statistical significance was observed. Of note, CXCR4-myc constructs did not have as large 
of a decrease in UMB2 detection upon clathrin knockdown. This is potentially due to the fact 
that these experiments were conducted in serum or potential inhibition of receptor PTMs by myc 
addition to the receptor C-terminus. (E) Quantification of relative myc antibody detection (i.e. 
total CXCR4) upon scramble or clathrin knockdown (shRNA 2755). Total CXC4 protein levels 
were unchanged with clathrin knockdown. Data is plotted with mean +/- SEM from 3 
independent experiments upon clathrin or scramble shRNA knockdown. 
 
Clathrin knockdown decreases CXCL12-dependent and independent cell migration in 
HeLa cells.  
To investigate the implication of CXCL12-induced increase of ERK1/2 phosphorylation 
in clathrin-silenced cell on cell migration, we used a wound-healing assay. Compared to 
scramble controls, irrespective of the type of ligand (CXCL12 vs. FBS), clathrin knockdown 
significantly reduced cell migration in HeLa cells (Figure 2-9). This result corroborated a 
previous report where compared to a wildtype receptor, a mutant CXCR4 has indistinguishable 
ERK1/2 phosphorylation yet has significantly reduced chemotaxis205. Since EGF- and CXCL12-
mediated ERK1/2 phosphorylation have been shown to occur at distinct membrane micro-
domains193, we investigated how EGF-dependent cell migration was affected by clathrin 
knockdown. Similar to CXCL12, clathrin knockdown reduced EGF-induced cell migration 
(Figure 2-10). This suggests that while CXCL12 and EGF signaling mechanisms are distinct and 
differentially regulated by clathrin, the effects on cell migration are comparable.  
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Figure 2-9 Clathrin knockdown decreased CXCL12-dependent and independent cell 
migration in HeLa cells.  
(A) Representative images of a scratch assay time course. HeLa cells transduced with scramble 
or clathrin shRNA (shRNA 2755 or 7981) (day 5) were serum-starved for 4 hrs and treated with 
medium containing 10% FBS or 25 nM CXCL12 in serum-free medium. A line was scratched on 
each plate and relative cell migration was measured by phase contrast microscopy at 0 hr or 20 
hr post scratching. Cell boundaries used to calculate cell migration are outlined in yellow dotted 
line. (B) Quantification of gap area (between dotted yellow boundaries) under each condition. 
Mean gap area +/- SEM is plotted from 4 independent experiments (* denotes statistical 
significance p < 0.05).  
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Figure 2-10 Clathrin knockdown decreases EGF-dependent HeLa cell migration.  
(A) Representative images of a scratch assay time course. Five days post transduction with either 
scramble or clathrin (shRNA 2755 or 7981) knockdown HeLa cells were serum-starved for 4 hrs 
and treated with medium containing 10 ng/mL EGF in serum-free medium. Using a p200 pipet 
tip, a line was scratched on each plate and relative cell migration was measured by phase contrast 
microscopy at 0 hr or 20 hr post scratching. Cell boundaries used to calculate cell migration are 
outlined by the yellow dotted line. (B) Quantification of gap area (between dotted yellow 
boundaries) under each condition. Mean gap area +/- SEM is plotted from 3 independent 
experiments (* denotes statistical significance p < 0.05). 
 
2.5 Discussion  
The expanded role of endocytosis in not only regulating receptor internalization but as a 
signaling platform and master regulator of protein expression is becoming increasingly clear206. 
Here we provide new evidence of how endocytic proteins regulate CXCR4 internalization, 
signaling, and receptor PTM level and highlight the redundancy of endocytic pathways.  
Redundancy of endocytic pathways is not a new idea and work in this area has been 
pioneered with EGFR203. Interestingly, we found that while clathrin knockdown increased 
CXCR4 PTM, this was not the case for EGFR as the antibody used to measure total EGFR has 
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been previously shown to not be sensitive to EGFR PTMs202 and previous research suggests that 
EGFR PTMs are unaffected by clathrin inhibition172. Additionally, while EGFR is preferentially 
internalized by CME at increasing high ligand levels, at times it is also internalized by clathrin-
independent mechanisms203. It was further reported that the endocytic mechanism of EGFR 
internalization predestined receptors for either receptor recycling or degradation in a PTM 
specific manner196,203,204. Consequently, it is possible that clathin knockdown leads to an increase 
in clathrin-independent EGFR internalization and subsequent degradation and provides 
additional evidence that clathrin inhibition differentially impacts receptors such as EGFR and 
CXCR4.  
Upon clathrin knockdown, we observed an increase in CXCR4 PTM pre-stimulus. 
However, total as well as surface receptor levels remained unchanged. Since clathrin is involved 
in multiple aspects of endocytic trafficking (Golgi transport as well as endocytosis), it is possible 
that clathrin knockdown may lead to changes in CXCR4 localization in plasma membrane 
micro-domains or intracellular compartments that are responsible for the observed change in 
receptor PTM. Even though CXCR4 is both phosphorylated and ubiquitinated, we did not 
discern which modification or combination of modifications were responsible for these 
observations and this remains to be a subject of further investigation.  
Interestingly, increased CXCR4 PTM increased and correlated with CXCL12-dependent 
ERK1/2 phosphorylation, further implicating compensatory mechanisms of CXCR4 regulation 
upon clathrin knockdown. It was previously reported that CXCL12-induced ERK1/2 
phosphorylation occurs independently of CXCR4 internalization and that CXCR4 localization in 
cholesterol rich lipid rafts is essential for complete ERK1/2 phosphorylation and that this effect 
was not observed with EGFR receptor193. Indeed, transient silencing of the caveolae resident 
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protein caveolin-1 was reported to lead to an approximately 50% reduction in CXCL12-induced 
ERK1/2 phosphorylation193. Together, these results provide additional evidence that modulation 
of endocytic dynamics regulates receptor biology differently. For CXCR4, clathrin is a negative 
regulator of ERK1/2 phosphorylation and increased receptor PTMs, whereas for EGFR 
dependent ERK1/2 signaling is unaffected and total protein levels are reduced during extended 
periods of clathrin knockdown.  
Interestingly, beta-arrestin (1 and 2) knockdown phenocopies ERK1/2 phosphorylation 
that we observed with clathrin knockdown193. Together these results suggest a potential shared 
mechanism by which clathrin and beta-arrestins are negative regulators of CXCR4-dependent 
ERK1/2 signaling and a compensatory mechanism by which cells increase CXCR4 localization 
in lipid rafts (caveolin-1 positive and/or negative) and become increasingly capable for 
CXCL12-induced ERK1/2 phosphorylation. Additionally, while AP2 inhibition has been shown 
to decrease CXCR4 internalization, it has not been shown to affect ERK1/2 signaling193. 
Coupled with our results, this provides evidence for a model where AP2 is important for CXCR4 
signaling but an independent adapter protein is important for mediating CXCL12-dependent 
ERK1/2 phosphorylation. Unfortunately, co-knockdown experiments of clathrin and caveolin-1 
resulted in cells that were not viable. However, consistent with the model, it is possible that 
clathrin knockdown increases clathrin-independent internalization of CXCR4 (clathrin 
knockdown slightly increased CXCR4/caveolin-1 colocalization) and that unlike EGFR, this 
mechanism of internalization does not lead to increased receptor degradation. 
Surprisingly, a significant increase in ERK1/2 phosphorylation was observed at the 0-
minute time point in CXCR4 RPE cells upon clathrin knockdown. We speculate that this 
observation could be due to the inability of clathrin knockdown cells to efficiently clear activated 
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receptor during serum starvation. This is supported by the observation that clathrin inhibition 
drastically reduced CXCR4 internalization. Interestingly, elevated ERK1/2 phosphorylation did 
not lead to increased cell migration. Clathrin silencing nearly ablated cell migration independent 
of agonist and our observation that clathrin knockdown increases ERK1/2 signaling suggests that 
CXCL12-induced ERK1/2 signaling and cell migration are decoupled or that there may be 
additional roles that clathrin plays in cell migration. While clathrin inhibition has not been 
previously associated with a change in ERK1/2 signaling, previous studies with CXCR4 have 
focused on transient pharmacological inhibition of CME (30 min timescale)171, whereas in this 
study shRNAs were used to specifically knockdown clathrin heavy chain over the course of 3-5 
days) and consequently provides additional evidence for cellular compensation. Additionally, 
this effect appears to be different in HL-60 derived neutrophils where inhibition of clathrin 
abrogated ERK1/2 signaling and polarization207. This could be due to a strong dependence of 
signaling on the clathrin scaffold for a professional migratory cell as well as differences between 
pharmacological vs. genetic perturbations. Our present findings are supported by the work of 
Mines et al. that used a lysine triple mutant CXCR4205. They showed that this mutant CXCR4 
had significantly reduced chemotactic potential independent of ERK1/2 phosphorylation. 
Together with the results presented, this evidence supports a model in which CXCL12-induced 
chemotaxis and cell migration is decoupled from CXCL12-induced ERK1/2 phosphorylation. 
We additionally investigated how EGF-dependent cell migration was affected upon clathrin 
knockdown. Irrespective of ligand, clathrin knockdown significantly reduced cell migration. This 
suggests that while CXCL12 and EGF signaling mechanisms are distinct (different membrane 
localization) and differentially regulated by clathrin, the effects on cell migration are similar. 
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Additionally, it is likely that clathrin is impacting cell migration via an ERK1/2-independent 
mechanism.  
In addition to advancing our knowledge of how endocytosis modulates CXCR4 biology, 
we also report that the UMB2 antibody differentially detects CXCR4 post receptor stimulus. This 
effect is agonist specific, independent of receptor internalization, and not due to differential 
protein extraction. While not directly tested in this work, and since the UMB2 antibody binds to 
the c-terminus of the receptor, we believe that the observed effect is due to changes in CXCR4 
PTM. As CXCR4 is rapidly post-translationally modified upon receptor-ligand binding, it is 
plausible that these modifications interfere with antibody binding. In agreement with previous 
work with EGFR, our results support that clathrin silencing does not modulate receptor PTM 
kinetics172. 
While our study along with a growing number of others supports a dynamic model of 
compensatory endocytic mechanism working together to precisely regulate receptor biology, 
additional research is necessary to determine whether these observations are direct effects of 
endocytic adapter protein-GPCR interactions or secondary effects of modulating this essential 
cellular process. Additionally, due to the extraordinary cell type and tissue specificity of GPCR 
expression, it is necessary to interpret these experiments within this context and it will be 
important to determine whether these observations are tissue- and/or GPCR-specific or more 
broadly applicable to other receptors. Together with knowledge that endocytic dynamics are 
modulated by cancer173,208, further mechanistic investigations of how CME and clathrin-
independent endocytosis regulate receptor biology is likely to reveal novel signaling mechanism 
that may provide new therapeutic strategies to selectively target pathogenic GPCR signaling such 
as CXCR4 in metastatic cancers.  
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Chapter 3 β-arrestin Regulates Communication Between Plasma 
Membrane and Intracellular GPCRs to Control Signaling 
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3.1 Abstract 
It has become increasingly apparent that G protein-coupled receptor (GPCR) localization 
is a master regulator of cell signaling. However, the molecular mechanisms involved in this 
process are not well understood. To date, observations of intracellular GPCR activation can be 
organized into two categories: a dependence on OCT3 cationic channel-permeable ligands or the 
necessity of endocytic trafficking. Using CXC chemokine receptor 4 (CXCR4) as a model, we 
identified a third mechanism of intracellular GPCR signaling. We show that independent of 
membrane permeable ligands and endocytosis, upon stimulation, plasma membrane and internal 
pools of CXCR4 are post-translationally modified and collectively regulate EGR1 transcription. 
We found that β-arrestin-1 (arrestin 2) is necessary to mediate communication between plasma 
membrane and internal pools of CXCR4. Notably, these observations may explain that while 
CXCR4 overexpression is highly correlated with cancer metastasis and mortality, plasma 
membrane localization is not. Together these data support a model were a small initial pool of 
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plasma membrane-localized GPCRs are capable of activating internal receptor-dependent 
signaling events.  
3.2 Introduction 
While extracellular inputs, cell membrane receptors, and resulting transcriptional 
programs are diverse, many receptor-signaling events converge to a reduced number of signaling 
hubs. Cellular mechanisms that mediate this process as well as strategies to control these actions 
remain outstanding questions. Over the last decade, we have learned that GPCR spatiotemporal 
signaling is one mechanism used by cells to translate diverse environmental information into 
actionable intracellular decisions while using seemingly redundant signaling cascades54. 
Extensive research has illustrated that GPCRs elicit distinct signaling events at different plasma 
membrane micro-domains as well as endocytic compartments that are important for cell 
physiology and disease pathogenesis54,100,131,135,153,154,209–211. These studies support a model where 
the location, in addition to magnitude, of a signaling event is important for cellular decision-
making. Others have shown that GPCR site-specific post-translational modifications (PTMs) 
modulate adaptor protein recruitment, GPCR localization, and consequently receptor signaling 
events60,61,212. Together these observations motivated us to reexamine some confounding 
observations pertaining to the relationship of receptor localization, PTM, and signaling for 
CXCR4.  
CXCR4 is a type 1 GPCR that regulates a variety of biological processes such as cell 
migration, embryogenesis, and immune cell homeostasis60,62–65. It is deregulated in 23 different 
cancers and overexpression is often correlated with metastasis and mortality74,75,163,213,214. 
However, surprisingly, plasma membrane expression is not correlated with metastasis163 and in 
some cancer tumor specimens as well as cell culture models, samples with poor CXCR4 plasma 
 56 
membrane localization remain responsive to CXCR4 agonist215–219. CXCR4 is activated by a 
highly receptor-specific 8 kDa chemokine, CXCL1284,220,221. Unlike β-adrenergic receptors 
which have been shown to be activated at intracellular compartments in an OCT3 cationic 
transporter-dependent mechanism153,154, endocytic-independent internalization of CXCL12 is 
unlikely due to its size. Given that receptor activation is dependent on ligand binding or 
transactivation by another receptor222,223, the aforementioned observations are confounding, as 
cells with low plasma membrane CXCR4 remain highly responsive to CXCL12. There are two 
potential explanations for this observation. Firstly, this could be due to spare receptors on the 
plasma membrane as it is well established that only a limited number of plasma membrane 
receptor contribute to signaling224. Alternatively, this could be due to activation of intracellular 
pools of receptors.  
 
3.3 Materials and Methods 
Table 3-1 Reagents 
Inhibitors PN Supplier 
Working 
Concentration 
Gallein 3090/50 R&D Systems 10 µM 
Dynasore 324410 Sigma 100 µM 
MTA D5011 Thermo Fisher 200 µM 
Antibodies    
ms-FLAG-647 A01811-100 Genscript 1:1000 (FC/IF) 
rb-MYC A190-105A Bethyl 1:5000 (WB) 
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Laboratories 
rb-CXCR4 
(UMB2) 
Ab124824 Abcam 
1:2000 (WB), 
1:1000 (FC/IF) 
Rb-phospho-
ERK1/2 
4370S 
Cell Signaling 
Technologies 
1:2000 (WB) 
ms-total-ERK1/2 4696S 
Cell Signaling 
Technologies 
1:1000 (WB) 
rb-phospho-AKT 
S473 
4060S 
Cell Signaling 
Technologies 
1:2000 (WB) 
rb-total AKT C67E7 
Cell Signaling 
Technologies 
1:1000 (WB) 
rb-GM130 12480S 
Cell Signaling 
Technologies 
1:1000 (IF) 
ms-GAPDH sc-47724 
Santa Cruz 
Biotechnology 
1:1000 (WB) 
STREP-568 S11226 Thermo Fisher 1:5000 (WB) 
ms-CXCR4-APC 
(12G5) 
FAB170A R&D Systems 1:200 – 1:2000 (FC) 
rb-β-Arrestin-1 30036S 
Cell Signaling 
Technologies 
1:1000 (WB) 
gt-anti-rb Dylight 
800 
SA5-35571 Thermo Fisher 1:5000 (WB) 
gt-anti-ms Dylight 35518 Thermo Fisher 1:5000 (WB) 
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680 
gt-anti-rb-488-
AlexaFluor-Plus 
A32731 Thermo Fisher 1:1000 (FC/IF) 
Gt-anti-rb-555 84541 Thermo Fisher 1:1000 (IF) 
Gt-anti-rb-
Alexafluor-Plus 
A32733 Thermo Fisher 1:1000 (IF) 
Gt-anti-ms-488 A10680 Thermo Fisher 1:1000 (IF) 
Gt-anti-ms-647 A21235 Thermo Fisher 1:1000 (IF) 
Biologics    
CXCL12 350-NS-050 R&D Systems 12.5 nM 
Pronase 10165921001 Sigma 0.1% Solution 
Lambda 
Phosphatase 
sc-200312A 
Santa Cruz 
Biotechnology 
Manual instructions 
Others    
Streptavidin 
agarose 
20361 Thermo Fisher  
DAPI D9542 Sigma 1µg /mL 
NewBlot PVDF 
Stripping buffer 
928-40032 LiCor Manual instructions 
PVDF 0.22 µm 
membranes 
IB401001 Thermo Fisher NA 
NHS-Sulfo-LC-
biotin 
21335 Thermo Fisher 1 mg/mL 
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ITAQ Universal 
SYBR Green 
1725121 BioRad Manual instructions 
iScript cDNA 
Synthesis Kit 
1706891 RioRad Manual instructions 
Quick-RNA 
miniprep 
R1054 Zymo Research Manual instructions 
 
Equipment 
LiCor Odessey CLX & SA Imagers 
Azure Sapphire 4 laser Imager 
BioRad RT-qPCR ThermoCycler 
 
Cell culture 
HeLa cells were originally obtained from ATCC. HeLa cells were cultured in DMEM media 
(Corning) supplemented with 10% FBS (Corning). Retinal pigment epithelial (RPE) cells were a 
gift from Dr. Sandra Schmid at UT Southwestern. All stable cell lines were directly derived from 
this RPE line. RPE cell lines were cultured in DMEM/F12 media (Corning) supplemented with 
HEPES, glutamate and 10% FBS (Corning). HEK293T cells were obtained from ATCC and 
grown in DMEM (Corning) media supplemented with 10% FBS.  
 
DNA constructs and stable cell lines 
WT CXCR4 was generated as previously described225. K3R and K3R/Q mutant receptors were 
generated by PCR mutagenesis of WT CXCR4 in the pLVX plasmid using the NEB Quick-
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change mutagenesis kit. The low plasma membrane CXCR4 construct was generated by PCR 
amplification (excluding the 5’ plasma membrane HA localization peptide) and restriction 
enzyme cloning using the BsrRI and EcoRI restriction enzymes. All CXCR4 constructs had an 
N-terminal FLAG tag and C-terminal MYC tag for easy antibody detection. Stable cell lines 
expressing WT and mutant CXCR4 receptors were generated by lentiviral transduction. 
Lentiviruses (shRNA and CXCR4 constructs for stable cell lines) were generated by co-
transfecting HEK293T cells with the pLVX transfer plasmid, psPAX2, and pMD2.G lentiviral 
envelope and packaging plasmids. To generate stable cell lines, supernatant media containing 
mature lentiviral particles was collected 4 days post transfection and added to RPE cells, and 
cells stably expressing the constructs were generated via puromycin selection (3 µg/mL). All 
transfections were conducted using Lipofectamine 2000 (Life technologies).  
 
Flow cytometry experiments 
Flow cytometry experiments for plasma membrane receptor labeling were conducted as 
previously described225. For intracellular staining, cells were first disassociated using 50 µM 
EDTA in Ca2+-free PBS and fix for 10 min in 4% paraformaldehyde at room temperature. 
Afterwards, cells were permeabilized using 0.2% Triton-X 100 for 10 min at room temperature. 
Intracellular targets were labeled with primary antibodies for 1 hr at room temperature after 
which cells were washed with PBS and incubated with secondary antibodies for 1 hr at room 
temperature – see Table 3-1 for antibody specifics. Afterwards, cells were washed 1x with PBS 
and 25,000 events were analyzed by the Guava EasyCyte flow cytometer for each experimental 
condition. When co-staining, compensation was conducted post experiment using controls with 
either 488 or 640 fluorescence alone. After fluorescence compensation, the median fluorescence 
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was calculated for each channel and sample as well as for no stain and RPE WT controls (not 
expressing CXCR4). As previously described, median control sample fluorescence was 
subtracted from each sample and data was normalized and plotted as described in each figure 
legend225. An example of flow cytometry raw data, gating strategy, and compensation controls 
are shown in Figure 3-1.         
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Figure 3-1 Representation of flow cytometry data and gating strategy.  
(A) Representative SSC and FSC for flow cytometry analysis. Gate 1 is defined by the red 
polygon. Two samples are shown from the same experiment investigating UMB2 detection. The 
second row of plots correspond to the UMB2 and FLAG detection of CXCR4 in RPE cells 
overexpressing CXCR4 during the CXCL12 stimulus time course.  Quadrants are shown to 
illustrate that while total CXCR4 detection remains constant, UMB2 detection decreases upon 
CXCL12 stimulation. X and Y axis are labeled accordingly. (B) Control experiments used for 
fluorophore compensation and deciding background fluorescence for quantification.  With the 
exception of compensation controls (b) where only 5000 events were recorded, 25,000 events 
were collected in all experiments. All analyses were repeated for a minimum of 3 independent 
biological replicates and is stated in figure legends. 
 
 
Cell signaling, shRNA and inhibitor experiments 
Cells were seeded in 12 well plates 24 hr prior to each signaling experiment achieving 70-80% 
confluence at the experimentation time. Cells were serum-starved in DMEM/F12 media without 
FBS for 4 hr prior to each signaling experiment. For inhibitor experiments (Gallein, Dynasore) 
cells were pretreated for 30 min with the respective inhibitors and throughout the signaling 
experiment. For shRNA experiments, cells were transduced with either scramble or β-arrestin-1 
or 2 shRNA (Table 3-2) for 3 days. shRNA knockdown levels are shown in Figure 3-2. shRNA 
lentiviral particles were generated as described above. Afterwards cells were stimulated with 
12.5 nM CXCL12 (R&D Systems) for the labeled time course. Samples were washed with PBS 
1x and lysed using RIPA buffer supplemented with protease inhibitors (EDTA-free Peirce 
protease inhibitor cocktail) and phosphatase inhibitors (HALT Phosphatase Inhibitor). For 
Lambda Phosphatase experiments, phosphatase inhibitors were excluded in the lysis buffer. 
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After incubating cells with lysis buffer for 10 min on ice, lysates were collected and centrifuged 
at 16,000 g for 45 min at 4 oC. Afterwards lysates were immediately stored at -20 oC or 
processed for immunoprecipitation or western blotting.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2 β-arrestin knockdown confirmation 
(A) Representative western blot illustrating relative β-arrestin-1 knockdown with two different 
shRNAs. (B) Quantification of β-arrestin-1 knockdown efficiency by western blot. Protein 
knockdown was calculated by dividing normalized β-arrestin-1 detection with β-arrestin-1 
shRNA with scramble shRNA. (C-D) Relative β-arrestin-1 and β-arrestin-2 transcript levels 
were calculated using the ΔΔct method normalized to GAPDH and the scramble shRNA control. 
All experiments were conducted in RPE cells overexpressing WT CXCR4 and stimulated with 
12.5 nM CXCL12 for the stated time course. Individual data points from each experiment are 
plotted; mean, SD, median line. Statistical significance (*) denotes p < 0.05.  
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Table 3-2 shRNA constructs 
shRNA (pKLO1 vector) Sequence 
Scramble (non-targeting) Sigma-SCH002 
β-arrestin-1  
TRCN0000230148 
CCGGAGATCTCAGTGCGCCAGTATGCTCGAGCAT
ACTGGCGCACTGAGATCTTTTTTG 
TRCN0000219075 
GTACCGGACACAAATGATGACGACATTGCTCGAG
CAATGTCGTCATCATTTGTGTTTTTTTG 
β-arrestin-2  
TRCN0000280686 
CCGGGATACCAACTATGCCACAGATCTCGAGATC
TGTGGCATAGTTGGTATCTTTTTG 
TRCN0000280619 
CCGGGCTAAATCACTAGAAGAGAAACTCGAGTTT
CTCTTCTAGTGATTTAGCTTTTTG 
 
Immunoprecipitation 
For plasma membrane biotinylation experiments, biotinylated plasma membrane proteins were 
isolated from WCL using high capacity streptavidin agarose beads (Table 3.1). Approximately 
35 µl of bead slurry was added to 350 µl WCL and incubated overnight (~ 18 hr) rotating at 4 
°C. Afterwards, samples were pelleted (centrifuged for 3 min at 2,000 g) and internal (non-
plasma membrane) proteins collected by removing the supernatant. To prevent potential 
biotinylated protein contamination, only 200 µl of supernatant was removed. Afterwards, beads 
were washed 3 times with RIPA buffer containing protease inhibitors. After the final wash, all 
buffer was removed.  
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Western blotting and data analysis  
Prior to western blotting, samples were incubated with Laminelli buffer supplemented with β-
mercaptoethanol (loading buffer). For surface biotinylation samples, β-mercaptoethanol 
concentration was increased 2-fold and samples were incubated at room temperature in the 
loading buffer for 30 min prior to western blotting to denature proteins from beads. Samples 
were run on SDS-PAGE 4-20% BioRad gels (15 well/15 µl or 10 well/50 µl gels). For all 
signaling experiments, 12.5 µl of lysate was loaded while for surface biotinylation assays, 35 µl 
of lysate was loaded. SDS-PAGE gels were run at constant 140 V for approximately 60 min. 
Afterwards, proteins were transferred to PVDF membranes using the iBlot transfer systems 
(mixed range proteins 7 min setting) and membrane incubated in blocking solution (1% BSA in 
TBST) rocking for 1 hr at room temperature. Afterwards, blots were incubated with their 
respective antibodies (Table 3-1) overnight at 4°C. Prior to secondary labeling, blots were wash 
3x for 5 min per wash with TBST. Blots were then incubated with the corresponding secondary 
antibody (Table 3-1) for 1 hr at room temperature. Blots were then washed with TBST as 
described above. Western blots were dried and imaged using a LiCor Odessey SA, LiCor CLX, 
or Azure Biosystems Sapphire System. Data was analyzed using the LiCor image studio software 
to calculate band intensity as previously described225. Specific normalization procedures for each 
experiment are described in the respective figure legends. All statistics were calculated using two 
tailed t-tests.  
 
RT-qPCR experiments 
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Cells were seeded in 6 well plates 24 hr prior to each signaling experiment achieving 70-80% 
confluence at the experimentation time. Cells were serum-starved in DMEM/F12 media for 4 hr 
prior to each signaling experiment. Afterwards, cells were stimulated with 12.5 nM CXCL12 
(R&D Systems) for the respective time courses shown in the figure legends. RNA was extracted 
using the Zymogen RNA extraction kit (R1054) and 1 µM cDNA was synthesized using the 
iScript synthesis kit (BioRad). qPCR assays were conducted using SYBR Green (BioRad) per 
BioRad protocol instructions using 12.5 ng of cDNA for each well. Samples were run in 
duplicate and primers used in this study are shown in Table 3-3. Samples were run on the 
BioRad CFX thermocycler and data was quantified using the ΔΔCT method as previously 
described225.  
 
Table 3-3 qPCR Primers 
Primers Forward Reverse 
GAPDH 
GAGTCAACGGATTTGGTC
GT 
CTTGATTTTGGAGGGATCTCGC 
EGR1 
GGTCAGTGGCCTAGTGAG
C 
GTGCCGCTGAGTAAATGGGA 
β-arrestin-1 
ATCCCTCCAAACCTTCCA
TG 
TGACCAGACGCACAGATTTC 
β-arrestin-2 AAGTGTCCTGTGGCTCAA TTGGTGTCCTCGTGCTTG 
 
Immunofluorescence Assays 
Cells were seeded in 6-well plates on glass coverslips 24 hr prior to each experiment and serum-
starved for 4 hr as described above. Cells were stimulated as specified in each figure legend and 
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immediately washed with PBS and fixed in 4% paraformaldehyde for 10 min at room 
temperature. Cells were permeabilized for 10 min with 0.2% Triton-X100 diluted in PBS and 
subsequently blocked with 2.5% BSA diluted in PBS (blocking solution) for 1 hr. Cells were 
incubated with primary antibody diluted in blocking solution and incubated overnight at 4 oC 
(Table 1). Slides were wash 3x for 5 min each with PBS and incubated with secondary 
antibodies diluted in blocking solution for 1 hr at room temperature (Table 1). Cells were washed 
with PBS 3x, 5 min per wash and incubated with DAPI (Table 1) diluted in PBS for 10 min at 
room temperature. Afterwards, cells were washed with PBS and mounted onto glass slides using 
Fluoromount G. Slides were imaged by spinning disk confocal microscopy as specified in the 
figure legends. Different experimental samples were imaged using the same imaging settings 
each day.   
 
3.4 Results 
We began first by investigating the role of CXCR4 localization on receptor signaling and 
PTM. To do so, we needed a strategy to robustly detect CXCR4 PTM as well as a method to 
modulate receptor localization. We previously established the use of a monoclonal CXCR4 
antibody (UMB2) as a robust tool to study CXCR4 PTM225. This commercially available 
antibody is raised against the C-terminus of the receptor, and upon CXCL12 stimulus quickly 
loses its ability to detect CXCR4 due to receptor PTM225. To attempt to identify the specific 
PTMs responsible, we treated lysates from WT and ubiquitination mutant receptor expressing 
cells with phosphatase. While phosphatase treatment ablated AKT S473 phosphorylation, no 
change in UMB2 detection was observed (Figure 3-3A, B). Since it has also been reported that 
CXCR4 is methylated at C-terminal arginine residues226,227, we tested whether CXCR4 
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methylation was responsible for the agonist-dependent loss in UMB2 detection. Similar to 
phosphatase treatment, protein methylation inhibition did not affect UMB2 detection (Figure 3-
3C). Together these results suggest that the agonist-dependent reduction in UMB2 antibody 
detection is likely due to a combination of CXCR4 PTMs.  
 
Figure 3-3 UMB2 antibody characterization 
(A) Representative western blot of on-blot phosphatase experiment with WT and K3R/Q mutant 
CXCR4 constructs. The K3R/Q mutant receptor is unable to be ubiquitinated at the canonical C-
terminal CXCR4 ubiquitination sites. The on-blot phosphatase blot was incubated with Lambda 
Phosphatase to remove phosphate groups from phosphorylated protein residues. Phospho-AKT 
S473 probing was included as a phosphatase treatment positive control. (B) Quantification of on-
blot phosphatase western blotting experiments. Data was normalized by dividing the UMB2 
detection at 20 min by the 0 min time point for either the WT or K3R/Q receptor. (C) Flow 
cytometry analysis of arginine protein methylation activity on CXCR4 UMB2 detection. As 
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illustrated, cells were treated with methylthioadenosine (MTA 200 µM), an arginine protein 
methyltransferase inhibitor. UMB2 detection was normalized to total CXCR4 fluorescence and 
secondly to 0 min control detection. (D) Flow cytometry analysis of UMB2 antibody detection 
for an extended CXCL12-stimulus time course using WT or K3R mutant CXCR4. UMB2 
detection was normalized to total CXCR4 fluorescence and secondly to 0 min detection for either 
WT or K3R mutant receptor. All experiments were conducted in RPE cells overexpressing WT 
CXCR4 and stimulated with 12.5 nM CXCL12 for the stated time course. Individual data points 
from each experiment are plotted; mean, SD, median line. 
 
To manipulate receptor localization, we generated several mutant receptors that modulate 
the steady-state distribution of CXCR4 within retinal pigment epithelial (RPE) cells (Figure 3-
4A). We chose RPE cells to study CXCR4 overexpression because they do not have appreciable 
endogenous CXCR4 expression, are unresponsive to CXCL12, and were previously established 
as a cell culture model to study CXCR4 biology225. We found that by mutating C-terminal lysine 
residues to arginine (K3R), CXCR4 plasma membrane localization was reduced by more than 
50% (Figure 3-4B, C). While the CXCR4 K3R mutant has been previously used to study 
CXCR4 degradation114,228, we found that these mutations caused a drastic change in the spatial 
distribution of CXCR4. This was due to the unintended creation of an R-X-R motif, which has 
been shown to increase GPCR retention in the Golgi155,161,229. Indeed, mutating a single residue 
in the R-X-R motif (i.e., K3R/Q) restored receptor plasma membrane localization to near WT 
levels (Figure 3-4B). Interestingly, while total CXCR4 expression was unchanged by the K3R 
mutant, the K3R/Q mutant had slightly higher expression compared to WT receptor (Figure 3-
4C). In accordance with previous literature, K3R mutant receptors partially colocalized with a 
Golgi compartment marker (Figure 3-4D)161,229. We also noticed a steady-state population of WT 
CXCR4 retained at the Golgi (Figure 3-4D). Non-plasma membrane localized CXCR4 has been 
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previously reported230  and could potentially be due to the presence of a K-X-K motif, which has 
also been implicated in Golgi protein retention231–233 or receptor overexpression. It is important 
to point out that while we observed partial CXCR4 colocalization with the Golgi, it is evident 
from our microscopy results that CXCR4 is present at other intracellular compartments as well 
(Figure 3-4D).   
 
Figure 3-4 CXCL12-depedent AKT S473 phosphorylation and CXCR4 PTM are 
independent of CXCR4 localization 
(A) Illustration of CXCR4 mutant receptor constructs. The gray box denotes the binding region 
of the UMB2 antibody that is sensitive to CXCR4 PTM. (B) Flow cytometry analysis of 
overexpressed WT and mutant receptor plasma membrane localization in RPE cells. Data was 
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normalized to total receptor and WT plasma membrane expression. (C) Flow cytometry analysis 
of WT and mutant receptor total expression. Individual data points were normalized to WT 
CXCR4 expression. (D) Representative microscopy images illustrating the distribution of WT 
and K3R CXCR4 localization within RPE cells overexpressing each construct. CXCR4 was 
labeled with a FLAG antibody and the Golgi was detected using a GM130 antibody. Scale bar is 
10 µm. Images were captured using 60x magnification on a spinning disk confocal microscope. 
(E) Representative western blot illustrating CXCL12-induced (12.5 nM) AKT S473 
phosphorylation and CXCR4 PTM for WT and mutant receptors. Total CXCR4 was detected 
using a MYC antibody and unmodified CXCR4 by UMB2. (F) Western blot quantification of 
AKT S473 phosphorylation for WT and mutant CXCR4. Relative AKT phosphorylation was 
calculated by normalizing phospho-AKT to total AKT band intensity and secondly to the 5 min 
control time point. (G) Western blot quantification of CXCR4 PTM (i.e. UMB2 detection). A 
decrease in UMB2 detection is correlated to increased CXCR4 PTM. CXCR4 PTM was 
calculated by dividing the UMB2 intensity by the MYC intensity (total CXCR4) and secondly to 
the 0 min time point for the WT receptor. (H) Flow cytometry analysis of agonist-dependent WT 
and mutant CXCR4 PTM. Relative UMB2 detection was determined by dividing median UMB2 
detection by total CXCR4 fluorescence and normalized to 0 min WT CXCR4. All experiments 
were conducted a minimum of 3 times in RPE cells overexpressing WT or mutant CXCR4. 
Individual data points from each experiment are plotted; mean, standard deviation (SD), median 
line. Statistical significance (*) denotes p < 0.05. 
 
Having established methods to modulate receptor localization and monitor PTM, we 
proceeded to investigate the role of CXCR4 plasma membrane localization on CXCL12-
dependent AKT S473 phosphorylation. Since CXCL12 is not membrane permeable, we 
hypothesized that plasma membrane localization is essential for CXCR4 signaling and that 
reducing receptor plasma membrane expression would decrease CXCL12-dependent AKT 
phosphorylation. Compared to WT, both mutants had significantly reduced CXCL12-dependent 
AKT phosphorylation (Figure 3-4E). This was expected as mutating biologically relevant 
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residues may affect G protein coupling to CXCR4. However, surprisingly, there was no 
difference in AKT phosphorylation between high (K3R/Q) and low (K3R) plasma membrane 
localized mutant receptors (Figure 3-4E, F). Additionally, while not explicitly investigated, 
earlier studies using the K3R mutant also reported that CXCL12-induced ERK1/2 
phosphorylation was similar between WT and K3R mutant receptor expressing cells228. Since 
receptor PTM plays a role in mediating receptor signaling, we investigated the effect of receptor 
localization on agonist-induced CXCR4 PTM. Although UMB2 detection continued to decrease 
over a course of three hours (Figure 3-3D), here we focused on the UMB2 detection in the first 
20 minutes post stimulus since we were interested in how early CXCR4 PTM regulates cell 
signaling. We hypothesized that receptor plasma membrane localization is essential for agonist-
dependent PTM as agonist-induced receptor PTM is believed to require ligand binding. 
Surprisingly, irrespective of plasma membrane localization, mutant receptor PTMs were similar 
(Figure 3-4E, G, H). Relative to total receptor expression, initial detection using the UMB2 
antibody for both mutant receptors was also reduced (Figure 3-4E, G, H). We believe this is 
because these mutations occur in the UMB2 antibody-binding region of the receptor (Figure 3-
4A). Alternatively, this could suggest a difference in steady-state mutant CXCR4 PTM.  
Intrigued by the observation of a similar degree of CXCR4 PTM despite vastly different 
plasma membrane localization, we wondered whether internal (non-plasma membrane) pools of 
CXCR4 could be post-translationally modified in response to agonist stimulation and contribute 
to signaling. To investigate this, we examined the localization of CXCR4 PTM during receptor 
signaling. As previously observed225, upon CXCL12 addition UMB2 detection was drastically 
reduced at both plasma membrane and intracellular compartments, suggesting that both plasma 
membrane and internal pools of CXCR4 are post-translationally modified (Figure 3-5A). To test 
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this directly, we developed an assay to selectively isolate plasma membrane proteins from whole 
cell lysate. We used a membrane-impermeable promiscuous biotin molecule to selectively label 
and immunoprecipitate plasma membrane proteins with accessible extracellular domains (Figure 
3-5B). Receptor internalization was blocked throughout these experiments to keep plasma 
membrane and internal receptor pools distinct. We hypothesized that only plasma membrane 
receptors would be post-translationally modified, as internal pools of receptors are inaccessible 
to ligand and endocytosis of plasma membrane receptors is blocked. Surprisingly, we found that 
both surface and internal pools of receptors were post-translationally modified after ligand 
addition (Figure 3-5C, D). To ensure that the labeling strategy was working as expected, we 
probed for GAPDH and biotinylated proteins and showed enrichment in expected localizations 
(Figure 3-5C). To further examine intracellular CXCR4 PTM, we utilized blocking antibodies to 
effectively tune plasma membrane activity of endogenous CXCR4 in HeLa cells by varying the 
concentration of blocking antibodies (Figure 3-5E). While the blocking antibody effectively 
reduced steady-state non-post-translationally modified CXCR4 (Figure 3-5F), agonist addition 
had no effect on CXCR4 PTM after 20 min stimulus irrespective of CXCR4 plasma membrane 
expression level (Figure 3-5G). Together these data support a model where internal pools of 
CXCR4 are post-translationally modified in response to CXCL12. Additionally, plasma 
membrane proteins are required for this process as removal of plasma membrane extracellular 
motifs using protease treatment completely ablated CXCL12-dependent CXCR4 PTM (Figure 3-
6).  
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Figure 3-5 Plasma membrane and internal pools of CXCR4 are post-translationally 
modified upon receptor stimulus 
(A) Representative microscopy images of total and non-post-translationally modified CXCR4 
pre and 20 min post CXCL12 (12.5 nM) stimulation. Total CXCR4 is detected by FLAG 
antibody and non-PTM CXCR4 by UMB2. Images were captured using 60x magnification on a 
spinning disk confocal microscope. Scale bar is 10 µm. (B) Plasma membrane and internal 
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CXCR4 isolation assay schematic. Receptor internalization was blocked using Dynasore (100 
µM) throughout the experiment. At the completion of CXCL12 stimulation, plasma membrane 
proteins from control and CXCL12-treated samples were covalently labeled using promiscuous, 
membrane impermeable NHS-sulfo-biotin. Afterwards, plasma membrane proteins were isolated 
from whole cell lysate (WCL) by immunoprecipitation and WCL, plasma membrane, and 
internal pools of CXCR4 were analyzed for PTM by western blot. (C) Representative western 
blot showing CXCL12-dependent (12.5 nM) CXCR4 PTMs of WCL, plasma membrane, and 
internal CXCR4. STREP and GAPDH were used as experimental validation. (D) Quantification 
of CXCR4 PTMs at plasma membrane and internal locations. CXCR4 PTMs were calculated by 
dividing UMB2 detection (non-PTM CXCR4) by MYC intensity (total CXCR4) and normalized 
to the 0 min WCL sample. (E) Experimental schematic for antibody blocking experiment. 
Incubating cells with different concentrations of CXCR4 antibody reduced plasma membrane-
localized, ligand-accessible, CXCR4. Afterwards, total plasma membrane, total CXCR4 and 
PTM CXCR4 were quantified by flow cytometry. Experiments were conducted in HeLa cells 
stimulated with or without 12.5 nM CXCL12. CXCR4 was blocked using various dilutions of a 
12G5 allophycocyanin-conjugated CXCR4 antibody. Receptor internalization was blocked 
throughout all experiments using Dynasore (100 µM). (F) Initial antibody block reduced relative 
CXCR4 expression and basal UMB2 detection. (G) Relative UMB2 detection 20 min post 
CXCL12 stimulus plotted against relative CXCR4 plasma membrane expression. R2 values are 
shown for each experiment. All experiments were conducted in RPE cells overexpressing 
CXCR4 unless noted. A minimum of 3 independent replicates were conducted for all 
experiments and individual data points from each experiment are plotted; mean, SD, median line.  
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Figure 3-6 Functional plasma membrane proteins are required for CXCR4 PTM 
(A) Experimental design schematic for the protease cleavage assay. Cells were pretreated with a 
protease (pronase 0.11% diluted in PBS) to remove extracellular motifs of transmembrane 
plasma membrane proteins. Afterwards, cells were stimulated with CXCL12 and plasma 
membrane CXCR4 and UMB2 detection was measured by flow cytometry. (B) Flow cytometry 
analysis of protease treatment on functional CXCR4 plasma membrane localization. Plasma 
membrane expression was measured using a FLAG antibody that detected an N-terminal FLAG-
tagged CXCR4 and normalized to total CXCR4 expression. Data was normalized to the 0 min 
control sample. (C) Flow cytometry analysis of protease treatment on CXCR4 UMB2 detection. 
Relative UMB2 detection was calculated by dividing UMB2 signal by total CXCR4 signal 
(FLAG antibody) and then normalized to the 0 min control sample. An increase in UMB2 
detection in the protease treatment sample is expected as the detectable total CXCR4 population 
is reduced due to protease cleavage of the N-terminal CXCR4 FLAG tag. All experiments were 
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conducted in RPE cells overexpressing WT CXCR4 and stimulated with 12.5 nM CXCL12 for 
the stated time course. Individual data points from each experiment are plotted; mean, SD, 
median line.  
 
 
Figure 3-7 Gβγ signaling is essential for CXCR4 signaling and PTM. 
(A) Illustration of the current model of GPCR desensitization. Perturbations used to antagonize 
different components of the pathway are highlighted in red. (B) Representative western blot 
illustrating the effects of Gβγ inhibition (Gallein, 10 µM) treatment on CXCL12-induced AKT 
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S473 and ERK1/2 phosphorylation. Cells were pretreated with Gallein for 30 min prior to and 
throughout each signaling time course. (C-D) Western Blot quantification of AKT S473 and 
ERK1/2 phosphorylation after Gβγ inhibition. Relative signaling protein phosphorylation was 
calculated by dividing the phosphorylated protein detection by total signaling protein detection 
and then normalized to the 5 min time point of the control sample. (E) Representative western 
blot illustrating the effect of Gβγ inhibition (Gallein 10 µM) on CXCR4 PTM. Cells were 
pretreated with Gallein for 30 min prior to and throughout the signaling time course. (F) Western 
blot quantification of CXCR4 UMB2 detection (i.e. PTM) upon Gβγ inhibition. CXCR4 PTM 
was calculated by dividing UMB2 detection (non-PTM CXCR4) by MYC intensity (total 
CXCR4) and normalized to the 0 min control sample. For all experiments a minimum of 3 
independent replicates were performed. All experiments were conducted in RPE cells 
overexpressing WT CXCR4 and stimulated with 12.5 nM CXCL12 for the stated time course. 
Individual data points from each experiment are plotted; mean, SD, median line. Statistical 
significance (*) denotes p < 0.05. 
 
Our findings so far suggest that a signaling cascade may be responsible for intracellular 
communication between plasma membrane and internal receptor pools. Next, we focused on 
identifying the proteins responsible for agonist-dependent internal CXCR4 PTM. G proteins are 
master regulators for GPCR signaling and recent studies have revealed tight spatiotemporal 
regulation of G protein signaling events154,210,234. Upon ligand binding, G protein Gαi and Gβγ 
subunits are released from the GPCR due to guanidine exchange factor activity. Gβγ activates 
GPCR kinases (GRKs), which quickly phosphorylate the C-terminus of activated receptors 
leading to β-arrestin recruitment (Figure 3-7A)235. Therefore, we hypothesized that Gβγ inhibition 
would reduce CXCL12-induced signaling and consequentially CXCR4 PTM. Indeed, 
pharmacological inhibition of Gβγ signaling significantly reduced both ERK1/2 and AKT 
phosphorylation (Figure 3-7B-D). Additionally, Gβγ inhibition completely ablated CXCL12-
dependent CXCR4 PTM (Figure 3-7E, F). 
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Since Gβγ activation leads to GPCR phosphorylation and β-arrestin recruitment, we 
decided to investigate whether β-arrestins were involved in regulating internal CXCR4 PTM. β-
arrestins have been previously implicated as potent messenger molecules. Coined signaling at a 
distance, work from the von Zastrow group proposed a new model for β-arrestin-dependent 
MAPK signaling in which β-arrestin-2, activated by stimulated GPCRs on the plasma 
membrane, traffics to nearby clathrin-coated structures to initiate localized MAPK 
signaling211,236. β-arrestin-1 and 2 are not equal, and significant research has revealed potential 
site-specific PTM and kinase phosphorylation-specific recruitment to CXCR4 as well as other 
GPCRs61. We hypothesized that β-arrestin 1 or 2 are important for communication between 
plasma membrane and internal CXCR4 (Figure 3-7A). β-arrestin-1 knockdown led to a reduction 
in agonist-dependent CXCR4 PTMs while β-arrestin-2 knockdown had no effect (Figure 2-8). β-
arrestin-1 knockdown did not affect ERK1/2 phosphorylation but led to a slight increase in AKT 
phosphorylation (Figure 3-8B-E). This is potentially due to a failure to arrest G protein signaling. 
Intrigued by the potential new role of β-arrestin-1 in regulating the communication between 
plasma membrane and internal pools of receptors, we used the plasma membrane biotinylation 
assay to determine which CXCR4 population is regulated by β-arrestin-1. While β-arrestin-1 
knockdown did not affect plasma membrane-localized CXCR4 PTM, internal CXCR4 PTM was 
reduced (Figure 3-8F-H). Together these data support a mechanism by which Gβγ and β-arrestin-
1 work together to regulate communication between plasma membrane and internal pools of 
CXCR4. 
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Figure 3-8 β-arrestin-1 regulates agonist-induced internal CXCR4 PTM 
(A) Representative western blot illustrating the effect of β-arrestin-1 and β-arrestin-2 knockdown 
on CXCR4 PTM. Relative shRNA knockdown efficiency is shown in Figure 3-1a-c. (B) 
Representative western blot illustrating the effect of β-arrestin-1 knockdown on CXCL12-
dependent AKT S473 phosphorylation. (C) Western blot quantification of CXCL12-dependent 
AKT S473 phosphorylation upon β-arrestin-1 knockdown. Data was normalized to phospho-
AKT:total AKT and to 5 min normalized control shRNA sample. (D) Representative western 
blot illustrating the effect of β-arrestin-1 knockdown on CXCL12-dependent ERK1/2 
phosphorylation. (E) Western blot quantification of CXCL12-dependent ERK1/2 
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phosphorylation upon β-arrestin-1 knockdown. Data was normalized to phospho-ERK1/2:total 
ERK1/2 and to 5 min normalized control shRNA sample (F-G) Representative western blots 
illustrating total, plasma membrane, and internal pools of CXCR4 PTM upon either scramble or 
β-arrestin-1 shRNA knockdown. (H) Quantification of CXCR4 PTM at plasma membrane and 
internal locations upon β-arrestin-1 knockdown. CXCR4 PTMs were calculated by dividing 
UMB2 detection (non-post-translationally modified CXCR4) by MYC intensity (total CXCR4) 
and normalized to the 0 min time point at each location. For all experiments a minimum of 3 
independent replicates were performed. All experiments were conducted in RPE cells 
overexpressing WT CXCR4 and stimulated with 12.5 nM CXCL12 for the stated time course. β-
arrestin-1 knockdown experiments were conducted using two validated shRNAs (Supplemental. 
Fig 3). Individual data points from each experiment are plotted; mean, SD, median line. 
Statistical significance (*) denotes p < 0.05. 
 
Since non-plasma membrane CXCR4 overexpression has been associated with metastatic 
potential215,219, we wanted to investigate whether the internal pool of CXCR4 activated distinct 
signaling pathways compared to plasma membrane-localized receptors. GPCR signaling at 
intracellular compartments has become increasingly apparent and has been shown to activate 
different signaling cascades compared to plasma membrane-localized counterparts54,133,135,237. 
Recent work has shown that activation of G protein signaling at the Golgi and endosomes 
regulates PI4P hydrolysis and PCK1 transcription respectively133,154. Therefore, we investigated 
whether activation of intracellular CXCR4 differentially activates downstream signaling 
compared to plasma membrane receptors. Rather than using mutant receptors that have 
preexisting signaling defects (Figure 3-3), we decoupled the effects of CXCR4 localization from 
these mutations by removing a synthetic plasma membrane localization sequence commonly 
used to increase CXCR4 plasma membrane trafficking114. Consistent with our earlier findings, 
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AKT and ERK1/2 phosphorylation as well as total CXCR4 PTM were not affected by 
modulating receptor localization (Figure 3-9).  
 
Figure 3-9  Modulation of CXCR4 plasma membrane localization does not affect CXCL12-
dependent AKT S473 and ERK1/2 phosphorylation or CXCR4 PTM. 
(A) Flow cytometry analysis of CXCR4 plasma membrane expression of high and low plasma 
membrane (PM) expressing CXCR4 constructs. Plasma membrane expression was normalized to 
total CXCR4 expression and secondly to the 0 min high plasma membrane CXCR4 sample. (B) 
Flow cytometry analysis of high and low plasma membrane expressing WT CXCR4 constructs. 
UMB2 detection was normalized to total CXCR4 expression and secondly to the 0 min control 
samples. (C) Representative western blot illustrating CXCL12-induced AKT S473 
phosphorylation and UMB2 detection in high and low plasma membrane expressing CXCR4 
cells. (D) Western blot quantification of agonist-induced AKT S473 phosphorylation. Data was 
normalized to phospho-AKT S473:total AKT and to 5 min high plasma membrane expression 
sample. (E) Representative western blot illustrating CXCL12-induced ERK1/2 phosphorylation 
in high and low plasma membrane expressing CXCR4 cells. (F) Western blot quantification of 
CXCL12-induced ERK1/2 phosphorylation. Data was normalized to phospho-ERK/12:total 
ERK1/2 and to 5 min high plasma membrane expression sample. All experiments were 
conducted in RPE cells overexpressing WT CXCR4 and stimulated with 12.5 nM CXCL12 for 
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the stated time course. Individual data points from each experiment are plotted; mean, SD, 
median line. Statistical significance (*) denotes p < 0.05. 
 
Since no overt defect in signaling was observed, we hypothesized that signal location is 
responsible for differential CXCL12-dependent transcription. To investigate this, we measured 
early growth response gene 1 (EGR1) transcript levels upon CXCL12 stimulus in RPE cells with 
high and low plasma membrane CXCR4 expression. EGR1 transcription is downstream of the 
ERK1/2 pathway and has been shown to be induced by CXCL12238,239. As expected, WT RPE 
cells (not overexpressing CXCR4) were unresponsive to CXCL12 (Figure 3-10A). However, 
compared to cells with high plasma membrane expression, cells with low plasma membrane 
CXCR4 expression had significantly increased CXCL12-induced EGR1 transcript levels (Figure 
3-10A). This result is inconsistent with the spare receptor model. Furthermore, in agreement with 
previous work133,154,210, this suggests that while cells often use some of the same signaling 
machinery, the localization of a signaling event can lead to different cellular responses. Since β-
arrestin-1 plays a role in activating internal CXCR4, we investigated whether inhibition of β-
arrestin-1 decreased CXCL12-induced EGR1 transcription. Indeed, β-arrestin-1 knockdown 
reduced agonist-induced EGR1 transcript levels (Figure 3-10B), providing additional evidence 
that intracellular pools of CXCR4 are physiologically relevant and that their function is 
dependent on β-arrestin-1.  
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Figure 3-10 Intracellular pools of CXCR4 are primarily responsible for EGR1 
transcription. 
(A) qPCR analysis of EGR1 transcription in WT RPE or RPE cells overexpressing high or low 
plasma membrane localized CXCR4. EGR1 transcript levels were calculated using the ΔΔCT 
method normalized to GAPDH and 0 min high plasma membrane CXCR4. (B) β-arrestin-1 
knockdown reduces CXCL12-dependent EGR1 transcript levels in RPE cells overexpressing 
CXCR4. EGR1 transcript levels were calculated using the ΔΔCT method. All experiments were 
conducted in RPE cells overexpressing WT CXCR4 and stimulated with 12.5 nM CXCL12 for 
the stated time course unless noted. β-arrestin-1 knockdown experiments were conducted using 
two validated shRNAs (Figure 3-2). Individual data points from each experiment are plotted; 
mean, SD, median line. Statistical significance (*) denotes p < 0.05. 
 
3.4 Discussion  
This work has revealed a new element of GPCR signaling whereby plasma membrane 
and internal pools of CXCR4 communicate to regulate cell signaling. These observations are 
distinct from previous work investigating intracellular GPCR signaling, where receptor 
internalization or OCT3 channel-permeable ligands were required131,135,143,153,154,160. CXCR4 
PTM is dependent on Gβγ activation and β-arrestin-1 plays a specific role in regulating 
intracellular CXCR4 PTM. This work expands upon the β-arrestin signaling at a distance concept 
and supports a model where β-arrestins are not only able signal at a distance at the plasma 
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membrane but also regulate communication between plasma membrane and internal GPCR 
populations to influence agonist-dependent transcriptional programs. A model for 
communication between plasma membrane and intracellular pools of CXCR4 and its 
ramification on signaling is summarized in Figure 3-11. There are several potential mechanisms 
for how this communication may occur that warrant additional research.   
 
 
 
 
 
 
 
 
 
Figure 3-11 Proposed model for intracellular CXCR4 PTM 
Schematic summarizing a potential model for communication between plasma membrane and 
internal GPCR pools.  
 
Many new questions regarding the molecular mechanism and physiological relevance of 
plasma membrane and intracellular CXCR4 activation remain unanswered. A limitation of our 
surface biotinylation approach to study intracellular CXCR4 PTMs is that it is unable parse out 
which subpopulation(s) of CXCR4 are being post-translationally modified. While agonist-
induced internal CXCR4 PTM appear to partially occur at the Golgi (Figure 3-4A), CXCR4 may 
also be post-translationally modified at other intracellular compartments. Understanding which 
intracellular CXCR4 populations are post-translationally modified is important for understanding 
which receptor pool is responsible for CXCL12-induced EGR1 transcription. Furthermore, 
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neither β-arrestin or Gβγ are believed to actively post-translationally modify proteins. However, 
Gβγ is a potent kinase activator therefore identification of the kinase or other protein machinery 
responsible for internal CXCR4 PTMs is necessary. Interestingly, Gβγ has been shown to traffick 
to intracellular compartments including the Golgi after agonist activation, independent of 
receptor endocytosis240,241. Understanding the specific PTMs of plasma membrane and internal 
CXCR4 populations could also provide important insights pertaining to the function and fate of 
activated intracellular receptors. It is possible that this mechanism may regulate receptor 
trafficking to the plasma membrane, effectively providing cells with a short-term memory of 
prior signaling events.  
While many questions remain, the data presented expand the role of Gβγ and β-arrestins in 
regulating GPCRs and support a new model of GPCR signaling whereby plasma membrane and 
internal pools of receptors communicate to collectively determine a cellular response. These 
observations may resolve the paradox that while CXCR4 overexpression is associated with 
metastatic potential, plasma membrane localization is not215,216. Additionally, this work supports 
a growing amount of evidence supporting that targeting specifically intracellular GPCR 
populations or the downstream signaling cascades activated by these pools might lead to 
improved therapeutic strategies for treating cancer, cardiovascular disease, and pain 
management154,155,210.  
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Chapter 4 Development of a Spatially Resolved Proteomics 
Approach to Study the CXCR4 Interactome During Endocytic 
Trafficking 
 
Work in this chapter is unpublished. I would like to extend a sincerest thank you to 
Venky Basrur, Datta Mellacheruvu, and Alexey Nesvizhskii for help with mass spectrometry and 
data analysis. Without their help, this work would not have been possible.  
4.1 Abstract  
C-X-C chemokine receptor 4 (CXCR4) is a GPCR and cognate clathrin-coated pit cargo. 
It is an important receptor for a variety of biological processes including immune cell 
homeostasis, embryonic development, and cell migration. CXCR4 signaling is activated by 
agonist binding (CXCL12) and depending on C-terminal tail post-translational modifications 
(PTM), regulates cell proliferation and growth, chromatin remodeling, or cell migration. CXCR4 
expression is deregulated in 23 cancers and has been shown to increase cancer cell metastasis 
towards CXCL12 expressing cells. Additionally, CXCR4 is a HIV co-receptor. While CXCR4 
endocytic trafficking is well established, the molecular players involved in regulating this 
process remain poorly understood. In this work we adopted APEX2 proteomics to study how the 
CXCR4 interactome changes during endocytic trafficking. Unfortunately, we were unable to 
confirm the top protein-protein interactions predicted by our initial proteomics experiments.  
Improved experimental design and additional experiments are necessary to advance this research.  
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4.2 Introduction 
There is compelling evidence that a more complex model of CXCR4 regulation at the cell 
membrane exists and it is unlikely that all of the molecular players involved in this process are 
known. Unfortunately, traditional experimental methodologies are not well suited to address this 
question. Fluorophore properties limit the number of proteins that can be simultaneously 
visualized and it is currently not possible to track protein PTMs or discover new protein-protein 
interactions using live cell imaging without a priori knowledge.  Furthermore, it is not feasible to 
isolate endocytic pits or plasma membrane microdomains for proteomic analysis. Consequently, 
to truly interrogate this process, a technique with both the spatial resolution of microscopy and 
discovery science capabilities of global proteomics is necessary.  
While proteomic approaches to study biological complexity are rapidly revolutionizing 
basic cell biology, traditional mass spectrometry-based proteomics is fundamentally limited by 
spatial resolution. One approach used by researchers to overcome this limitation is co-
immunoprecipitation of protein complexes. However, during this protocol, transient protein-
protein interactions are oftentimes lost and not identified. This is particularly true for membrane 
proteins as the use of harsh detergents to solubilize membrane proteins also disassociates protein 
complexes. Recently, two different approaches – BioID/TurboID and APEX2 - have been 
developed to overcome these limitations and add spatial resolution to proteomics experiments 
242–244. Both techniques use enzymes to promiscuously label neighboring proteins with biotin. 
After protein extraction, biotinylated proteins can be isolated by immunoprecipitation and 
quantified by mass spectrometry to reveal protein-protein interactions. These techniques remove 
the necessity of maintaining protein-complex integrity during protein extraction allowing 
researchers to use harsh protein extraction protocols to solubilize membrane proteins. By 
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creating a fusion protein between a protein of interest and the biotin-labeling enzyme, 
researchers can study the local interactome of their protein of interest.  
BioID and APEX2 work by different mechanisms. BioID is an E. coli biotin ligase that 
has been mutated to promiscuously biotinylate neighboring proteins at lysine residues via a 
Biotin-AMP intermediate244. Originally, BioID experiments were limited to longer time scales as 
effective labeling required 12-18 hours, however, recent advancements have shortened labeling 
time to within a couple minutes242,244. APEX2 is a modified soybean ascorbate peroxidase that 
utilizes hydrogen peroxide to convert biotin-phenol into biotin-phenol radicals 243,245,246. These 
short-lived radicals are highly reactive and covalently label endogenous proteins at electron rich 
tyrosine residues promiscuously in cells (Figure 4-1), which can then be isolated and identified 
by mass spectrometry. One advantage of the APEX2 methodology is that labeling happens 
within 30 seconds and is dependent on hydrogen peroxide, which gives researchers sub-minute 
resolution. This is particularly useful when studying how the GPCR interactome changes during 
receptor signaling and has been used to study δ opioid and β2 adrenergic receptor interacting 
partners during endocytic trafficking247,248.  
 
Figure 4-1 APEX2 Proteomic labeling 
Upon hydrogen peroxide addition, APEX2 converts biotin-phenol into biotin-phenol radicals. 
Biotin-phenol radicals are highly reactive and covalently bind to endogenous proteins at electron 
rich tyrosine residues (20 nm labeling radius). Afterwards, biotinylated proteins can be isolated 
by immunoprecipitation and identified and quantified by mass spectrometry.  
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We recently adopted the APEX2 approach to study how the CXCR4 interactome changes 
during endocytic trafficking. While we were able to confirm proper localization and trafficking 
of the CXCR4-APEX2 fusion protein, we were unable to confirm the biological relevance of the 
top protein targets from our proteomics experiments. To make definite conclusion from this 
work, further experimental optimization and additional mass spectrometry experiments are 
necessary.   
4.3 Materials and Methods 
Cell culture 
Retinal pigment epithelial (RPE) cells were obtained from Dr. Sandra Schmid at UT 
Southwestern and all stable cell lines were derived directly from this line. RPE cell lines were 
cultured in DMEM/F12 media (Corning) supplemented with 10% FBS.  
 
Constructs and stable cell line generation.  
FLAG-CXCR4-APEX2, APEX-NES (cytosol control), Lyn11-EGFP-APEX2 (plasma 
membrane control), and EGFP-APEX2-Rab5 (endosomal control) constructs were generated and 
cloned into the pLVX lentiviral transfer plasmid by PCR and restriction enzyme cloning. 
Individual stable RPE cell lines expressing each construct were generated by lentiviral 
transduction. Lentiviruses were generated in our lab by co-transfecting HEK293T cells (ATCC) 
with the transfer plasmid, psPAX2, and pMD2.G lentiviral envelope and packaging plasmids. 
Cell supernatant containing mature lentiviral particles was collected 4 days after transfection. 
RPE cells were transduced in DMEM/F12 media supplemented with FBS and 10 µg/mL 
polybrene and stable cell lines were generated through puromycin selection (3 µg/mL).  
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Biotinylation experiments  
RPE cells stably expressing an APEX2 construct were incubated with biotin-phenol (500 
µM) for 30 min. Afterwards, hydrogen peroxide (at a final concentration of 1 mM) was added to 
initiate APEX2-mediated biotinylation for 30 seconds at room temperature. The biotinylation 
was quench by washing the cells with quencher solution (10 nM sodium azide, 5 nM Trolox 
dissolved in DPBS) 3 times as previously described246. If cells were going to be used for protein 
or mass spectrometry analysis, samples were lysed (RIPA buffer supplemented with protease 
inhibitor) and either stored for western blotting or immediately used for immunoprecipitation 
(described below). Please see Immunofluorescence section for information on downstream 
immunofluorescence methods.  
 
Cell signaling and time course experiments  
 Prior to all time course experiments, cells were serum-starved for 4 hrs. Serum starvation 
creates a starting point for ligand-induced CXCR4 internalization as well as increased plasma 
membrane localization. In order to track how the CXCR4 proteome changed endocytic 
trafficking, cells were stimulated with CXCL12 (50 nM) for the following time course: 0, 5, 10, 
30, 60, and 180 minutes. While data was collected at later time points, we decided to focus our 
analysis on the 0 and 30 min time points.  Biotinylation experiments using cytosol-localized 
APEX2 (APEX2-NES), plasma membrane-localized APEX2 (Lyn11-EGFP-APEX2), and 
endosome-localized APEX2 (EGFP-APEX2-Rab5) were included as spatial 
references/experimental controls. Additionally, a streptavidin bead control was used to control 
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for off-target protein-bead associations. Besides accounting for off-target biotinylation, these 
controls provided us with expected proteomic hits (spatial references) during CXCR4 endocytic 
trafficking. 
 
Western Blotting  
 Prior to western blotting, samples were incubated with Laminelli buffer supplemented 
with β-mercaptoethanol (loading buffer). Samples were run on SDS-PAGE 4-20% BioRad gels 
(15 well/15 µl or 10 well/50 µl gels). For all signaling and biotinylation experiments, 12.5 - 40 
µl of lysate was loaded. SDS-PAGE gels were run at constant 140 V for approximately 60 min. 
Afterwards, proteins were transferred to PVDF or nitrocellulose membranes using the iBlot 
transfer systems (mixed range proteins 7 min setting) or Thermo Fisher Fast Blotter (mixed 
range transfer). Resulting membranes were incubated in blocking solution (1% BSA in TBST or 
5% nonfat milk in TBST) rocking for 1 hr at room temperature. Afterwards, blots were incubated 
with their respective antibodies (Table 4-1) overnight at 4°C. Prior to secondary labeling, blots 
were wash 3x for 5 min per wash with TBST. Blots were then incubated with the corresponding 
secondary antibody (Table 4-1) for 1 hr at room temperature. Blots were then washed with TBST 
as described above. Western blots were imaged using a LiCor Odessey SA System. 
 
Immunofluorescence Assays 
Cells were seeded in 6-well plates on glass coverslips 24 hr prior to each experiment and 
serum-starved for 4 hr as described above. Cells were stimulated with CXCL12 as specified in 
each figure legend and immediately washed with PBS and fixed in 4% paraformaldehyde for 10 
min at room temperature. Cells were permeabilized for 10 min with 0.2% Triton-X100 diluted in 
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PBS and subsequently blocked with 2.5% BSA diluted in PBS (blocking solution) for 1 hr. Cells 
were incubated with primary antibody diluted in blocking solution and incubated overnight at 4 
oC (Table 4-1). Slides were wash 3x for 5 min each with PBS and incubated with secondary 
antibodies diluted in blocking solution for 1 hr at room temperature (Table 4-1). Cells were 
washed with PBS 3x, 5 min per wash and incubated with DAPI (Table 4-1) diluted in PBS for 10 
min at room temperature. Afterwards, cells were washed with PBS and mounted onto glass slides 
using Fluoromount G. Slides were imaged by spinning disk confocal microscopy as specified in 
the figure legends. Different experimental samples were imaged using the same imaging settings 
each day.   
 
Flow cytometry experiments 
Cells were plated onto 10 cm dishes 24 hrs prior to each experiment, washed and serum-
starved as described above. Afterwards, cells were non-enzymatically disassociated from each 
plate using 50 µM EDTA in Ca2+-free PBS. Cells were pelleted by centrifugation (500 g for 10 
min) and resuspended in serum-free media on ice. Cells were transferred into 1.5 ml eppendorf 
tubes and treated with either a vehicle or ligand and transferred to a heat block at 37 oC for the 
time course described in figure legends. Immediately afterwards, cells were transferred back on 
ice, pelleted (centrifuged 3,000 g for 3 min), and resuspended in 4% paraformaldehyde for 10 
min on ice. Cells were pelleted and incubated with conjugated antibody (Table 4-1) diluted in 
2.5% BSA for 1.5 hrs on ice. Afterwards, cells were washed 1x with PBS and 10,000 cells were 
analyzed by the Guava EasyCyte Flow Cytometer and its accompanied software. Internalization 
was quantified as previously described 197,225.  
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Immunoprecipitation (IP) 
For APEX2 biotinylation mass spectrometry experiments, biotinylated plasma membrane 
proteins were isolated from whole cell lysate using high capacity streptavidin agarose beads. 
Approximately 70 µl of bead slurry was added to 900 µl whole cell lysate and incubated 
overnight (~ 18 hr) rotating at 4 °C. Afterwards, samples were pelleted (centrifuged for 3 min at 
2,000 g) and non-biotinylated/bead bound proteins removed. Beads were washed 5 times with 
RIPA buffer containing protease inhibitors. Ammonium bicarbonate was used for the final wash 
and afterwards all remaining buffer was remove as previously described 249. To ensure high 
capture efficiency, prior to mass spectrometry total protein and biotinylated protein levels were 
evaluated by SDS-PAGE and western blotting. Upon biotinylation IP confirmation, captured 
biotinylated proteins were submitted for mass spectrometry analysis at the UM Medical School 
Proteomics Resource Facility (PRF).  
 
Mass spectrometry  
A minimum of 3 independent biological replicates was submitted for mass spectrometry 
analysis for each experiment. Biotinylated protein peptide fragments were released from beads 
via trypsin digestion. Resulting peptides were dried to completeness in a lyophilizer and 
reconstituted in 0.1% formic acid and cleaned up with C18 tips before being redried 250. Dried 
peptides were reconstituted in formic acid/acetonitrile solution before being analyzed by mass 
spectrometry. Peptides were separated using reverse phase nano-capillary column (PepMap C18, 
2m, 75 m x 25 cm) at a flow rate of 300 nl/min and directly sprayed onto the Orbitrap Fusion 
mass spectrometer using an EasySpray source. The mass spectrometer was set to collect a survey 
scan (resolution 240,000@200 m/z) followed by data-dependent, higher-energy collisional 
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dissociation spectra on the 20 most abundant ions using the instrument settings optimized at the 
Facility. For help with analyzing the proteomic data we were assisted by Alexey Nesvizhskii’s 
lab. Acquired tandem mass spectra were searched against a UniProt protein sequence database 
using the Proteome Discovery software (ThermoFisher). This resulted in a summary matrix of 
protein identifications and the corresponding quantification values across all samples and time 
points. The quantification was performed using spectral counts 251. We took several steps to 
remove contaminants and solely identify high yield peptide hits. Firstly, only high confidence 
hits as determined by the Proteome Discovery software were considered. Secondly, common 
contaminants proteins such as keratins, myosins, and heterogenous ribonucleoproteins were 
discarded. We also removed samples that did not have greater than or equal to 10 spectral counts 
in at least one of the CXCR4-APEX experimental conditions. Once establishing our list of high 
confidence hits, we imported the data into REPRINT, an online tool developed by the 
Nesvizhskii lab for analyzing proteomic data (unpublished). As part of REPRINT, we used the 
statistical scoring tool SAINT 252–254 and prior knowledge of the most common background 
proteins assembled in the Contaminant Repository for Affinity Purification (CRAPome; 
www.crapome.org) to determine high confidence protein-protein interactions 255.   
 
Table 4-1 Reagents 
Reagent Supplier Dilution Experiment 
ms-FLAG-647 Genscript 1:1000 WB, IF, FC 
Gt-anti-rb Dylight 800 Invitrogen 1:10000 WB 
Gt-anti-ms Dylight 680 Invitrogen 1:10000 WB 
Human CXCR4 R-PE Invitrogen 1:500 FC 
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ms-GAPDH Santa Cruz 1:1000 WB 
rb-Phospho-pERK1/2 CST 1:2000 WB 
rb-Phospho-AKTS473 CST 1:2000 WB 
rb-UMB2 ABCAM 1:2000 WB 
STREP-568 Thermo Fisher 1:1000 IF 
STREP-700 Thermo Fisher 1:2000 WB 
CXCL12 R&D Systems 50 nM NA 
Streptavidin agarose Thermo Fisher NA NA 
AMD3100 Sigma 10 nM NA 
AG-1296 Santa Cruz  10 uM NA 
AG-556 Santa Cruz 10 uM NA 
 
 
4.4 Results 
APEX2 is functional when attached to the C-terminus of CXCR4 and spatial references 
Before proceeding to the proteomics experiments we first needed to confirm that generation of 
the APEX2 fusion proteins did not impact APEX2 biotinylation activity. Additionally, since we 
were interested in studying how the CXCR4 interactome changed during endocytic trafficking 
with sub-minute temporal resolution, we needed to confirm that protein biotinylation was 
dependent on both biotin-phenol, and H2O2. To test whether APEX2 was necessary for protein 
biotinylation, we expressed both WT CXCR4 and CXCR4-APEX2 constructs in RPE cells and 
tested whether biotin-phenol and H2O2 addition induced protein biotinylation. Indeed, while 
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expression of CXCR4 alone was unable to induced protein biotinylation, CXCR4-APEX2 
robustly biotinylated proteins 
upon biotin-phenol and H2O2 
addition (Figure 4-2A).  
 
 
Figure 4-2 APEX2 fusion 
proteins retain biotinylation 
activity 
(A) CXCR4-APEX2 fusion 
protein biotinylation activity is 
dependent on APEX2 expression, 
biotin-phenol and H2O2 addition. 
This experiment was conduct in 
CHO cells transiently 
overexpressing FLAG-CXCR4 or 
FLAG-CXCR4-APEX2 
constructs. (B) Confirmation of 
APEX2 fusion protein control 
construct, expression, localization, 
and biotinyation activity in RPE 
cells stably overexpressing each 
construct. Where noted all 
samples were incubated with 
biotin-phenol (100 µM) for 30 
min prior to H2O2 addition  (1 
mM) for 1 min. DAPI was used to 
label nuclei, FLAG antibody to 
label each construct, and 
fluorescently conjugated 
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streptavidin to label biotinylated proteins. All samples were imaged using a 60x objective on a 
spinning disk confocal microscope. Scale bar is 10 µm.  
 
Next we evaluated whether APEX2 biotinylation activity was dependent on biotin-
phenol. To do so we performed the APEX2 biotinylation experiment +/- pre-incubation with 
biotin-phenol. As expected, protein biotinylation was restricted to samples that were treated with 
both biotin-phenol and H2O2 (Figure 4-2B). This was confirmed for each construct used in the 
study (Figure 4-2B).  
As CXCR4 traffics through the cell, it’s local proteome changes significantly and 
therefore the local background (non-specific proteome) also changes. Therefore, it was important 
to consider this in our proteomics experiments. To do so, we used cytosol-, plasma membrane- 
and endosome-localized APEX2 controls. These controls allowed us to probe the local proteome 
at different intracellular locations and identify which CXCR4-APEX proteomic targets were 
bona fide protein-protein interactions instead of non-specific resident bystanders present at the 
same intracellular compartments. Therefore it was necessary to confirm that each APEX2 control 
construct localized properly. As expected, the cytosol-APEX was diffuse within the cytosol, 
plasma membrane-APEX (by Lyn11) was enriched at the plasma membrane, and endosomal 
APEX (by Rab5b) control primarily localized at intracellular vesicles/EEA1-positive endosomes 
(Figure 4-2B and data not shown).  
 
CXCR4-APEX2 retains internalization, signaling and post-translational modification 
ability 
 After confirming that APEX2 fusion proteins retained APEX2 biotinylation activity, we 
needed to confirm that the CXCR4-APEX2 fusion protein did not alter CXCR4 function. 
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Confirmation of biological functions of control constructs was not necessary as only proper 
intracellular localization and APEX2 biotinlyation activity were necessary for the proteomics 
experiments. There were 3 different aspects of CXCR4 function that we tested: receptor post-
translational modification (PTM), signaling, and internalization. Since the C-terminal tail of 
GPCRs are important for regulating GPCR activity, we were concerned that the addition of a 
bulky protein to the receptor C-terminus might interfere with agonist-induced CXCR4 signaling, 
PTM and internalization. While the negative control (BMP receptor ALK2-APEX) was 
unresponsive to CXCL12 addition, cells overexpressing CXCR4-APEX2 robustly induced AKT 
and ERK1/2 phosphorylation (Figure 4-3A). This experiment confirmed that WT RPE cells are 
unresponsive to CXCL12 and that the CXCR4-APEX2 construct was able induce CXCL12 
dependent signaling (Figure 4-3A). Since PTMs regulate CXCR4 protein-protein interactions 
61,256,  we needed to confirm that CXCR4-APEX2 was able to be post-translationally modified. 
To test this, we used the UMB2 antibody to measure agonist-induced CXCR4 PTM. As 
described in Chapters 2 and 3, we have previously established this antibody as a robust tool to 
detect CXCR4 PTM. Indeed, upon CXCL12 stimulus, both WT CXCR4 and CXCR4-APEX2 
proteins were rapidly post-translationally modified (Figure 4-3B). The observed band shift in 
CXCR4 detection was expected as the CXCR4-APEX2 fusion protein has a higher molecular 
weight. This also provided a good control for UMB2 antibody specificity (Figure 4-3B).  AKT 
phosphorylation was included as a signaling control (Figure 4-3B). Interestingly, during this 
process we also discovered that, unlike APEX2, addition of EGFP to the C-terminus of CXCR4 
drastically decreased agonist-induced CXCR4 PTM (Figure 4-3C). This highlights the necessity 
for confirming function of fusion proteins prior to conducting experiments. Interestingly, while 
not to the extent of WT CXCR4, CXCR4-EGFP was able to induce AKT phosphorylation, 
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however this was not quantified (Figure 4-3C). Lastly, we needed to confirm that the CXCR4-
APEX2 fusion protein internalized in response to CXCL12. As expected, CXCR4-APEX2 
rapidly internalized upon agonist addition (Figure 4-3D). CXCR4del19-APEX2 was used as a 
control as this mutant has attenuated internalization (Figure 4-3D) 82.  
 
Figure 4-3 CXCR4-APEX does not alter normal CXCR4 function 
(A) Representative western blot illustrating that RPE cells overexpressing CXCR4-APEX2 
activates AKT S473 and ERK1/2 phosphorylation upon CXCL12 addition. Control RPE cells 
not expressing CXCR4 were unresponsive to CXCL12. (B) Representative western blot 
illustrating that the CXCR4-APEX2 fusion protein exhibits similar agonist-induced UMB2 
detection compared to WT CXCR4. AKT phosphorylation is shown as a control. (C) 
Representative western blot illustrating that the addition of EGFP to the C-terminus of CXCR4 
alters agonist-induced CXCR4 UMB2 detection. EGFP is shown to illustrate total CXCR4 for 
the CXCR4-EGFP fusion construct. AKT phosphorylation is shown as a control. (D) Flow 
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cytometry analysis illustrating that CXCR4-APEX2 internalizes upon CXCL12 stimulation. RPE 
cells overexpressing CXCR4-APEX2 or CXCR4del19-APEX were stimulated with CXCL12 (50 
nM) for the described time course. CXCR4del19 is a mutant receptor that does not internalize 
upon agonist addition. Data was normalized to plasma membrane receptor detection at 0 min and 
is plotted mean +/- SEM. With the exception of the 15 min time point for the CXCR4del19-
APEX mutant (single replicate), 3 independent biological replicates were conducted. Unless 
noted all experiments were conducted in RPE cells overexpressing each stated construct. 
CXCL12 stimulus was 50 nM unless stated.   
 
CXCR4-APEX2 proteomic hits confirm proper fusion protein endocytic trafficking  
Having established that the CXCR4-APEX2 fusion protein retained biotinylation activity 
and did not alter CXCR4 signaling, PTM, or internalization, we proceeded with preliminary 
mass spectrometry experiments. To confirm that the proteomics experiments recapitulated 
CXCR4 trafficking, we conducted Gene Ontology (GO) analysis of the top hits enriched at the 0 
and 30 minute time points. We decided to start with these time points as they represented two 
distinct CXCR4 localizations – plasma membrane and endosomal. Consequently we 
hypothesized that these time points would be easily identifiable and that the CXCR4 interactome 
at each time point would be noticeably different. Prior to CXCL12 stimulus, cell membrane 
proteins were highly enriched compared to cytosolic controls and 30 min post-CXCL12 stimulus 
samples. Interestingly, both clathrin endocytic machinery and lipid rafts (a hallmark of clathrin 
independent endocytosis) proteins were significantly enriched in this population (Figure 4-4) 
257,258. We also observed an enrichment of focal adhesion proteins at both time points (Figure 4-
4). This was particularly promising, as CXCR4 is important for cell migration and recent 
evidence has implicated CXCR4 stimulation in focal adhesion kinase and β-integrin signaling 60. 
As expected, at 30 min post-stimulus, we found significant enrichment of early endosome 
 104 
resident proteins (Figure 4-4). Together, these results suggest the feasibility of our proteomic 
approach to monitor CXCR4 interactome during its trafficking.  
 
Figure 4-4 CXCR4-APEX2 Gene Ontology (GO) Analysis 
(A) Pre-stimulus and (B) 30 min post-CXCL12 stimulus GO analysis. After data processing and 
cytosolic protein background subtraction, proteins with > 10 spectral counts and > 2 fold 
enrichment over other conditions were identified and GO determined. For each time point > 50 
proteins met the criteria. The top 5 GO fold enrichment categories are listed as well as their 
corresponding p-values compared to a random protein population (with Bonferroni correction).  
 
PDGFRβ inhibition does not impact CXCR4 signaling, PTM or internalization in RPE cells 
overexpressing CXCR4.  
Platelet derived growth factor receptor beta (PDGFRβ) was one of the top hits at the 0 
min time point and intrigued by the potential crosstalk with CXCR4, we investigated whether 
PDGFRβ was involved in regulating CXCR4 signaling, internalization, or PTM. CXCR4 and 
PDGFRβ crosstalk has been previously described in glioblastoma cells and researchers found 
that inhibition of either receptor influenced agonist-induced migration by the other receptor when 
activated 222. Therefore, we hypothesized that CXCR4 or PDGFRβ inhibition would impact 
(increase or decrease) CXCL12 or PDGF-BB stimulus-induced AKT phosphorylation. As 
expected, blocking CXCR4 or PDGFRβ activity inhibited CXCL12- and PDGF-BB-dependent 
AKT phosphorylation respectively (Figure 4-5A). However, inhibition of PDGFRβ had no effect 
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on CXCL12-dependent AKT phosphorylation (Figure 4-5A). Likewise, inhibition of CXCR4 did 
not affect PDGF-BB-induced AKT phosphorylation (Figure 4-5A). Next we investigated 
whether PDGF-BB stimulus increased CXCR4 PTM. In contrast to previously literature, PDGF-
BB did not induced CXCR4 PTM (Figure 4-5A). Furthermore, inhibition of PDGFRβ did not 
impact CXCL12-induced CXCR4 PTM (Figure 4-5A). EGF stimulus was used as a control and, 
as expected, it did not impact either CXCL12- or PDGF-BB-induced signaling or CXCR4 PTM 
(Figure 4-5A).  
Next we explored whether PDGF-BB could induce heterologous CXCR4 internalization. 
Since, CXCR4 phosphorylation is believed to be a precursor of CXCR4 internalization, we 
expected that PDGF-BB stimulation would not lead to CXCR4 internalization. Indeed, while 
CXCL12 resulted in rapid CXCR4 internalization, PDGF-BB did not (Figure 4-5B). Together 
these results suggest that PDGFRβ and CXCR4 do not have functional crosstalk in RPE cells.  
 
 
 
 
 
 
Figure 4-5 PDGFRβ and CXCR4 do not have functional crosstalk in RPE cells 
overexpressing CXCR4 
(A) Representative western blot illustrating the effects of CXCL12 and PDGF-BB stimulation 
and receptor inhibition on AKT S473 phosphorylation and CXCR4 PTM. (B) Flow cytometry 
analysis of CXCL12 or PDGF-BB dependent CXCR4 internalization. Data was normalized to 
plasma membrane receptor detection at 0 min and is plotted mean +/- SD. Three independent 
biological replicates were conducted. Unless noted all experiments were conducted in RPE cells 
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overexpressing each stated construct. CXCL12 stimulus was 50 nM unless stated. PDGF-BB 
stimulus was 10 nM unless stated.  Inhibitor concentrations are listed in Table 4-1.  
 
4.5 Discussion  
Through this work we adopted an APEX2 proteomics approach to study how the CXCR4 
interactome changes during endocytic trafficking. While our work suggests that this technique 
has great potential to inform future CXCR4 research, interpretation of our current results is 
limited and to this point we are unable to confirm the biological relevance of the identified 
CXCR4-PDGFRβ protein-protein interaction.  
During this study we encountered several challenges that might be useful to disclose to 
others who are considering using APEX2 proteomics in their work. Firstly, it is important to 
confirm that fusion proteins localize and function as expected prior to conducting any proteomics 
experiments. Early on we discovered that in RPE cells, overexpressed CXCR4 primarily resides 
at intracellular compartments and has poor plasma membrane expression (Figure-4-6). This was 
concerning as we were interested in studying how the CXCR4 interactome changes during 
endocytic trafficking from the plasma membrane to endosomes. Interestingly, while not 
considered at the time, intracellular localization of CXCR4 has been previously reported in 
cancer tumors and cell lines 148,163 suggesting that this intracellular pool might be functional. 
This observation would later inspire the work described in Chapter 3. Regardless, plasma 
membrane localization was necessary for this study. We were able to increase plasma membrane 
trafficking by adding an N-terminal plasma membrane localization peptide (hemagglutinin; HA) 
to CXCR4. Addition of this peptide significantly improved CXCR4 membrane trafficking and 
allowed us to proceed with our study (Figure 4-6A). This was particularly important for this 
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study as plasma membrane-localized CXCR4 are exposed to the cytosol and maximizing the 
difference between experimental conditions is best for assay optimization. 
 
Figure 4-6 Addition of a viral membrane localization peptide to the C-terminus of CXCR4 
improves receptor plasma membrane trafficking  
(A) Flow cytometry analysis of CXCR4-APEX2 and APEX-NES plasma membrane localization 
in RPE cells overexpressing either construct. Green is total CXCR4 detection, purple is plasma 
membrane localized CXCR4-APEX detection and cyan is plasma membrane localized APEX-
NES. APEX2-NES is strictly intracellular and as expected has low plasma membrane detection. 
Therefore, this data suggest that CXCR4-APEX2 has poor plasma membrane localization. (B) 
Flow cytometry detection of HA-CXCR4-APEX2 plasma membrane localization compared to 
APEX2-NES. HA-CXCR4-APEX2 is denoted in red while APEX2-NES is denoted in yellow. 
Compared to (A), the addition of the HA plasma membrane localization peptide drastically 
improves CXCR4 plasma membrane localization.  
 
Moving forward with mass spectrometry analysis there are several other things that 
should be considered. Firstly, it was important to ensure that the bait protein (CXCR4-APEX2) 
spectral counts were equally detected in each experimental condition. This was particularly 
important, as GPCRs are notoriously difficult to isolate from membrane fractions and are highly 
post-translationally modified during endocytic trafficking, which can affect peptide detection. A 
second important feature that unfortunately was overlooked in our experiments was protein 
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expression and biotinylation efficacy of each bait protein, as well as day-to-day experimental 
variability. One issue that we encountered was differences in CXCR4-APEX2, plasma 
membrane, and endosomal spatial reference control spectral counts. While normalization to total 
spectral counts can account for some of this variation, differences in biotinylation efficiency and 
bait protein expression were not considered and made comparisons between spatial references 
and CXCR4-APEX2 difficult particularly when changes in detected protein abundance were 
minor (i.e. ~ 2 fold difference). 
While our initial proteomics results confirmed proper endocytic trafficking and suggested 
that our approach was working, we were unable to confirm the biological relevance of identified 
protein-protein interactions. Our investigation of crosstalk between CXCR4 and PDGFRβ was 
one example where we were unable to confirm the biological relevance of this potential 
interaction in follow-up experiments. This was particularly disappointing as crosstalk between 
CXCR4 and PDGFRβ has been previously reported and shown in impact CXCR4-dependent 
migration222. There are several potential explanations for the differences between these 
seemingly conflicting data. Firstly, it is possible that the CXCR4-PDGFRβ interaction regulates 
an aspect of CXCR4 biology that we did not test such as CXCR4 degradation, cell migration, 
receptor recycling, or downstream transcriptional programming. This is possible as we only 
investigated whether PDGFRβ inhibition altered CXCR4 AKT phosphorylation, PTM, and 
internalization. In Chapter 3 we show that while CXCL12-dependent AKT and ERK1/2 
phosphorylation levels are independent of CXCR4 localization, downstream transcriptional 
implications are drastically altered by CXCR4 localization. Therefore we cannot rule out that a 
similar observation may occur with PDGFRβ inhibition as well. Secondly, it is possible that 
CXCR4 regulates PDGFRβ PTM or internalization, as this was not tested by our experiments. 
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Thirdly, glioblastoma cells are inherently different than RPE cells and it is possible that CXCR4-
PDGFRβ crosstalk may be cell type specific. One reason why GPCRs are advantageous 
therapeutic targets is that they often have highly restricted expression profiles and therefore, 
since RPE cells do not express endogenous CXCR4 it is possible that PDGFRβ-CXCR4 
crosstalk might require the presence of a cell type specific intermediate that is not expressed in 
RPE cells. This led us to further investigate the co-expression of CXCR4 and top hits from our 
proteomics experiment.  
We hypothesized that evolutionarily regulators of CXCR4 would likely be co-expressed 
with CXCR4 or ubiquitously expressed in all cell types. Consequently, proteins that were likely 
non-specific protein-protein interactors would likely have a negative correlation with CXCR4 
expression. To investigate this, we utilized publically available RNAseq data from the Cancer 
Cell Line Encyclopedia (CCLE) and made pairwise comparisons between CXCR4 and top target 
proteins identified in our proteomics screen. Interestingly, CXCR4 and PDGFRβ co-expression 
was slightly negatively correlated (Figure 4-7A-B). Notably, cell lines that had similar 
expression of CXCR4 and PDGFRβ were brain cancer cell lines (data not shown) suggesting that 
the CXCR4-PDGFRβ crosstalk might be cell type specific. For comparison, we conducted the 
same analysis on TOM1 a high-confidence interacting protein identified in a recently published 
APEX2 proteomics experiment investigating δ opioid receptor interacting proteins 247. TOM1 is 
an ubiquitin-linked protein that binds ubiquitin and localizes to endosomes. However prior to the 
work of Lobingier et al., its link to GPCR trafficking was unknown 247. They found that TOM1 
was involved in sorting GPCRs at endosomes, highlighting the potential of using APEX2 
proteomics to study GPCR-protein interactions. Similarly to CXCR4 expression, δ opioid 
receptor expression is cell line specific (Figure 4-7C). However, in contrast to PDGFRβ, TOM1 
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is ubiquitously expressed (Figure 4-7D). Interestingly, while TOM1 was not the highest-ranking 
protein in terms of false discover rate or abundance in their dataset it was selected for follow-up 
investigation 247. Together these data suggest that additional information of bait and prey co-
expression might be a useful additional tool to parse complex proteomic data. A major limitation 
of this approach is that it is well established that RNA transcript levels do not necessarily 
correlate with protein expression 259. However, if this information is considered qualitatively 
instead of quantitatively – i.e. if no transcript is detected, then no protein will be present – or 
used to identify ubiquitously expressed proteins, this approach may have some utility in 
successfully parsing complex proteomic data.  
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Figure 4-7 Relative mRNA abundance in different cell lines 
(A) CXCR4 transcript levels across various cell lines. Data is sorted by CXCR4 abundance. (B) 
PDGFRβ transcript levels in cancer cell lines. Data is sorted by CXCR4 transcript level. 
Interestingly, there is a general trend of increased PDGFRβ expression in cell lines with low 
CXCR4 expression. (C) δ opioid receptor mRNA abundance in different cell lines. Cell lines are 
sorted by receptor expression level. (D) TOM1 transcript levels in cancer cell lines. Data is 
sorted by δ opioid receptor transcript level. Unlike PDGFRβ, TOM1 is ubiquitously express in 
all cell lines tested suggesting that this protein is highly conversed and likely plays an essential 
cellular function. Data was obtained from the Cancer Cell Line Encyclopedia 
(https://portals.broadinstitute.org/ccle).  
 
In conclusion, while we established that APEX2 proteomics could be a useful tool to 
study the CXCR4 interactome and confirmed that the CXCR4-APEX2 fusion protein does not 
drastically alter CXCR4 signaling, PTM, and internalization, I believe that the current data is not 
useful for identifying bona fide CXCR4 interacting partners. To move forward with this research 
project, I recommend repeating all proteomics experiments (CXCR4 time course as well as 
controls and replicates) under the same experimental conditions and with better experimental 
techniques. Additionally, I recommend using intensity-based analysis and parallel reaction 
monitoring to obtain higher resolution mass spectrometry peptide quantification.   
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Chapter 5 Biometrology in Cell Biology 
 
This chapter is currently in preparation for submission. MSD and SS conceived and wrote 
the manuscript. MSD conducted all experiments.  
5.1 Abstract 
As technological and analytical innovations rapidly advance our ability to reveal 
increasingly complex biological processes, the importance of understanding the assumptions 
behind biological measurements and sources of uncertainty are essential for data interpretation. 
This is particularly important in fields such as cell signaling, as due to its importance for both 
homeostatic and pathogenic biological processes, a quantitative understanding of the basic 
mechanisms of these transient events is fundamental to drug development. While developed 
decades ago, western blotting remains an indispensible research tool to probe cell signaling, 
protein expression, and protein-protein interactions. While improvements in statistical and 
methodology reporting have improved data quality, understanding the basic experimental 
assumptions and visual inspection of western blots provides additional information that is useful 
when evaluating experimental conclusions. Using agonist-induced receptor post-translational 
modification as an example we highlight the assumptions of western blotting and showcase how 
clues from raw western blots can hint at experimental variability that is not captured by statistics 
and methods that influences quantification. The purpose of this article is not to serve as a 
detailed review of the technical nuances and caveats of western blotting. Instead using an 
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example we illustrate how experimental assumptions, design, and data normalization can be 
identified in raw data and influence data interpretation.   
5.1 Introduction 
The ability to measure and determine the uncertainty of measurements is fundamental to 
all science. Quantities in cell biology are inherently small, but vary across multiple scales. For 
instance, intracellular protein concentrations range from pM to nM, length of cellular structures 
range from nm to µm, forces generated by molecular motors in the pN range, and timescale of 
signaling transduction events from sub-seconds to hours. Biological systems also interact in 
complicated ways with their internal and external environment, and are dynamically changing, 
making specific attributes difficult to measure. As a consequence, biological measurements often 
result in a distribution of values. Coupled with biological complexity and the observational 
nature of the biological sciences, much of our current knowledge of molecular mechanisms is 
largely semi-quantitative. Recent advancements in -omics approaches as well as technical and 
analytical improvements in microscopy, flow cytometry, and western blotting have ushered in a 
new era of cell biology in which increasingly high-throughput screening and data collection are 
rapidly becoming feasible and minute differences between single cells increasingly quantifiable.  
A measurement consists of two parts: a value determined by a particular method as well 
as the uncertainty of the measured value260,261. While uncertainty is commonly defined as the 
experimental variability in a measurement between replicates, in theory it is additive of all 
uncertainties throughout the experimental process262. One often overlooked source of uncertainty 
as highlighted in the Guide to Expression of Uncertainty in Measurement  (GUM), is the 
incomplete definition of the measurand (thing being measured) and assumptions about what is 
being measured262. Additionally, the possibility of non-representative or incomplete sampling of 
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what was intended to be measured as well as an incomplete definition of the measurand are 
common sources of uncertainty defined within the GUM262. While these additional sources of 
uncertainty are not always readily apparent in biological systems, the inherent nature of 
biological measurements makes understanding these sources of uncertainty critically important 
when interpreting research results.  
While new tools are continually developed to protein abundance, post-translational 
modification (PTM) and cell signaling – flow cytometry, FRET biosensors, microscopy, etc. 
102,263–266 – due to cost and easy implementation, for almost a half-century, western blotting has 
been and remains an indispensable tool for biologist267. In this perspective we take a closer look 
at several factors that may influence western blot interpretation. The purpose of this perspective 
is not to review the best practices for western blotting. Several exceptional articles have 
previously delved into these issues in great deal and readers are strongly encouraged to read if 
interested268,269. Instead we focus on assumptions and aspects of western blots that 
experimentalists should consider when evaluating data.   
5.2 Materials and Methods 
Retinal pigment epithelial (RPE) cells overexpressing CXCR4 were grown to 75% 
confluence a treated with fresh FBS (10%) supplemented media (Gibco PN: 11330-032) 24 
hours before the experiment. Cells were serum starved for 4 hours and treated with 12.5 nM 
CXCL12 (R&D Systems PN: 350-NS-050) for the described time course. Lysates were extracted 
using RIPA buffer (Pierce PN: 89900) supplemented with protease and phosphatase inhibitors 
(Thermo Scientific PN: and respectively) and incubated ice for 20 minutes and centrifuged at 
16,100g for 45 minutes at 4°C. Loading buffer supplemented with β mercaptoethanol was added 
to denature lysates and samples were loaded on a 4-20% BioRad gel and transferred onto PVDF 
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membranes using the iBlot system mixed range transfer (Thermo Scientific). Total protein was 
quantified using the REVERT Total Protein Stain (LiCor PN: 926-11016). Afterwards, blots 
were blocked with 5% BSA (Thermo Scientific PN: 37520) in TBST for 1 hour and incubated 
with primary antibodies ms-GAPDH (1:1000), rb-UMB2 (1:2000) overnight at 4°C. Blots were 
incubated with secondary antibodies (Gt anti ms-700, gt anti rb-800) for 1 hour in 5% BSA in 
TBST and imaged using the LiCor Odyssey SA Imaging System. Afterwards, blots were stripped 
using NewBlot stripping buffer (LiCor PN:928-40032) per manufacture instructions and 
reprobed with rb-MYC antibody (1:5000) as described above. UMB2 antibody was purchased 
from ABCAM (PN: Ab124824), MYC from Bethyl (PN: A190-105A) and GAPDH from Santa 
Cruz Biotechnology (PN: sc-47724). Secondary antibodies were purchased from invitrogen (PN: 
SA535571 and 35518). 
5.3 Results 
Experimental assumptions of western blotting and how they can influence results 
While statistical analyses and the practice of plotting individual data points improve the 
accurate portrayal of experimental results, additional information can be gained from looking at 
raw data. This is particularly true when evaluating western blots or immunofluorescence images. 
One example from our research that showcases several important factors to consider when 
evaluating western blots is shown in Figure 5-1. The goal of this experiment was to investigate 
how CXCR4 (Chemokine receptor 4) mutation (S338/39A and S324/25A) impacts CXCR4 
expression and downstream signaling. In addition to probing for total protein and GAPDH 
(loading controls), CXCR4 was detected using two antibodies: UMB2 and MYC (Figure 5-1). 
UMB2 is a commercial monoclonal antibody that was initially marketed to detect total CXCR4. 
However, it has recently been shown to be sensitive to CXCR4 PTMs225,270. MYC is a polyclonal 
 116 
antibody that detects the MYC epitope tag. Experiments were conducted in RPE cells 
overexpressing individual CXCR4 constructs, which had a C-terminal MYC tag. Wildtype RPE 
cells have negligible endogenous CXCR4 expression and are unresponsive to CXCL12 (CXCR4 
agonist)225,271.  
 
 
Figure 5-1 Western blotting assumptions are not always true 
Representative western blot of non-post-translationally modified (UMB2) and total CXCR4 
(MYC) detection for WT and serine mutant receptors (S338/39A and S324/25A). Total Protein 
and GAPDH staining illustrate protein loading for each replicate. 
 
When initially evaluating a western blot, it is first important to examine the loading 
control. While loading controls such as GAPDH and Actin are still common practice, total 
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protein stain should be used whenever possible269,272–274. However, when not feasible, loading 
controls should be confirmed to not fluctuate with experimental treatment269. In this case, while 
loading controls appear similar within each signaling time course, WT and mutant CXCR4 
(S338/39A and S324/25A) samples are different. While not ideal, loading protein abundance 
variability is relatively common in experiments where multiple cell lines or +/- protein 
knockdown are compared due to unaccounted factors such as differences in cell growth. 
However, this should be considered when interpreting results as it could suggest that cells were 
not grown under the same conditions, were seeded differently or have differential growth rates. 
Protein concentration quantification prior to western blotting can be used to ensure equal 
loading. In this case, unless sample protein concentrations are listed, information about changes 
growth conditions or cell density are indistinguishable by western blot.  A second assumption is 
that subsequent antibody detection is within the linear range. However, unless western blot bands 
are clearly over saturated, is difficult to assess by inspecting individual western blot without 
additional information. Additional details of this are explained in depth in other reviews268,269. 
For experiments with short timescales in particular (i.e. signaling experiments), a third 
assumption is that total signaling protein detection remains constant between experimental time 
points. This is illustrated with the UMB2 antibody detection of CXCR4 (Figure 5-1). The UMB2 
antibody was originally thought to detect total CXCR4, however upon agonist-addition, there is a 
drastic reduction in CXCR4 detection (Figure 5-1 – first 4 lanes). There are several explanations 
for this observation. Firstly, it is possible that CXCR4 is degraded. However, since this 
phenomenon happens within minutes, degradation is highly unlikely and inconsistence with 
knowledge of CXCR4 trafficking225. Alternatively, since CXCR4 stimulus induces receptor 
internalization, it is possible that CXCR4 is more difficult to extract from different intracellular 
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compartments. However, investigation of CXCR4 detection using a second antibody (MYC) 
revealed that this is not the case as MYC detection is not lost upon agonist-addition (Figure 5-1 – 
first 4 lanes) – this has been confirmed in the literature225. A third explanation is that upon 
receptor stimulus there is a change in the ability for the UMB2 antibody to detect CXCR4 which 
is most likely due to CXCR4 PTM as agonist-induced CXCR4 PTM is well established in the 
region where the UMB2 antibody recognizes CXCR461,114,225,256. While the UMB2 antibody has 
become a useful research tool to study CXCR4225,270, understanding why there is a change in 
antibody detection can provide useful information regarding quantification accuracy. This 
phenomenon is not unique to CXCR4 as changes in protein localization, PTM, or structure are 
often essential for proper protein function. However, understanding experimental design caveats 
can provide critical information about the underlying biological principles investigated.  
Incomplete stripping is another common western blotting issue that can lead to inaccurate 
data quantification. This is particularly true when evaluating signaling cascade activity using 
phospho-specific antibodies.  It is common that phospho and total signaling protein antibodies 
are raised in the same species – i.e. both are anti-rb – and therefore removal of the phospho-
specific antibody is required to obtain both total and phosopho-specific band quantification. 
While stripping is relatively effective at removing antibodies, failure to completely remove 
antibody leads to inaccurate quantification, which can alter interpretation in more complicated 
experiments if incomplete stripping is not consistent between samples. An example of 
incomplete stripping is illustrated by MYC antibody staining in Figure 5-1. As we established 
earlier, UMB2 detection is negatively correlated with CXCR4 PTM. Therefore in the scenario 
the MYC antibody is the total signaling protein antibody and UMB2 is PTM sensitive. Close 
inspection of the staining shows that there is a visible decrease in MYC detection at later time 
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points. This is not biologically relevant as we have previously confirmed that CXCR4 is not 
degraded or differentially extracted at the 20 min stimulus time point225. While most of the 
UMB2 staining is removed by stripping, some residual staining remains (data not shown). 
Therefore, earlier time points with higher UMB2 detection have higher background UMB2 
detection, which is subsequently detected in the MYC quantification. This breaks the third 
assumption of western blotting that the total signaling protein is constant during the experiment. 
In this case, when normalizing UMB2 to MYC detection to quantify CXCR4 PTM, this leads to 
an underestimate for actual CXCR4 PTM. Only inspection of raw western blots allows this 
information to become evident to the reader. While in many cases this should not impact overall 
interpretation, in the case of comparisons between WT and mutant proteins or +/- genetic 
knockdown, this may change data interpretation as well as statistical significance if incomplete 
stripping is not consistent between experimental samples.  
A more realist experimental situation, where mutant and WT CXCR4 expression and 
agonist-induced receptor PTM are investigated is illustrated the subsequent western blot lanes (5-
12) in Figure 5-1. CXCR4 S338/39A and CXCR4 S324/25A are phospho-null mutant receptors 
of biological relevant serine residues that regulate CXCR4 internalization and signaling61. As is 
illustrated in Figure 5-1, mutation of just 2 residues in this case can have drastic implications in 
term of CXCR4 detection. We found that at the 0 min time point S338/39A mutant UMB2 
detection was drastically higher compared to WT, while the S324/25A mutant UMB2 detection 
was negligible (Figure 5-1). Superficially, this could suggest that S338/39A increases CXCR4 
expression while the S324/25A mutant is poorly expressed. However, investigation again with 
the MYC antibody clarifies that the S324/25A mutant is expressed (Figure 5-1 – lanes 9-12). 
Again, there are several hypotheses that may explain why this occurs. It is possible that 
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S324/25A completely prevents CXCR4 UMB2 antibody detection due to a change in structure or 
leads to a different CXCR4 PTM state that decreased UMB2 antibody affinity. In contrast, 
S338/39A detection with both the UMB2 and MYC antibody was elevated compared to WT 
CXCR4 suggesting that these mutations may have attenuated degradation and possibly PTM 
(Figure 5-1). Further comparisons of how agonist-induced PTM is influenced by CXCR4 
mutation further highlights the difficulty of solely relying on these data for interpretation as 
incomplete stripping differentially impacts the MYC detection of each of these receptors and 
decoupling of receptor mutation from CXCR4 detectability is not possible in this data alone 
(Figure 5-1). These are important questions that should be considered when evaluating western 
blots and can only be evaluated by raw data inspection. In this case the interpretation of the 
presented results are confounding and additional lines of evidence are necessary for 
interpretation.  
Another important aspect to consider when evaluating western blots is antibody-banding 
pattern. While it is well established that protein PTMs such as ubiquitination or phosphorylation 
can influence protein migration on SDS-PAGE gels, the phospho-specific antibody should detect 
a subset of the total antibody detection bands – in this example total antibody refers to the total 
detection of a single protein such as the total ERK1/2 antibody. In our experiment, this condition 
was met as the UMB2 detection bands are contained within a subset of the MYC (Figure 5-1). 
Failure of this assumption can have similar effects to incomplete stripping and inaccurate 
quantification. Additionally, when evaluating short timescale time course data it is important to 
consider the experimental approach used to collect data as this can be a source of uncertainty 
particularly at early time points. Assume that it takes approximately 30 seconds to take cells 
from the incubator, remove media, and prep samples for protein extraction. In this case, a 1 min 
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stimulus is in practice closer to 1.5 min – a 50% increase in stimulus time. At later time points, 
this is less of an issue as 20.5 min vs. 20 min is only a 2.5% increase in stimulus time. 
Complications arise when collecting data from multiple samples as the order of experiments can 
lead to unintended but relevant differences in collection time. Therefore, caution should be used 
when evaluating experiments with short timescales. Among other approaches to mitigate these 
limitations, conducting all post-experiment processes on ice or using technology (such as 
microfluidics) to precisely add ligands and lyse cells can be used to improve accuracy275.  
While the caveats described in this section are illustrated through comparison of WT and 
mutant CXCR4 PTM, the core assumptions are broadly applicably to other western blotting 
experiments as well as other techniques such as microscopy.  
 
How do western blotting assumptions influence quantification?  
In the aforementioned section, we highlighted some of the caveats to consider in western 
blotting experiments. In this section, we will illustrate how they can influence quantification and 
interpretation. The first step in quantification is data normalization. While technical and 
experimental variability between experimental replicates make this step necessary, normalization 
protocols can drastically influence result interpretation. To illustrate this, a simple hypothetical 
case is illustrated in Figure 5-2A. In this experiment, total protein loading is assumed constant 
and we are making a comparison between a control and treatment (i.e. inhibitors, knockdown, 
mutant protein etc.) group at 0 and 5 min post-stimulus. One approach seen in the literature is to 
normalize values to the initial pre-treatment sample (Figure 5-2B (I)). An issue with this 
approach is that typically pre-treatment (no stimulus in the case) samples have significantly 
lower signal-to noise-ratios compared to later time points in this case when the intensity is much 
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higher. As illustrated in Figure 5-2B (I) by doing so, minor changes in the base of the 
normalization can have significant implications on the relative change in the signal. While the 
reciprocal approach mitigates many of the concerns of amplifying value uncertainty to other 
samples as maximum values have a higher signal to noise ratio, this approach does not permit 
comparisons between maximum values between multiple treatments (Figure 5-2B (II)). A third 
strategy builds on this approach and normalizes samples to the “maximum value time point” of 
the control experiment. Using this approach, the issue of inter-western blot variability is limited 
and by normalizing to the maximum or close to maximum value, concerns of amplifying value 
uncertainty to other time points is greatly reduced (Figure 5-2B (III)). Additionally, by 
normalizing to the maximum value of the control, comparisons between maximum signaling 
values of different treatments is possible. However, due to the normalization, the uncertainty of 
the control maximum value is not considered and the assumption that the treatment does not 
significantly influence other secondary factors such as signaling protein expression need to be 
considered. While the practice of multiple normalization should be limited whenever possible, 
when used it is imperative to describe the approach in explicitly in figure legends and methods.  
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Figure 5-2 Normalization methodology can influence result interpretation 
(A) Hypothetical western blot results for a control and treatment experiment. Circles diameters 
are representative of western blot band intensities and are listed.  (B) Quantification of 
hypothetical western blot results illustrating that normalizing to samples with low signal to noise 
ratio can propagate error throughout normalization and influence result interpretation.  For this 
representation, noise was assumed to be constant for each sample. (i) Hypothetical quantification 
of data when normalized to the 0 min time point of each treatment (i.e. normalizing value: 0.1 
and 0.01 for the control and treatment respectively). (ii) Hypothetical quantification of data when 
normalized to 5 minute time point of each condition (i.e. normalizing value: 1 and 0.91 for the 
control and treatment respectively). (iii) Hypothetical quantification of data when normalized to 
the 5 minute time point of the control condition (i.e. normalizing value: one for all samples).  
 
Other considerations for cell signaling experiments  
 In part due to the recent discoveries of the importance of compartmentalization of 
receptor signaling, a common approach to study the role of a particular organelle or protein in 
regulating signaling is to transiently knockdown or knockout a protein of interest and measure 
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the effect of receptor signaling127,135,211,225,276. However, due to the importance of many of these 
proteins, potential compensatory pathways, and multiple uses of many of the proteins involved in 
endocytic trafficking, it is important to consider secondary affects of knockdowns/knockouts on 
receptor signaling and attempt to decouple secondary effects when possible277. Recent work has 
estimated that over 50% of human proteins have multiple intracellular localizations278. One 
classical example from endocytic trafficking is that clathrin-mediated endocytosis occurs at both 
the plasma membrane and Golgi apparatus279 (Figure 5-3). Additionally, in unpublished work 
from our lab, we have shown that an ubiquitination-deficient CXCR4 mutant receptor artificially 
localizes to intracellular compartments (Chapter 3). Compared to WT, this mutant receptor has 
reduced signaling and agonist-dependent PTM. However, without additional experiments it was 
not possible to determine whether these observations were due to the change in receptor 
localization or mutation. To attempt to decouple these affects, we generated additional constructs 
that restored mutant receptor plasma membrane localization to confirm that these defects were 
indeed due to receptor mutation and not localization. Likewise, due to the fundamental 
importance of signal transduction and receptor regulation, cells have evolved multiple 
compensatory pathways to control receptor endocytosis. Multiple receptors have been shown to 
be internalized by both clathrin- and clathrin-independent endocytic mechanisms (Figure 5-
3)118,119 and specific research of epidermal growth factor receptor (EGFR) has revealed that these 
changes are to due ligand concentration-dependent receptor PTMs116,119. Additionally when 
relating signaling potential back to receptor expression it also is important to consider the spare 
receptor hypothesis as it has been shown that activation of only a subset of receptors is sufficient 
for maximal signaling224. This is particularly true when evaluating the signaling potential of 
receptors when treatment (i.e. WT vs. mutant receptor, protein knockdown etc.) affects receptor 
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trafficking or expression. Lastly, it is important to note that truly rigorous and robust science is 
ideally supported by multiple methodologies and whenever possible, alternative approaches 
implemented to test initial conclusions280,281. 
 
 
 
 
 
 
 
 
 
 
Figure 5-3 Unintended secondary effects of a treatment can influence result interpretation 
A schematic representation of endocytic trafficking that highlights some facts to consider when 
interpreting receptor-signaling experiments. As illustrated by the schematic, receptors can 
internalize by different and potentially compensatory endocytic mechanisms. Additionally, 
clathrin-mediated endocytosis occurs at both the plasma membrane and the Golgi, therefore it is 
important to consider the multiple roles of proteins in cells when conducting isolated 
knockdown/knockouts experiments as it is possible that the observed effect on cell signaling 
might be due to a secondary effect of the treatment or genetic perturbation. While this schematic 
is by no means all encompassing, it highlights some areas that should be considered when 
designing and interpreting receptor-signaling experiments.  Different types of receptors are 
illustrated in different colors, clathrin triskelia by magenta lattice-like structure and dynamin 2 
by the rope-like structure. Internal cellular structures, as well as, the flow of receptors within the 
cell labeled.  
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5.5 Discussion  
Innovation, creativity, and pushing the limits of technology and research methodologies 
are fundamental to scientific innovation. Unfortunately, a byproduct of this process is the 
increased likelihood of honest yet irreplicable results. The failure to replicate could result from 
heterogenous factors that include a lack of standardized reporting and sharing of experimental 
protocols, poor experimental design, statistical problems, or biases in hypothesis testing. In this 
work, we illustrate another important factor that could be playing an important role in the failure 
to replicate experimental results: the fundamental assumptions made to carry out biological 
measurements. We believe implementation of core metrology principles within receptor 
signaling has the potential not only reduce replicability issues but more importantly facilitate 
discoveries that approach absolute scientific truth. Throughout this article, we have revisited the 
fundamental assumptions of western blotting and highlighted important features to consider 
when evaluating western blot data that contribute to data uncertainty.  
As the biological sciences become more quantitative, the replicability of measurements 
between different research groups is the minimum gold standard of science. The culture of 
replicability requires members of the scientific community to become responsible for the gold 
standards of reporting measurement protocols and assumptions. These gold standards do not 
inhibit novelty and significance, but carefully ensure the validity of research findings and 
whether those finding support the conclusions presented in the research.  While western blotting 
was highlighted in this work, many of the core concepts are applicable to other methodologies 
used to measure cell signaling and cell biology processes in general. 
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Chapter 6 Conclusions and Future Directions 
6.1 Overview  
 Through the work described in this thesis, I have investigated the role of endocytic 
trafficking and CXCR4 localization in regulating CXCR4 post-translational modification (PTM) 
and signaling as well as established several new tools to probe CXCR4 biology. 
6.2 Chapter 2 summary and future directions  
In Chapter 2, I investigated the effects of clathrin heavy chain knockdown in regulating 
CXCL12-dependent ERK1/2 phosphorylation and CXCR4 PTM. We found that clathrin heavy 
chain knockdown reduced CXCR4 internalization and increased ERK1/2 phosphorylation. 
Interestingly, increased ERK1/2 activation was dependent on lipid rafts, as sequestration of 
plasma membrane cholesterol abrogated this increase. Additionally, while not statistically 
significant, clathrin knockdown was correlated with increased CXCR4 colocalization with 
caveolin-1 suggesting potential endocytic pathway compensation. During this work we also 
discovered that the monoclonal CXCR4 antibody UMB2 is sensitive to CXCR4 PTM and, using 
this antibody, revealed that clathrin knockdown increased steady-state CXCR4 PTM. Together 
these results support a model where shifting the localization of CXCR4 within clathrin and 
clathrin-independent endocytic pits changes receptor steady state PTM and signaling.     
While there is growing evidence that receptor plasma membrane microdomain 
localization regulates signaling, many questions remain unanswered. One exciting question is 
how receptors move to different plasma membrane microdomains. For EGFR, it has been 
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suggested that ligand concentration-dependent receptor ubiquitination determines clathrin and 
clathrin-independent receptor internalization as well as receptor fate and signaling115,116,119. One 
mechanism by which this could occur is that upon sensing ligand concentration, receptors 
actively cluster in different membrane domains. This could be driven by ligand concentration, as 
ligands (such as CXCL12) have been shown to oligomerize at high concentrations and induce 
receptor clustering84,87. Alternatively, endocytic components (from clathrin- or clathrin-
independent endocytosis) could spontaneously assemble at activated receptors. It is possible that 
receptor PTM and subsequent protein-protein interactions mediate this process. Recently, 
receptor tail phospho-barcodes have been shown to favor different β-arrestin conformations that 
preferentially interact with clathrin or other signaling proteins such as Src. Unfortunately, our 
inability to use live cell imaging to identify receptor PTMs makes direct investigation of these 
hypotheses difficult. Harsh detergents to selectively isolate CXCR4 at different plasma 
membrane microdomains could be used to isolate receptors and the UMB2 antibody to 
subsequently investigate PTM state. However, this approach is restricted to biochemical analyses 
and is incompatible with microscopy. Alternatively, receptors could be selectively tagged upon 
entering specific membrane microdomains. This could be accomplished using a modified BirA 
biotinylation stategy169,198,282. Receptors could be cloned with a BirA acceptor peptide (as 
previously described)198,282 and the BirA enzyme localized to different plasma membrane 
compartments. Therefore, when the receptor moves to a BirA containing plasma membrane 
microdomain, it would be irreversibly biotinylated at the acceptor peptide. By isolating 
biotinylated receptors or co-labeling with streptavidin and UMB2 we could identify whether 
CXCR4 PTM is plasma membrane compartment-specific. Additionally, this could be used to 
relate receptor trafficking back to initial plasma membrane microdomain receptor localization. 
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Using this readout, we could explore the molecular mechanism involved in regulating this 
process. Alternatively, it could be interesting if we could generate a CXCR4 nanobody based on 
the UMB2 antibody. In theory this tool would allow us to track CXCR4 PTM in real time.  
6.3 Chapter 3 summary and future directions   
 In Chapter 3, I investigated the role of receptor intracellular localization as a regulator of 
CXCR4 signaling and PTM.  This project arose serendipitously as we were originally interested 
in studying how CXCR4 PTM impacted CXCR4 signaling and endocytosis. However, I noticed 
that one of the ubiquitin-deficient mutant receptors (K3R) did not traffic properly to the plasma 
membrane and was retained at intracellular compartments such as the Golgi. An observation that 
CXCR4 PTM was unchanged by high plasma membrane and low plasma membrane expression 
inspired us to directly explore whether intracellular CXCR4 is post-translationally modified. 
Using a modified immunoprecipitation approach to selectively isolate plasma membrane and 
intracellular receptors, we found that both plasma membrane and intracellular CXCR4 are post-
translationally modified in response to agonist. In contrast to previous observations in the 
literature131,154, intracellular CXCR4 activation was independent of endocytic trafficking and 
membrane permeable ligand. We found that intracellular CXCR4 PTM was dependent on Gβγ 
and β-arrestin-1 and initial results suggest that activation of intracellular CXCR4 is important for 
CXCL12-dependent Egr1 transcription. This work revealed a new mechanism for intracellular 
GPCR activation and adds to the growing evidence that GPCR localization regulates signaling 
outcomes131,133,143,154. There are several important unanswered questions regarding intracellular 
CXCR4 activation including the location and specific PTM(s) of intracellular CXCR4, the 
molecular mechanism for intracellular CXCR4 PTM, and the downstream consequences of 
intracellular CXCR4 activation. 
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6.3.1 CXCR4 intracellular localization and PTM 
 Identification of the intracellular localization(s) and PTM state of activated CXCR4 is 
necessary. While our preliminary data suggest that a subset of CXCR4 is retained in the Golgi, it 
also stably resides in other secretory pathway intracellular vesicles that we did not stain for 
(Figure 3-2). Furthermore, inspection of agonist-induced CXCR4 PTM using the UMB2 
antibody suggests that CXCR4 PTM may occur at multiple intracellular compartments (Figure 3-
3A). Therefore, characterizing CXCR4’s precise intracellular localizations and PTM state at each 
compartment could provide additional clues regarding the biological function or molecular 
mechanism of intracellular CXCR4 PTM. Comprehensive microscopy experiments investigating 
CXCR4 co-localization at different intracellular compartments or subcellular fractionation could 
be used to quantify the relative CXCR4 abundance and PTM at different intracellular 
compartments pre- and post-CXCL12 stimulation. While these experiments would provide 
information about CXCR4 localization and CXCR4 PTM, the precise PTMs and potential 
compartment-dependent differences are indistinguishable as the UMB2 antibody is not PTM 
specific – site or type.     
The C-terminus of CXCR4 is littered with many sites of phosphorylation, ubiquitination, 
and methylation61,114,205,226,227. Each is thought to serve a distinct regulatory purpose84,256. 
Therefore, it would be interesting to investigate whether there are any differences in site specific 
or type (i.e. phosphorylation, ubiquitination…etc.) of CXCR4 PTM at different localizations. 
Since the UMB2 antibody cannot resolve specific PTMs, it would be interesting to use mass 
spectrometry or PTM-specific antibodies to probe CXCR4 PTMs at different intracellular 
compartments. We previously attempted to use mass spectrometry to identify the PTMs 
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responsible for the CXCL12-dependent loss of CXCR4 UMB2 detection. Our initial efforts were 
unsuccessful for two reasons – (1) difficulty in isolating post-translationally modified CXCR4 
peptides and (2) PTM complexity/poor protease digestion cleavage sites to resolve different 
PTMs. To overcome these issues, we could enrich for post-translationally modified CXCR4 
peptides and use mutant receptors to systematically reduce the PTM complexity of the C-
terminal tail. Alternatively, CXCR4 site-specific phospho-antibodies could be used61,256. 
However, since phosphatase treatment failed to rescue CXCR4 UMB2 detection, we believe that 
a combination of multiple PTMs (i.e. phosphorylation and non-phosphorylation) are responsible 
for changes in UMB2 detection and would not be captured by using phospho-specific antibodies 
alone. Additionally, I have not had reproducible success using CXCR4 phospho-antibodies. 
Regardless, the ability to identify the specific PTMs at plasma membrane and intracellular 
CXCR4 would represent a significant advancement in our understanding of the biological 
relevance of different intracellular receptor populations.  
6.3.2 How are intracellular GPCRs activated? 
  While we discovered that intracellular CXCR4 PTM is dependent on Gβγ activity and β-
arrestin-1, it remains unclear how intracellular CXCR4 are post-translationally modified. Since 
Gβγ activation is necessary for CXCR4 PTM and Gβγ is functional at multiple intracellular 
compartments153,154,210,234, it is possible that localized Gβγ activation is responsible for 
intracellular CXCR4 PTM. To investigate this, we could inhibit Gβγ at different cellular 
compartments and measure CXCR4 PTM. By exploiting the strong interaction between activated 
Gβγ and the C-terminus of GRK2, researchers have developed a suite of localized Gβγ protein 
inhibitors – known as GRK2 C-terminus (GRK2ct)153,154,210,234. These inhibitors work by 
recruiting activated Gβγ to nonfunctional GRK2ct, preventing activation of endogenous GRKs. 
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By adding peptide localization motifs to localize GRK2ct to different cellular compartments, 
researchers have used this approach to study Gβγ-dependent processes at the plasma membrane, 
Golgi, and endosomes153,154,210,234. A similar approach could be implemented to investigate 
whether localized Gβγ activation is necessary for intracellular CXCR4 PTM. One caveat of this 
approach is that it fails to decouple whether Gβγ was activated at the plasma membrane and 
trafficked to an intracellular compartment or is directly activated at an intracellular compartment.  
Interestingly, it is known that Gβγ rapidly translocates from the plasma membrane to 
different intracellular compartments including the Golgi upon GPCR activation240,241. Gβγ 
translocation occurs at a variety of timescales (from on the order of seconds to many minutes), is 
reversible, and independent of receptor internalization283. This phenomenon is ubiquitous and 
occurs with all Gβγ complexes and endogenously in multiple cell types283. However, the precise 
biological function and mechanism by which this Gβγ translocation occurs remains unclear. One 
proposed mechanism for Gβγ translocation is that agonist-induced Gβγ depalmitoylation 
decreases plasma membrane localization and leads to the rapid diffusion to intracellular 
compartments284. Using parathyroid hormone receptor as a model system, the Vilardaga group 
recently found that Gβγ exchanges between activated β2-adrenergic receptors and PTHR and this 
promoted sustained endosomal PTHR cAMP signaling143. Interestingly, while it was initially 
thought that G proteins and β-arrestin GPCR binding was mutually exclusive, recently 
researchers have found that Gβγ, β-arrestin, and GPCRs can form mega signaling 
complexes143,144. Building on this model, it is possible that β-arrestins plays a role in mediating 
Gβγ translocation and would be interesting to investigate agonist-dependent Gβγ and β-arrestin-1 
trafficking as well as Gβγ translocation in β-arrestin-1 knockdown cells. Since it is well 
established that activated Gβγ recruits GRKs to phosphorylate GPCRs, this could be a potential 
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mechanism for intracellular activation. Alternatively, β-arrestin-1 itself may dissociate from 
activated plasma membrane CXCR4 and traffic to intracellular CXCR4 to facilitate receptor 
PTM. Interestingly, there is also experimental precedence for GPCR-independent β-arrestin 
trafficking; β-arrestin 2 has been shown to traffic independently of its activated GPCR to nearby 
clathrin-coated structures on the plasma membrane to induce ERK1/2 signaling211. Several 
potential hypotheses are illustrated in Figure 6-1.  
 
 
Figure 6-1 Potential mechanism for intracellular CXCR4 post-translational modification.  
(A) Gβγ and β-arrestin-1 co-translocate to intracellular compartments to initiate intracellular 
CXCR4 PTM. (B) β-arrestin-1 regulates Gβγ intracellular translocation to initiate intracellular 
CXCR4 PTM. (C) β-arrestin-1 activates an unknown signaling cascade that leads to intracellular 
CXCR4 PTM. (D) β-arrestin-1 translocates to intracellular compartments to activate CXCR4.  
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Figure 6-2 GRK2/3 inhibition reduces agonist-induced CXCR4 PTM  
(A) Representative western blot showing agonist induced CXCR4 PTM upon GRK2/3 inhibition. 
B) Western blot quantification of CXCR4 PTMs upon GRK2/3 inhibition. CXCR4 PTMs were 
calculated by dividing UMB2 detection (non-PTM CXCR4) by MYC intensity (total CXCR4) 
and normalized to the 0 min control sample. All experiments were conducted in RPE cells 
overexpressing WT CXCR4 and stimulated with 12.5 nM CXCL12 unless specified. GRK2/3 
activity was inhibited by Cmp101 (10 µM). Cells were pretreated for 30 min prior to and 
throughout the experiment. (Individual data points from each experiment are plotted; mean +/- 
SD, median line. n=3 for all experiments.  
 
It is important to note that neither β-arrestin-1 nor Gβγ are known to actively post-
translationally modify GPCRs, therefore it is likely that an unidentified kinase, ubiquitin ligase 
or other PTM-capable protein is directly involved in intracellular CXCR4 PTM. Particularly, if 
localized Gβγ activity is necessary for intracellular CXCR4 PTM, GRKs are likely candidate 
kinases. Intrigued by this hypothesis, we preliminarily investigated the role of GRK2/3 in 
regulating CXCR4 PTM. As expected, pharmacological inhibition of GRK2/3 increased agonist-
induced CXCR4 UMB2 detection (Figure 6-2). Interestingly, while GRK2/3 inhibition led to a 
reduction in CXCR4 PTM, especially at later time points, CXCR4 UMB2 detection decreased 
suggesting that some CXCR4 PTMs are GRK2/3 independent. Unfortunately, we did not have 
time to investigate whether GRK2/3 inhibition specifically inhibited plasma membrane or 
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intracellular CXCR4 PTM – it would be particularly interesting to see whether GRK2/3 
inhibition ubiquitously decreases CXCR4 PTM or is location-specific.  
Alternatively, it is possible that β-arrestin-1 and/or Gβγ activate other signaling pathways 
that lead to intracellular CXCR4 PTM. If this is the case, there are two different approaches that 
could be used to identify the molecular mechanism. Firstly, I would continue to investigate 
whether other known downstream signaling proteins were involved in intracellular CXCR4 
PTM. To do this, we could systematically inhibit downstream signaling proteins and measure 
changes in CXCR4 PTM. Preliminary data suggest that neither AKT or ERK1/2 activation are 
required or CXCR4 PTM (data not shown). However, CXCR4 activation is also known to 
activate both JAK/STAT signaling as well as calcium signaling84 which could play a role in 
modulating intracellular CXCR4 PTM. Alternatively, an unknown signaling mechanism could be 
responsible for intracellular CXCR4 PTM. To investigate this, we could start by conducting a 
kinase inhibitor screen to identify kinases that reduce intracellular CXCR4 PTM. Alternatively, 
APEX2 proteomics can be used to identify CXCR4 interacting partners at intracellular locations. 
This could be accomplished by removing plasma membrane-localized CXCR4 and enriching for 
protein interactions at intracellular compartments. Finally, a genome-wide CRISPR screen could 
be used to determine regulators of CXCR4 PTM. In this case, plasma membrane and intracellular 
CXCR4 agonist-induced UMB2 detection could be used as the readout.    
6.3.3 What is the biological relevance of intracellular CXCR4 activation?  
Additional investigation of the downstream implications of intracellular GPCR activation 
in terms of signaling and receptor fate is another exciting future direction. While we found that 
Egr1 transcript levels correlate with intracellular CXCR4 activation, whether intracellular 
CXCR4 is actually activated should be directly tested. To do so, we could use live cell 
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microscopy tools to confirm that intracellular CXCR4 activation using mini-G proteins (mG). 
mG proteins are miniaturized version of the G proteins that are fluorescently tagged that upon 
receptor stimulus, localize to activated GPCRs285,286. While preliminary, using the mGi protein, 
we saw a CXCL12-dependent increase in mGi-CXCR4 colocalization (Figure 6-3). Identified 
intracellular puncta suggest that intracellular CXCR4 activation occurs at endosomal 
compartments and potentially the Golgi (yellow arrows in inset images Figure 6-3). Interestingly, 
while not directly tested, others have suggested that endosomal CXCR4 signaling is necessary 
for complete AKT activation135. Additional replicate experiments are necessary to confirm these 
observations and it would also be interesting to explore whether these observations are 
independent of GPCR endocytosis, Gβγ, or β-arrestin-1. To do so, analogous experiments could 
be conducted in the presence of inhibitors or shRNA knockdowns for each of these 
proteins/pathways. In agreement with our previous findings, I expect that mGi and intracellular 
CXCR4 agonist-induced colocalization is independent of CXCR4 internalization but requires 
Gβγ and β-arrestin-1. We could further extend these experiments to test whether Gβγ localization 
regulates this process by using localized GRK2ct inhibitors.  
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Figure 6-3 mini-G protein CXCR4 agonist-induced colocalization  
Representative confocal microscopy images of Venus-mGi and CXCR4 colocalization upon 
CXCL12 (12.5 nM) stimulus. CXCR4 is labeled using the FLAG antibody whereas the Golgi is 
denoted by GM130 staining. Yellow arrows show colocalization between mGi and CXCR4. 
Scale bar 10 µm. Images were captured using 60x magnification on a spinning disk confocal 
microscope. This data is n = 1.  
 
It would also be interesting to investigate whether there are other transcriptional 
implications besides Egr1 transcription of intracellular CXCR4 activation. For example, it is 
possible that activation of intracellular GPCRs promote cell growth and proliferation whereas 
activation at the plasma membrane primarily activates transcription of chemotactic factors. 
Additionally, the temporal sequence of downstream signaling events would be interesting to 
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explore. RNAseq experiments could be used to determine the broader transcriptional 
implications of CXCR4 activation and coupled with localized inhibition of CXCR4 to discover 
transcriptional consequences of localized GPCR signaling. Additionally, it would be interesting 
to know which transcriptional implications are G protein-dependent vs. independent.  
 The long-term implications and receptor fate of intracellular CXCR4 PTM are also 
unknown. Inspired by recent work from the Luker lab, it is possible that intracellular CXCR4 
PTM functions as memory for subsequent signaling events. Researchers found that conditioning 
cells with growth factors prior to CXCL12 increased the number of cells that activate CXCL12-
dependent signaling cascades287. This finding provides two insights: firstly only a subset of cells 
actively signal and secondly cells have a short-term memory of prior signal exposure that 
influences subsequent rounds of signaling. It is possible that CXCR4 PTM could play a role in 
regulating this process. Additionally, since only a subset of cells signal, it would be interesting to 
multiplex signaling with CXCR4 PTM and internalization. This could be accomplished by flow 
cytometry.  
 We also could investigate how multiple rounds of CXCL12 stimulation affect CXCR4 
membrane trafficking, signaling, and PTM. This experiment could also reveal information 
regarding where post-translationally modified intracellular CXCR4 traffic. To exclude the 
plasma membrane labeled receptors, we could use the surface biotinylation assay pre-stimulus to 
label plasma membrane receptors with a biotin-tag and monitor receptor trafficking as well as 
fate of intracellular vs. plasma membrane CXCR4 post-receptor stimulus. We could also re-
stimulate the cells after several hours and investigate subsequent CXCL2-dependent signaling, 
internalization, and CXCR4 PTM. This could provide insight into whether intracellular CXCR4 
PTMs regulate future signaling events or trafficking.   
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6.3.4 Mathematical modeling to investigate the implications of plasma membrane and 
intracellular CXCR4 signaling  
 A modeling approach could also be used to investigate the biological relevance of 
intracellular GPCR activation. Recently the Schnell lab used a mathematical model to investigate 
the efficacy of different sensors to detect unfolded protein in the ER288. A modified version of 
this approach could be used to understand the biological and evolutionary rationale of having 
multiple localization of CXCR4 contribute to controlling a downstream response. Stroberg et al. 
tested three different mechanisms to sense ER stress: an unfolded-protein sensor, free-chaperone 
sensor, and a combined sensor. Each sensor was benchmarked for resource utilization and 
accuracy. While the AND switch coincided with the best of both the unfolded protein and 
chaperone-mediated sensors, it did not significantly improve the outcomes of either individual 
mechanism288. Interestingly, the combined sensor is what occurs in nature and the authors 
concluded that it likely serves a different purpose than minimizing the overproduction of 
chaperones during ER stress288.  
A similar approach could be used to model plasma membrane and intracellular CXCR4-
dependent signaling. Instead of having a single compartment, two compartments could be used 
to model how localized CXCR4 activation leads to downstream transcription in a β-arrestin-1-
dependent mechanism. It would be interesting to investigate whether modulating either of these 
two populations changes a cell’s ability to accurately and adeptly respond to CXCL12. As 
discussed in Chapter 3, plasma membrane and intracellular CXCR4 activation resemble a feed-
forward positive feedback loop (Figure 3-11). In nature, cells encounter many different signals 
and their ability to accurately respond is essential. Feed-forward loops increase sensor robustness 
and sensitivity and allows for cells to distinguish signaling from noise289. It is possible that 
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modulating the balance of receptors in these two pools could lead to over-activation or increased 
variability in cellular response. Using the mathematical model we would be able to investigate 
these different scenarios. Additionally, we have great experimental control of this system and are 
able to measure total receptor level and PTM state at plasma membrane and intracellular 
compartments. Furthermore, we have established assays to measure intermediate (ERK1/2 
phosphorylation) and final transcriptional output (Egr1 transcript levels) as well as response 
variability. These readouts could be used as a proxy for the fitness of each situation. Similarly to 
Stroberg et al., we could test different mechanisms such as plasma membrane alone vs. the 
combined signaling mechanism. This could then be expanded to include how the distribution of 
plasma membrane and intracellular CXCR4 localization may modulate downstream signaling 
response, resource utilization, and variability. These experiments would provide information 
about how receptor localization impacts downstream signaling as well as fitness consequences of 
modulating this balance.  
6.4 Chapter 4 summary and future directions  
 In Chapter 4, we adopted APEX2 proteomics to study how the CXCR4 interactome 
changes during endocytic trafficking. While we were able to confirm that the CXCR4-APEX2 
fusion protein did not drastically affect CXCR4 function, we were unable to confirm the 
biological relevance of the protein-protein interactions identified by our proteomics experiment. 
PDGFRβ was one of the top hits identified in our proteomics experiment. Ultimately, we found 
no functional crosstalk between CXCR4 and PDGFRβ signaling, agonist-induced CXCR4 PTM 
or CXCR4 internalization in retinal pigment epithelial (RPE) cells. This could be due to several 
reasons including cell type specificity or the fact that we only tested a subset of potential 
CXCR4-PDGFRβ crosstalk processes. While we believe that the APEX2 technology is a 
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promising tool to study the CXCR4 interactome, additional proteomics experiments are 
necessary to advance this research. 
 While spatiotemporal proteomics provides information about CXCR4 interacting 
partners, protein PTMs play an essential role in regulating these interactions as well as the 
downstream signaling implications61,290. Therefore, it would be interesting to investigate how 
local proteomic architecture correlates with the CXCL12-dependent phospho-proteome. This 
could be accomplished by running APEX2 proteomics experiments simultaneously with 
phosphoproteomics. Samples could be divided into two groups one for streptavidin pulldown and 
the other phosphopeptide enrichment. While CXCR4 phosphoproteomics has been previously 
investigated60, this experiment would add important spatial information pertaining to CXCR4 
localization and interacting partners during these signaling events. This research could be 
extended further by inhibiting different signaling cascades or endocytic trafficking pathways to 
determine how specific proteins not only regulate the CXCR4 interactome but also downstream 
signaling implications. For example, since caveolae are known to be important for CXCL12-
dependent ERK1/2 signaling102,225, we would expect that inhibition of CME would increase 
ERK1/2 phosphorylation and potentially shift the balance of downstream signaling events or 
CXCR4 endocytic trafficking towards CIE-dependent processes.  
6.5 Chapter 5 summary and future directions 
During the course of my thesis research, I became increasingly interested in how we 
measure cell biology processes and interpret receptor-signaling data. In Chapter 5, I summarized 
some useful practices when evaluating western blotting data. Using agonist-induced receptor 
PTM as an example, I highlighted the assumptions of western blotting and showcased how clues 
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from raw western blots can hint at experimental variability that is not captured by statistics and 
methods that influence quantification.  
As technological and analytical innovations rapidly advance our ability to reveal 
increasingly complex biological processes, the importance of understanding the assumptions 
behind biological measurements and sources of uncertainty are essential for data interpretation. 
This is particularly important in fields such as cell signaling and synthetic biology. Due to its 
importance for both homeostatic and pathogenic biological processes, a quantitative 
understanding of the cell signaling mechanisms is fundamental to drug development. Likewise, 
the ability to accurately predict and design standard components is necessary for biomedical 
engineering and synthetic biology innovation. 
6.6 Conclusions 
Understanding how cells decipher complex extracellular information using limited 
resources and conserved signaling hubs remains in my opinion one of the biggest outstanding 
questions in biology. Together with recent work from other groups, the contents of this thesis 
highlight the important role of receptor localization as a master regulating of cellular decision-
making; this not only challenges our traditional understanding of receptor signaling but how we 
study and interpret cell-signaling events. Additional research is necessary to truly elucidate the 
mechanisms and importance of intracellular GPCR activation.  
The implications of spatiotemporal signaling span both basic and translational science as 
it is becoming apparent that intracellular GPCR activation leads to distinct signaling outcomes 
and dysfunction is associated with a growing number of diseases133,154,155. An improved 
understanding of the molecular mechanism of intracellular GPCR activation has the potential to 
lead to the development of a new class of therapeutics that selectively modulate these pathways.  
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